Formulations of factor viii chimeric proteins and uses thereof
Patent Information
- Application Number
- TW111123492
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-08-11
- Filing Date
- 2022-06-23
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2042-06-22
Smart Images

Figure TWG2TB001919974_001 
Figure TWG2TB001919974_002 
Figure TWG2TB001919974_003
Abstract
Description
[Technical Field]
[0001] This disclosure provides a pharmaceutical composition comprising a chimeric protein containing a factor VIII (FVIII) polypeptide and a von Willebrand factor (VWF) polypeptide. A pharmaceutical kit and a method of treating hemophilia A using the disclosed pharmaceutical composition are also disclosed. [Previous Technology]
[0002] Hemophilia A is a bleeding disorder caused by a genetic defect encoding coagulation factor VIII (FVIII), affecting 1-2 out of every 10,000 male births. Graw et al., Nat. Rev. Genet. 6(6): 488-501 (2005). Patients with hemophilia A can be treated with infusions of purified plasma FVIII or recombinant FVIII. Many commercially available FVIII products are known to have a half-life of approximately 8-12 hours, requiring frequent intravenous administration. See Weiner MA and Cairo, MS, Pediatric Hematology Secrets, Lee, MT, 12. Disorders of Coagulation, Elsevier Health Sciences, 2001; Lillicrap, D. Thromb. Res. 122 Supplement 4: S2-8 (2008). In addition, various methods have been attempted to prolong the half-life of FVIII. For example, methods under development for extending the half-life of clotting factors include PEGylation, glycosyl PEGylation, and albumin conjugation. See Dumont et al., Blood. 119(13): 3024-3030 (2012). Consistent results have been shown in humans, for example, in patients with hemophilia A, rFVIII-Fc fusion protein has been reported to improve the half-life by approximately 1.7 times compared to ADVATE®. See Powell et al., Blood. 119(13): 3031-3037 (2012). Therefore, the increase in half-life, but the small amount of improvement, suggests the presence of other half-life limiting factors, such as clearance by VWF. Pipe et al., Blood. 128(16): 2007-2016 (2016)).
[0003] Evanesoctocog alfa (also known as Efa and BIVV001) is a fusion protein designed to uncouple circulating recombinant coagulation factor VIII from VWF. This chimeric protein comprises a single recombinant factor VIII protein fused to a dimer Fc, the D′D3 domain of VWF, and two ELNN peptides. Chhabra et al. Blood 135(17): 1484-1496 (2020). In an earlier study involving patients with severe hemophilia A, a single intravenous injection of evanesoctocog alfa resulted in highly sustained levels of factor VIII activity with a half-life up to four times longer than that associated with recombinant factor VIII. See Konkle et al., NEJM.383:1018-27 (2020).
[0004] However, there is still a need for improved pharmaceutical compositions. [Summary of the Invention]
[0005] This disclosure relates in particular to pharmaceutical compositions comprising factor VIII (“FVIII”) protein, kits comprising such pharmaceutical compositions, and treatment methods and uses of said pharmaceutical compositions.
[0006] In some embodiments, the pharmaceutical composition comprises a chimeric protein comprising: a first polypeptide chain comprising an FVIII protein or a portion thereof and a first immunoglobulin (“Ig”) constant region or a portion thereof, and a second polypeptide chain comprising a von Willebrand factor (“VWF”) protein and a second Ig constant region or a portion thereof. In some embodiments, the chimeric protein comprises (i) an FVIII protein comprising an FVIII polypeptide, an ELNN polypeptide (e.g., replacing at least a portion of the B domain) inserted into the B domain of the FVIII polypeptide, and an FVIII protein comprising a first Fc region; and (ii) a VWF protein comprising a VWF fragment (e.g., a fragment comprising the D'D3 domain of VWF, the fragment may contain a mutation), a second ELNN polypeptide, a thrombin-cleavable linker (such as an a2 linker), and a second Fc region. In some embodiments, the chimeric protein disclosed herein is an FVIII-ELNN-Fc / D'D3-ELNN-Fc heterodimer.
[0007] In some embodiments, the pharmaceutical composition comprises: (a) FVIII protein; (b) sucrose; (c) histidine; (d) arginine; (e) calcium chloride; and (f) polysorbate. In some embodiments, the pharmaceutical composition comprises: (a) FVIII protein; (b) sucrose; (c) L-histidine; (d) L-arginine; (e) calcium chloride; and (f) polysorbate. In some embodiments, the pharmaceutical composition comprises: (a) factor VIII (“FVIII”) protein; (b) sucrose; (c) L-histidine; (d) L-arginine-HCl; (e) calcium chloride dihydrate; and (f) polysorbate.
[0008] In some embodiments, the pharmaceutical composition comprises: (a) FVIII protein; (b) about 1% (w / v) to about 4% (w / v) sucrose; (c) about 5 mM to about 15 mM histidine; (d) about 150 mM to about 300 mM arginine; (e) about 2.5 mM to about 10 mM calcium chloride; and (f) about 0.008% (w / v) to about 0.1% (w / v) polysorbate. In some embodiments, the pharmaceutical composition comprises: (a) FVIII protein; (b) about 1% (w / v) to about 4% (w / v) sucrose; (c) about 5 mM to about 15 mM histidine; (d) about 200 mM to about 300 mM arginine; (e) about 2.5 mM to about 10 mM calcium chloride; and (f) about 0.008% (w / v) to about 0.1% (w / v) polysorbate. In some embodiments, the pharmaceutical composition comprises: (a) FVIII protein; (b) about 1% (w / v) to about 4% (w / v) sucrose; (c) about 5 mM to about 15 mM L-histidine; (d) about 200 mM to about 300 mM L-arginine; (e) about 2.5 mM to about 10 mM calcium chloride; and (f) about 0.008% (w / v) to about 0.1% (w / v) polysorbate. In some embodiments, the pharmaceutical composition comprises: (a) factor VIII (“FVIII”) protein; (b) about 1% (w / v) to about 4% (w / v) sucrose; (c) about 5 mM to about 15 mM L-histidine; (d) about 200 mM to about 300 mM L-arginine-HCl; (e) about 2.5 mM to about 10 mM calcium chloride dihydrate; and (f) about 0.008% (w / v) to about 0.1% (w / v) polysorbate.
[0009] In some embodiments, the pharmaceutical composition comprises: (a) FVIII protein; (b) about 5% (w / v) to about 7.5% (w / v) sucrose; (c) about 5 mM to about 15 mM histidine; (d) about 150 mM to about 300 mM arginine; (e) about 2.5 mM to about 10 mM calcium chloride; and (f) about 0.008% (w / v) to about 0.1% (w / v) polysorbate. In some embodiments, the pharmaceutical composition comprises: (a) FVIII protein; (b) about 5% (w / v) to about 7.5% (w / v) sucrose; (c) about 5 mM to about 15 mM histidine; (d) about 200 mM to about 300 mM arginine; (e) about 2.5 mM to about 10 mM calcium chloride; and (f) about 0.008% (w / v) to about 0.1% (w / v) polysorbate. In some embodiments, the pharmaceutical composition comprises: (a) FVIII protein; (b) about 5% (w / v) to about 7.5% (w / v) sucrose; (c) about 5 mM to about 15 mM L-histidine; (d) about 200 mM to about 300 mM L-arginine; (e) about 2.5 mM to about 10 mM calcium chloride; and (f) about 0.008% (w / v) to about 0.1% (w / v) polysorbate. In some embodiments, the pharmaceutical composition comprises: (a) factor VIII (“FVIII”) protein; (b) about 5% (w / v) to about 7.5% (w / v) sucrose; (c) about 5 mM to about 15 mM L-histidine; (d) about 200 mM to about 300 mM L-arginine-HCl; (e) about 2.5 mM to about 10 mM calcium chloride dihydrate; and (f) about 0.008% (w / v) to about 0.1% (w / v) polysorbate.
[0010] In some embodiments, the pharmaceutical composition comprises about 1% (w / v) to about 4% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 5% (w / v) to about 7.5% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 5 mM to about 15 mM histidine. In some embodiments, the pharmaceutical composition comprises at least 150 mM arginine. In some embodiments, the pharmaceutical composition comprises about 150 mM to about 300 mM arginine. In some embodiments, the pharmaceutical composition comprises at least 250 mM arginine. In some embodiments, the pharmaceutical composition comprises about 200 mM to about 300 mM arginine. In some embodiments, the pharmaceutical composition comprises about 2.5 mM to about 10 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises polysorbate 20. In some embodiments, the pharmaceutical composition comprises polysorbate 80. In some embodiments, the pharmaceutical composition comprises about 0.008% (w / v) to about 0.1% (w / v) of polysorbate 20 or polysorbate 80.
[0011] In some embodiments, the composition comprises at least about 250 mM L-arginine. In some embodiments, the composition comprises at least about 250 mM L-arginine-HCl. In some embodiments, the composition comprises about 250 mM L-arginine. In some embodiments, the composition comprises about 250 mM L-arginine-HCl. In some embodiments, the polysorbate is polysorbate 80. In some embodiments, the polysorbate is polysorbate 20.
[0012] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) a chimeric protein comprising a first polypeptide chain comprising a factor VIII (“FVIII”) protein and a constant region or portion thereof of a first immunoglobulin (“Ig”), and a second polypeptide chain comprising a von Willebrand factor (“VWF”) protein and a constant region or portion thereof of a second Ig; (b) sucrose; (c) histidine; (d) arginine; (e) calcium chloride; and (f) polysorbate.
[0013] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) a chimeric protein comprising a first polypeptide chain comprising a factor VIII (“FVIII”) protein and a constant region or portion thereof of a first immunoglobulin (“Ig”), and a second polypeptide chain comprising a von Willebrand factor (“VWF”) protein and a constant region or portion thereof of a second Ig; (b) about 1% (w / v) to about 4% (w / v) sucrose; (c) about 5 mM to about 15 mM histidine; (d) about 150 mM to about 300 mM arginine; (e) about 2.5 mM to about 10 mM calcium chloride; and (f) about 0.008% (w / v) to about 0.1% (w / v) polysorbate.
[0014] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) about 5% (w / v) to about 7.5% (w / v) sucrose; (b) about 5 mM to about 15 mM histidine; (c) about 150 mM to about 300 mM arginine; (d) about 2.5 mM to about 10 mM calcium chloride; and (e) about 0.008% (w / v) to about 0.1% (w / v) polysorbate 20 or polysorbate 80.
[0015] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) a chimeric protein comprising a first polypeptide chain comprising a factor VIII (“FVIII”) protein and a constant region or portion thereof of a first immunoglobulin (“Ig”), and a second polypeptide chain comprising a von Willebrand factor (“VWF”) protein and a constant region or portion thereof of a second Ig; (b) about 1% (w / v) to about 4% (w / v) sucrose; (c) about 5 mM to about 15 mM histidine; (d) about 200 mM to about 300 mM arginine; (e) about 2.5 mM to about 10 mM calcium chloride; and (f) about 0.008% (w / v) to about 0.1% (w / v) polysorbate.
[0016] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) about 5% (w / v) to about 7.5% (w / v) sucrose; (b) about 5 mM to about 15 mM histidine; (c) about 200 mM to about 300 mM arginine; (d) about 2.5 mM to about 10 mM calcium chloride; and (e) about 0.008% (w / v) to about 0.1% (w / v) polysorbate 20 or polysorbate 80.
[0017] In some embodiments, the pharmaceutical composition comprises about 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU, or 4000 IU of a chimeric protein. In some embodiments, the first polypeptide chain comprises an amino acid sequence as shown in SEQ ID NO: 1 and the second polypeptide chain comprises an amino acid sequence as shown in SEQ ID NO: 2, wherein the first polypeptide chain and the second polypeptide chain are covalently linked by two disulfide bonds between the Fc domains in the first polypeptide chain and the second polypeptide chain. In some embodiments, the chimeric protein is eprenin α.
[0018] In some embodiments, the pharmaceutical composition comprises about 1% (w / v) to about 4% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 5 mM to about 15 mM histidine. In some embodiments, the pharmaceutical composition comprises at least 150 mM arginine. In some embodiments, the pharmaceutical composition comprises about 150 mM to about 300 mM arginine. In some embodiments, the pharmaceutical composition comprises at least 250 mM arginine. In some embodiments, the pharmaceutical composition comprises about 200 mM to about 300 mM arginine. In some embodiments, the pharmaceutical composition comprises about 2.5 mM to about 10 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises polysorbate 20. In some embodiments, the pharmaceutical composition comprises polysorbate 80. In some embodiments, the pharmaceutical composition comprises about 0.008% (w / v) to about 0.1% (w / v) polysorbate 20 or polysorbate 80.
[0019] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) about 1% (w / v) to about 4% (w / v) sucrose; (b) about 5 mM to about 15 mM histidine; (c) about 150 mM to about 300 mM arginine; (d) about 2.5 mM to about 10 mM calcium chloride; and (e) about 0.008% (w / v) to about 0.1% (w / v) polysorbate 20 or polysorbate 80.
[0020] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) about 1% (w / v) to about 4% (w / v) sucrose; (b) about 5 mM to about 15 mM histidine; (c) about 200 mM to about 300 mM arginine; (d) about 2.5 mM to about 10 mM calcium chloride; and (e) about 0.008% (w / v) to about 0.1% (w / v) polysorbate 20 or polysorbate 80.
[0021] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) about 2% (w / v) sucrose; (b) about 10 mM histidine; (c) about 250 mM arginine; (d) about 5 mM calcium chloride; and (e) about 0.05% polysorbate 20 or polysorbate 80.
[0022] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) about 2% (w / v) sucrose; (b) about 10 mM L-histidine; (c) about 250 mM L-arginine-HCl; (d) about 5 mM calcium chloride; and (e) about 0.05% polysorbate 80.
[0023] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 10 mg / mL to 40 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 40 mg / mL to 70 mg / mL L-arginine-HCl; (d) 0.4 mg / mL to 0.9 mg / mL calcium chloride; and (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80.
[0024] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 22.45 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 59.11 mg / ml L-arginine-HCl; (d) 0.82 mg / ml calcium chloride dihydrate; and (e) 0.56 mg / ml polysorbate 80.
[0025] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 22.45 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 59.11 mg / ml L-arginine-HCl; (d) 0.62 mg / ml calcium chloride; and (e) 0.56 mg / ml polysorbate 80.
[0026] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 10 mg / mL to 40 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 40 mg / mL to 70 mg / mL L-arginine-HCl; (d) 0.5 mg / mL to 0.9 mg / mL calcium chloride dihydrate; and (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80.
[0027] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) about 20 mg / mL sucrose; (b) about 1.6 mg / mL L-histidine; (c) about 52.7 mg / mL L-arginine-HCl; (d) about 0.7 mg / mL calcium chloride dihydrate; and (e) about 0.5 mg / mL polysorbate 80.
[0028] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) about 20 mg / mL sucrose; (b) about 1.6 mg / mL L-histidine; (c) about 52.7 mg / mL L-arginine-HCl; (d) about 0.6 mg / mL calcium chloride; and (e) about 0.5 mg / mL polysorbate 80.
[0029] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) about 20 mg / mL sucrose; (b) about 1.6 mg / mL L-histidine; (c) about 43.6 mg / mL L-arginine; (d) about 0.7 mg / mL calcium chloride dihydrate; and (e) about 0.5 mg / mL polysorbate 80.
[0030] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) about 20 mg / mL sucrose; (b) about 1.6 mg / mL L-histidine; (c) about 43.6 mg / mL L-arginine; (d) about 0.6 mg / mL calcium chloride; and (e) about 0.5 mg / mL polysorbate 80.
[0031] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 10 mg / mL to 40 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 50 mg / mL to 70 mg / mL L-arginine-HCl; (d) 0.7 mg / mL to 0.9 mg / mL calcium chloride dihydrate; and (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80.
[0032] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 10 mg / mL to 40 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 50 mg / mL to 70 mg / mL L-arginine-HCl; (d) 0.4 mg / mL to 0.8 mg / mL calcium chloride; and (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80.
[0033] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 10 mg / mL to 40 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 40 mg / mL to 60 mg / mL L-arginine; (d) 0.7 mg / mL to 0.9 mg / mL calcium chloride; and (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80.
[0034] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 10 mg / mL to 40 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 40 mg / mL to 60 mg / mL L-arginine; (d) 0.4 mg / mL to 0.7 mg / mL calcium chloride dihydrate; and (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80.
[0035] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 22.45 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 59.11 mg / ml L-arginine-HCl; (d) 0.82 mg / ml calcium chloride dihydrate; and (e) 0.56 mg / ml polysorbate 80.
[0036] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 22.45 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 48.88 mg / ml L-arginine; (d) 0.82 mg / ml calcium chloride dihydrate; and (e) 0.56 mg / ml polysorbate 80.
[0037] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 22.45 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 59.11 mg / ml L-arginine-HCl; (d) 0.62 mg / ml calcium chloride; and (e) 0.56 mg / ml polysorbate 80.
[0038] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 22.45 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 48.88 mg / ml L-arginine; (d) 0.62 mg / ml calcium chloride; and (e) 0.56 mg / ml polysorbate 80.
[0039] In some embodiments, the pharmaceutical composition comprises about 5% (w / v) to about 7.5% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 5 mM to about 15 mM histidine. In some embodiments, the pharmaceutical composition comprises at least 150 mM arginine. In some embodiments, the pharmaceutical composition comprises about 150 mM to about 300 mM arginine. In some embodiments, the pharmaceutical composition comprises at least 250 mM arginine. In some embodiments, the pharmaceutical composition comprises about 200 mM to about 300 mM arginine. In some embodiments, the pharmaceutical composition comprises about 2.5 mM to about 10 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises polysorbate 20. In some embodiments, the pharmaceutical composition comprises polysorbate 80. In some embodiments, the pharmaceutical composition comprises about 0.008% (w / v) to about 0.1% (w / v) polysorbate 20 or polysorbate 80.
[0040] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) about 5% (w / v) to about 7.5% (w / v) sucrose; (b) about 5 mM to about 15 mM histidine; (c) about 150 mM to about 300 mM arginine; (d) about 2.5 mM to about 10 mM calcium chloride; and (e) about 0.008% (w / v) to about 0.1% (w / v) polysorbate 20 or polysorbate 80.
[0041] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) about 5% (w / v) to about 7.5% (w / v) sucrose; (b) about 5 mM to about 15 mM histidine; (c) about 200 mM to about 300 mM arginine; (d) about 2.5 mM to about 10 mM calcium chloride; and (e) about 0.008% (w / v) to about 0.1% (w / v) polysorbate 20 or polysorbate 80.
[0042] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) about 5% (w / v) sucrose; (b) about 10 mM histidine; (c) about 250 mM arginine; (d) about 5 mM calcium chloride; and (e) about 0.05% polysorbate 20 or polysorbate 80.
[0043] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) about 5% (w / v) sucrose; (b) about 10 mM L-histidine; (c) about 250 mM L-arginine-HCl; (d) about 5 mM calcium chloride; and (e) about 0.05% polysorbate 80.
[0044] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 45 mg / mL to 60 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 40 mg / mL to 70 mg / mL L-arginine-HCl; (d) 0.4 mg / mL to 0.9 mg / mL calcium chloride; and (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80.
[0045] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 56.12 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 59.11 mg / ml L-arginine-HCl; (d) 0.82 mg / ml calcium chloride dihydrate; and (e) 0.56 mg / ml polysorbate 80.
[0046] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 56.12 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 59.11 mg / ml L-arginine-HCl; (d) 0.62 mg / ml calcium chloride; and (e) 0.56 mg / ml polysorbate 80.
[0047] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 45 mg / mL to 60 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 40 mg / mL to 70 mg / mL L-arginine-HCl; (d) 0.5 mg / mL to 0.9 mg / mL calcium chloride dihydrate; and (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80.
[0048] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) about 50 mg / mL sucrose; (b) about 1.6 mg / mL L-histidine; (c) about 52.7 mg / mL L-arginine-HCl; (d) about 0.7 mg / mL calcium chloride dihydrate; and (e) about 0.5 mg / mL polysorbate 80.
[0049] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) about 50 mg / mL sucrose; (b) about 1.6 mg / mL L-histidine; (c) about 52.7 mg / mL L-arginine-HCl; (d) about 0.6 mg / mL calcium chloride; and (e) about 0.5 mg / mL polysorbate 80.
[0050] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) about 50 mg / mL sucrose; (b) about 1.6 mg / mL L-histidine; (c) about 43.6 mg / mL L-arginine; (d) about 0.7 mg / mL calcium chloride dihydrate; and (e) about 0.5 mg / mL polysorbate 80.
[0051] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) about 50 mg / mL sucrose; (b) about 1.6 mg / mL L-histidine; (c) about 43.6 mg / mL L-arginine; (d) about 0.6 mg / mL calcium chloride; and (e) about 0.5 mg / mL polysorbate 80.
[0052] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 45 mg / mL to 60 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 50 mg / mL to 70 mg / mL L-arginine-HCl; (d) 0.7 mg / mL to 0.9 mg / mL calcium chloride dihydrate; and (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80.
[0053] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 45 mg / mL to 60 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 50 mg / mL to 70 mg / mL L-arginine-HCl; (d) 0.4 mg / mL to 0.8 mg / mL calcium chloride; and (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80.
[0054] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 45 mg / mL to 60 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 40 mg / mL to 60 mg / mL L-arginine; (d) 0.7 mg / mL to 0.9 mg / mL calcium chloride; and (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80.
[0055] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 45 mg / mL to 60 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 40 mg / mL to 60 mg / mL L-arginine; (d) 0.4 mg / mL to 0.7 mg / mL calcium chloride dihydrate; and (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80.
[0056] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 56.12 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 59.11 mg / ml L-arginine-HCl; (d) 0.82 mg / ml calcium chloride dihydrate; and (e) 0.56 mg / ml polysorbate 80.
[0057] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 56.12 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 48.88 mg / ml L-arginine; (d) 0.82 mg / ml calcium chloride dihydrate; and (e) 0.56 mg / ml polysorbate 80.
[0058] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 56.12 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 59.11 mg / ml L-arginine-HCl; (d) 0.62 mg / ml calcium chloride; and (e) 0.56 mg / ml polysorbate 80.
[0059] In some embodiments, a pharmaceutical composition is disclosed herein comprising: (a) 56.12 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 48.88 mg / ml L-arginine; (d) 0.62 mg / ml calcium chloride; and (e) 0.56 mg / ml polysorbate 80.
[0060] In some embodiments, a pharmaceutical composition according to any of the disclosed embodiments is disclosed herein, the pharmaceutical composition further comprising a pH of about 6.5 to about 7.5. In some embodiments, the pH of the pharmaceutical composition disclosed herein is about 6.8 to about 7.3. In some embodiments, the pH of the pharmaceutical composition disclosed herein is about 7.0. In some embodiments, the pH of the pharmaceutical composition disclosed herein is about 6.8. In some embodiments, the pharmaceutical composition disclosed herein does not contain NaCl. In some embodiments, the pharmaceutical composition does not contain NaOH. In some embodiments, the pharmaceutical composition does not contain sodium ions. In some embodiments, the pharmaceutical composition disclosed herein contains less than 8.8 mg / mL sodium chloride (NaCl). In some embodiments, the pharmaceutical composition disclosed herein contains L-histidine. In some embodiments, the pharmaceutical composition disclosed herein contains L-arginine. In some embodiments, the pharmaceutical composition disclosed herein contains arginine-HCl. In some embodiments, the pharmaceutical composition disclosed herein contains L-arginine-HCl. In some embodiments, the pharmaceutical composition disclosed herein contains calcium chloride dihydrate.
[0061] In some embodiments, a pharmaceutical composition according to any one of the disclosed embodiments is disclosed herein, wherein the concentration of the chimeric protein in the pharmaceutical composition is from about 0.8 to about 1.2 mg / mL. In some embodiments, the pharmaceutical composition disclosed herein comprises a chimeric protein of 75 IU / mL to 2,000 IU / mL. In some embodiments, the pharmaceutical composition disclosed herein has a weight molar osmolality of from about 525 to about 725 mOsm / kg. In some embodiments, the pharmaceutical composition disclosed herein has a weight molar osmolality of from about 600 to about 650 mOsm / kg. In some embodiments, the pharmaceutical composition disclosed herein has a turbidity of less than about 7 turbidimetric units (NTU).
[0062] This document also discloses a method for treating hemophilia A in an individual of need, the method comprising administering to the individual an effective amount of a pharmaceutical composition according to any one of the embodiments disclosed herein. In some embodiments, the pharmaceutical composition is self-administered. In some embodiments, the pharmaceutical composition is administered intravenously. In some embodiments, the pharmaceutical composition is administered intravenously at a dose of about 20 IU / kg to about 70 IU / kg. In some embodiments, the pharmaceutical composition is administered intravenously at a dose of about 50 IU / kg. In some embodiments, the pharmaceutical composition is administered intravenously once every 7-10 days. In some embodiments, the pharmaceutical composition is administered intravenously once weekly.
[0063] This document also discloses a pharmaceutical kit comprising: (i) a first container containing a lyophilized pharmaceutical composition comprising (a) a chimeric protein comprising a first polypeptide chain comprising a factor VIII (“FVIII”) protein or a portion thereof and a first immunoglobulin (“Ig”) constant region or a portion thereof, and a second polypeptide chain comprising a von Willebrand factor (“VWF”) protein and a second Ig constant region or a portion thereof; (b) sucrose; (c) histidine; (d) arginine; (e) calcium chloride; and (f) polysorbate 20 or polysorbate 80; and (ii) a second container containing sterile water.
[0064] In some embodiments, the chimeric protein comprises a first polypeptide chain and a second polypeptide chain, the first polypeptide chain comprising an amino acid sequence as shown in SEQ ID NO: 1 and the second polypeptide chain comprising an amino acid sequence as shown in SEQ ID NO: 2, wherein the first polypeptide chain and the second polypeptide chain are covalently linked by two disulfide bonds between the Fc domains in the first polypeptide chain and the second polypeptide chain.
[0065] This document also discloses a pharmaceutical kit comprising: (i) a first container containing a lyophilized pharmaceutical composition comprising (a) a chimeric protein comprising a first polypeptide chain comprising a factor VIII (“FVIII”) protein or a portion thereof and a constant region or a portion thereof of a first immunoglobulin (“Ig”), and a second polypeptide chain comprising a von Willebrand factor (“VWF”) protein and a constant region or a portion thereof of a second Ig; (b) about 30 mg to about 135 mg of sucrose; (c) about 2.5 mg to about 7.5 mg of histidine; (d) about 140 mg to about 200 mg of arginine; (e) about 1.5 mg to about 5 mg of calcium chloride; and (f) about 1 mg to about 5 mg of polysorbate 20 or polysorbate 80; and (ii) a second container containing sterile water. In some embodiments, the chimeric protein comprises a first polypeptide chain and a second polypeptide chain, the first polypeptide chain comprising an amino acid sequence as shown in SEQ ID NO: 1 and the second polypeptide chain comprising an amino acid sequence as shown in SEQ ID NO: 2, wherein the first polypeptide chain and the second polypeptide chain are covalently linked by two disulfide bonds between the Fc domains in the first polypeptide chain and the second polypeptide chain.
[0066] In some embodiments, the pharmaceutical kits disclosed herein comprise a lyophilized pharmaceutical composition containing: (a) about 30 mg to about 135 mg of sucrose; (b) about 2.5 mg to about 7.5 mg of histidine; (c) about 140 mg to about 200 mg of arginine; (d) about 1.5 mg to about 5 mg of calcium chloride; and (e) about 1 mg to about 5 mg of polysorbate 20 or polysorbate 80.
[0067] In some embodiments, the pharmaceutical kit comprises a lyophilized pharmaceutical composition that does not contain NaCl. In some embodiments, the lyophilized pharmaceutical composition contains less than 8.8 mg / mL sodium chloride (NaCl). In some embodiments, the pharmaceutical composition does not contain NaOH. In some embodiments, the pharmaceutical composition does not contain sodium ions. In some embodiments, the lyophilized pharmaceutical composition contains L-histidine. In some embodiments, the lyophilized pharmaceutical composition contains L-arginine. In some embodiments, the lyophilized pharmaceutical composition contains arginine-HCl. In some embodiments, the lyophilized pharmaceutical composition disclosed herein contains calcium chloride dihydrate.
[0068] In some embodiments, the pharmaceutical kit comprises a lyophilized pharmaceutical composition containing: (a) about 67.3 mg of sucrose; (b) about 5.2 mg of L-histidine; (c) about 177.3 mg of L-arginine-HCl; (d) about 2.5 mg of calcium chloride; and (e) about 1.7 mg of polysorbate 20 or polysorbate 80.
[0069] In some embodiments, the pharmaceutical kit comprises a lyophilized pharmaceutical composition containing: (a) about 67.3 mg of sucrose; (b) about 5.2 mg of L-histidine; (c) about 146.6 mg of L-arginine-HCl; (d) about 2.5 mg of calcium chloride; and (e) about 1.7 mg of polysorbate 20 or polysorbate 80.
[0070] In some embodiments, the pharmaceutical kits disclosed herein comprise a lyophilized pharmaceutical composition containing: (a) about 160 mg to about 200 mg of sucrose; (b) about 2.5 mg to about 7.5 mg of histidine; (c) about 140 mg to about 200 mg of arginine; (d) about 1.5 mg to about 5 mg of calcium chloride; and (e) about 1 mg to about 5 mg of polysorbate 20 or polysorbate 80.
[0071] In some embodiments, the pharmaceutical kit comprises a lyophilized pharmaceutical composition that does not contain NaCl. In some embodiments, the lyophilized pharmaceutical composition contains less than 8.8 mg / mL sodium chloride (NaCl). In some embodiments, the pharmaceutical composition does not contain NaOH. In some embodiments, the pharmaceutical composition does not contain sodium ions. In some embodiments, the lyophilized pharmaceutical composition contains L-histidine. In some embodiments, the lyophilized pharmaceutical composition contains L-arginine. In some embodiments, the lyophilized pharmaceutical composition contains arginine-HCl. In some embodiments, the lyophilized pharmaceutical composition disclosed herein contains calcium chloride dihydrate.
[0072] In some embodiments, the pharmaceutical kit comprises a lyophilized pharmaceutical composition containing: (a) about 168.3 mg of sucrose; (b) about 5.2 mg of L-histidine; (c) about 177.3 mg of L-arginine-HCl; (d) about 2.5 mg of calcium chloride; and (e) about 1.7 mg of polysorbate 20 or polysorbate 80.
[0073] In some embodiments, the pharmaceutical kit comprises a lyophilized pharmaceutical composition containing: (a) about 168.3 mg of sucrose; (b) about 5.2 mg of L-histidine; (c) about 146.6 mg of L-arginine-HCl; (d) about 2.5 mg of calcium chloride; and (e) about 1.7 mg of polysorbate 20 or polysorbate 80.
[0074] In some embodiments, the pharmaceutical kit comprises a lyophilized pharmaceutical composition with a moisture content of less than 2%. In some embodiments, the moisture content of the lyophilized pharmaceutical composition is less than 1.8%. In some embodiments, the moisture content of the lyophilized pharmaceutical composition is less than 1.6%. In some embodiments, the lyophilized pharmaceutical composition is a lyophilized cake. In some embodiments, the lyophilized cake is white. In some embodiments, the lyophilized cake is smaller than Y4 in the European Pharmacopoeia color scale. In some embodiments, the lyophilized pharmaceutical composition is a powder.
[0075] In some embodiments, the medical kit includes a first container containing 100 IU to 10,000 IU of chimeric protein. In some embodiments, the first container contains 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU, or 4,000 IU of chimeric protein.
[0076] In some embodiments, the pharmaceutical kit further includes instructions for combining the lyophilized pharmaceutical composition with sterile water. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the lyophilized pharmaceutical composition is reconstituted within 7 to 12 seconds.
[0077] In some embodiments, the pharmaceutical composition includes a second container containing a volume of sterile water, which, when combined with the lyophilized powder in the first container, is sufficient to produce the injectable solution disclosed herein.
[0078] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a weight molar osmolality of about 525 to about 725 mOsm / kg. In some embodiments, the resulting solution has a weight molar osmolality of about 600 to about 650 mOsm / kg. In some embodiments, the resulting solution has a pH of about 6.5 to about 7.5. In some embodiments, the resulting solution has a pH of about 7.0. In some embodiments, the resulting solution has a pH of about 6.8. In some embodiments, the resulting solution has a turbidity of less than about 7 turbidimetric units (NTU). In some embodiments, the resulting solution has a protein concentration of about 0.8 to about 1.2 mg / mL. In some embodiments, less than 3% of the protein aggregates.
[0079] In some embodiments, the pharmaceutical kit includes a second container containing a volume of sterile water, which, when combined with the lyophilized pharmaceutical composition in the first container, is sufficient to produce a solution containing: (a) 10 mg / mL to 40 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 40 mg / mL to 70 mg / mL L-arginine-HCl; (d) 0.5 mg / mL to 0.9 mg / mL calcium chloride; and (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80.
[0080] In some embodiments of the pharmaceutical kits disclosed herein, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 10 mg / mL to 40 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 40 mg / mL to 70 mg / mL L-arginine-HCl; (d) 0.5 mg / mL to 0.9 mg / mL calcium chloride; and (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80.
[0081] In some embodiments of the pharmaceutical kits disclosed herein, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 22.45 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 59.11 mg / ml L-arginine-HCl; (d) 0.62 mg / ml calcium chloride; and (e) 0.56 mg / ml polysorbate 80.
[0082] In some embodiments of the pharmaceutical kits disclosed herein, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 22.45 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 48.88 mg / ml L-arginine; (d) 0.62 mg / ml calcium chloride; and (e) 0.56 mg / ml polysorbate 80.
[0083] In some embodiments, the pharmaceutical kit includes a second container containing a volume of sterile water, which, when combined with the lyophilized pharmaceutical composition in the first container, is sufficient to produce a solution containing: (a) 45 mg / mL to 60 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 40 mg / mL to 70 mg / mL L-arginine-HCl; (d) 0.5 mg / mL to 0.9 mg / mL calcium chloride; and (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80.
[0084] In some embodiments of the pharmaceutical kits disclosed herein, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 45 mg / mL to 60 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 40 mg / mL to 70 mg / mL L-arginine-HCl; (d) 0.5 mg / mL to 0.9 mg / mL calcium chloride; and (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80.
[0085] In some embodiments of the pharmaceutical kits disclosed herein, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 56.12 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 59.11 mg / ml L-arginine-HCl; (d) 0.62 mg / ml calcium chloride; and (e) 0.56 mg / ml polysorbate 80.
[0086] In some embodiments of the pharmaceutical kits disclosed herein, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 56.12 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 48.88 mg / ml L-arginine; (d) 0.62 mg / ml calcium chloride; and (e) 0.56 mg / ml polysorbate 80.
[0087] In some embodiments, the medical kit includes a second container containing about 2 mL to about 5 mL of sterile water. In some embodiments, the medical kit includes a second container containing about 3 mL of sterile water. In some embodiments, the medical kit includes a second container containing about 3.3 mL of sterile water.
[0088] In some embodiments, the medicine kit includes a first container, which is a glass vial containing a rubber stopper. In some embodiments, the medicine kit includes a second container, which is a syringe body. In some embodiments, the sterile water is contained in the syringe body. In some embodiments, the syringe body is associated with a plunger. In some embodiments, the medicine kit further includes an adapter connecting the glass vial to the syringe body. In some embodiments, the medicine kit further includes an infusion tubing associated with a needle and connected to the syringe body, suitable for intravenous infusion.
[0089] This document also discloses a method for treating hemophilia A in an individual in need, the method comprising combining a lyophilized pharmaceutical composition from a pharmaceutical kit according to any one of the embodiments disclosed herein with sterile water, and administering an effective amount of the resulting combination (i.e., solution) to the individual. In some embodiments, the individual combines the lyophilized pharmaceutical composition from the kit with sterile water. In some embodiments, the combination is self-administered by the individual.
Implementation Method
[0118] Cross-reference to related applications
[0119] This application claims the benefit of the following U.S. Provisional Application serial numbers: 63 / 214,245, filed June 23, 2021; 63 / 214,246, filed June 23, 2021; 63 / 214,752, filed June 24, 2021; and 63 / 231,909, filed August 11, 2021; each of which is incorporated herein by reference in its entirety. Reference to the electronically filed sequence list
[0120] The contents of the sequence list (name: SA9-480PC_ST25.txt; size: 158 kb; created on: June 22, 2022) submitted electronically as an ASCII text file are incorporated herein by reference in their entirety.
[0121] This disclosure relates particularly to formulations (including aqueous formulations and lyophilized formulations and related kits) containing FVIII proteins. In some embodiments, the FVIII protein is a chimeric FVIII protein comprising two polypeptides, such as Evans thrombin α: a first polypeptide comprising an FVIII protein containing a first ELNN polypeptide sequence insert fused to a first Fc region, and a second polypeptide comprising a VWF protein fused to a second Ig constant region via a second ELNN polypeptide sequence, wherein the first ELNN polypeptide sequence contains about 288 amino acids and the second ELNN polypeptide sequence contains about 144 amino acids, and the first Ig constant region and the second Ig constant region are covalently linked together by disulfide bonds.
[0122] This disclosure provides formulations of chimeric proteins (including aqueous formulations and lyophilized formulations, and related kits) comprising (i) a factor VIII (FVIII) polypeptide and (ii) a von Willebrand factor (VWF) fragment containing the D' domain and the D3 domain of VWF. This document includes lyophilizable compositions and compositions formed by reconstructing lyophilized formulations with a diluent. Therapeutic methods and uses are also provided. I. Definitions
[0123] It should be noted that the terms “a” or “an” refer to one or more of the aforementioned entities: for example, “a nucleotide sequence” should be understood to represent one or more nucleotide sequences. Therefore, the terms “a” (or “an”), “one or more” and “at least one” are used interchangeably herein.
[0124] Furthermore, as used herein, “and / or” is considered to be a specific disclosure of each of two specified features or components with or without the other features or components. Therefore, the term “and / or” as used herein in phrases such as “A and / or B” is intended to include “A and B”, “A or B”, “A” (alone), and “B” (alone). Similarly, the term “and / or” as used herein in phrases such as “A, B, and / or C” is intended to cover each of the following: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0125] It should be understood that, in addition to the use of the language “comprising” to describe various aspects herein, other similar aspects described in the terms “consisting of” and / or “substantially consisting of” are also provided.
[0126] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. For example, *Concise Dictionary of Biomedicine and Molecular Biology*, Juo, Pei-Show, 2nd edition, 2002, CRC Press; *The Dictionary of Cell and Molecular Biology*, 3rd edition, 1999, Academic Press; and *Oxford Dictionary of Biochemistry and Molecular Biology*, revised edition, 2000, Oxford University Press can provide a general interpretation of many of the terms used in this disclosure for those skilled in the art.
[0127] Units, initials, and symbols are represented in a form recognized by the International System of Units (SI). Numerical ranges include the digits defining the range. Unless otherwise specified, amino acid sequences are written from left to right in the direction from amino to carboxyl groups. The headings provided herein are not intended to limit any aspect of this disclosure. Therefore, the terms defined below can be defined more fully by referring to the specification as a whole.
[0128] The term “about” is used herein to mean approximately, roughly, or about. When the term “about” is used in conjunction with a range of digits, it modifies the range by extending the upper and lower boundaries of the value. Typically, the term “about” can modify a value to be above or below the value (higher or lower) by variance (e.g., 10%, up or down). In some embodiments, the term indicates a deviation from the indicated value of ±10%, ±5%, ±4%, ±3%, ±2%, ±1%, ±0.9%, ±0.8%, ±0.7%, ±0.6%, ±0.5%, ±0.4%, ±0.3%, ±0.2%, ±0.1%, ±0.05%, or ±0.01%. In some embodiments, “about” indicates a deviation from the indicated value of ±10%. In some embodiments, “about” indicates a deviation from the indicated value of ±5%. In some embodiments, “about” indicates a deviation from the indicated value of ±4%. In some embodiments, “about” indicates a deviation from the indicated value of ±3%. In some embodiments, "about" indicates a deviation from the indicated value by ±2%. In some embodiments, "about" indicates a deviation from the indicated value by ±1%. In some embodiments, "about" indicates a deviation from the indicated value by ±0.9%. In some embodiments, "about" indicates a deviation from the indicated value by ±0.8%. In some embodiments, "about" indicates a deviation from the indicated value by ±0.7%. In some embodiments, "about" indicates a deviation from the indicated value by ±0.6%. In some embodiments, "about" indicates a deviation from the indicated value by ±0.5%. In some embodiments, "about" indicates a deviation from the indicated value by ±0.4%. In some embodiments, "about" indicates a deviation from the indicated value by ±0.3%. In some embodiments, "about" indicates a deviation from the indicated value by ±0.1%. In some embodiments, "about" indicates a deviation from the indicated value by ±0.05%. In some embodiments, "about" indicates a deviation from the indicated value by ±0.01%.
[0129] Depending on the context, the term "polynucleotide" or "nucleotide" may cover both singular and plural nucleic acids. In some embodiments, a polynucleotide is an isolated nucleic acid molecule or construct, such as messenger RNA (mRNA) or plasmid DNA (pDNA). In some embodiments, a polynucleotide contains conventional phosphodiester bonds. In some embodiments, a polynucleotide contains unconventional bonds (e.g., amide bonds, as seen in peptide nucleic acids (PNA)). The term "nucleic acid" may refer to any one or more nucleic acid segments, such as DNA or RNA fragments, present in a polynucleotide. "Isolated" nucleic acid or polynucleotide refers to a nucleic acid molecule, DNA, or RNA that has been removed from its natural environment. For example, for the purposes of this disclosure, a recombinant polynucleotide encoding a factor VIII polypeptide contained in a vector is considered isolated. Other examples of isolated polynucleotides include recombinant polynucleotides maintained in a heterologous host cell or purified (partially or substantially) from other polynucleotides in solution. Isolated RNA molecules include in vivo or in vitro RNA transcripts of polynucleotides of this disclosure. Isolated polynucleotides or nucleic acids according to this disclosure further include such molecules produced synthetically. In addition, polynucleotides or nucleic acids may include regulatory elements such as promoters, enhancers, ribosome binding sites, or transcription termination signals.
[0130] Certain proteins secreted by mammalian cells are associated with secretion signal peptides, which are cleaved from mature proteins once the output of the growing protein chain across the rough endoplasmic reticulum has been initiated. Those skilled in the art will know that signal peptides are typically fused to the N-terminus of a polypeptide and cleaved from the whole or “full-length” polypeptide to produce the secretory or “mature” form of the polypeptide. In some embodiments, a native signal peptide or a functional derivative of the sequence that retains the ability to direct polypeptide secretion is operatively associated with the polypeptide. Alternatively, a heterologous mammalian signal peptide (e.g., human tissue plasminogen activator (TPA) or mouse β-glucuronidase signal peptide) or a functional derivative thereof may be used.
[0131] As used herein, the term "polypeptide" is intended to cover both the singular and plural "polypeptide" and refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (also known as peptide bonds). The term "polypeptide" refers to any one or more chains of two or more amino acids and does not relate to the specific length of the product. Thus, peptide, dipeptide, tripeptide, oligopeptide, "protein," "amino acid chain," or any other term used to refer to one or more chains of two or more amino acids is included within the definition of "polypeptide," and the term "polypeptide" may be used in place of or interchangeably with any of these terms. The term "polypeptide" is also intended to refer to products of post-expression modifications of a polypeptide, including but not limited to glycosylation, acetylation, phosphorylation, amideation, derivatization by known protecting / blocking groups, protein hydrolysis cleavage, or modification by non-naturally occurring amino acids. Polypeptides may be derived from natural biological sources or produced by recombinant technologies, but are not necessarily translated from a specified nucleic acid sequence. They can be produced in any manner, including by chemical synthesis.
[0132] "Isolated" polypeptide or its fragments, variants or derivatives refer to polypeptides that are not in their natural environment. No specific level of purification is required. For example, isolated polypeptides may simply be removed from their natural or native environment. For the purposes of this disclosure, recombinant polypeptides and proteins expressed in host cells are considered to be isolated, as are natural or recombinant polypeptides that have been isolated, fractionated or partially or substantially purified by any suitable technique.
[0133] This disclosure also includes fragments or variants of polypeptides and any combination thereof. The terms “fragment” or “variant” in relation to the polypeptide-binding domains or binding molecules of this disclosure include any polypeptide that retains at least some properties of the reference polypeptide, such as FcRn binding affinity to the FcRn binding domain or Fc variants, agglutination activity to FVIII variants, or FVIII binding activity to VWF fragments. In addition to specific antibody fragments discussed elsewhere herein, polypeptide fragments include protein hydrolysis fragments and deletion fragments, but do not include naturally occurring full-length polypeptides (or mature polypeptides). Variants of the polypeptide-binding domains or binding molecules of this disclosure include fragments as described above, as well as polypeptides having altered amino acid sequences due to amino acid substitution, deletion, or insertion. Variants may be naturally occurring or non-naturally occurring. Non-naturally occurring variants may be generated using mutagenesis techniques known in the art. Variant polypeptides may contain conserved or non-conserved amino acid substitutions, deletions, or additions.
[0134] As used herein, the term “VWF protein” means any VWF fragment that interacts with FVIII and retains at least one or more properties typically provided to FVIII by full-length VWF, such properties being, for example, preventing premature initiation to FVIIIa, preventing premature protein hydrolysis, preventing clearance, preventing association with phospholipid membranes that could lead to premature clearance, preventing binding to FVIII clearance receptors that can bind naked FVIII instead of VWF, and / or stabilizing FVIII heavy and light chain interactions. The VWF fragments mentioned herein are VWF polypeptides smaller than full-length VWF proteins, wherein the VWF fragment retains the ability to interact with and / or bind to FVIII. In some embodiments, the VWF protein is a fragment of full-length VWF (mutable) that binds to an FVIII protein such that the FVIII protein has reduced binding to or no binding to full-length VWF (e.g., an individual's endogenous VWF).
[0135] "Conservative amino acid substitution" is the substitution of an amino acid residue with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, aspartic acid, glutamic acid, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), β-branched side chains (e.g., threonine, leucine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Therefore, if an amino acid in a polypeptide is replaced by another amino acid from the same side chain family, the substitution is considered conservative. In some embodiments, amino acid strings can be conservatively replaced by strings that are structurally similar but have different order and / or composition of side chain family members.
[0136] As is known in the art, “sequence identity” between two polypeptides is determined by comparing the amino acid sequence of one polypeptide with the sequence of a second polypeptide. Similarly, “sequence identity” between two polynucleotides is determined by comparing the nucleotide sequence of one polynucleotide with the sequence of a second polynucleotide. The terms “identity %”, “identity %”, or similar terms are intended to specifically refer to the percentage of identical nucleotides or amino acids (if applicable) in the optimal alignment between the sequences to be compared. The percentage is purely statistical, and the differences between the two sequences may, but are not necessarily, randomly distributed across the entire length of the sequences to be compared. The comparison of two sequences is typically performed by comparing the sequences with respect to segments or “comparison windows” after the optimal alignment to identify local regions of the respective sequences. For example, the best alignment for comparison can be performed manually, or with the local homology algorithm of Smith and Waterman, 1981, Ads App. Math. 2, 482, with the local homology algorithm of Neddleman and Wunsch, 1970, J. Mol. Biol. 48, 443, with the similarity search algorithm of Pearson and Lipman, 1988, Proc. Natl Acad. Sci. USA 88, 2444, or with computer programs that use the algorithms (GAP, BESTFIT, FASTA, BLAST P, BLAST N, and TFASTA in the Wisconsin Genetics Software Installer (Genetics Computer Group, 575 Science Drive, Madison, Wisconsin)). In some embodiments, the percentage of identity between two sequences is determined using algorithms such as BLASTN or BLASTP, available on websites such as the United States National Center for Biotechnology Information (NCBI) (e.g., blast.ncbi.nlm.nih.gov / Blast.cgi?PAGE_TYPE=BlastSearch&BLAST_SPEC=blast2seq&LINK_LOC=align2seq). In some embodiments, the algorithm parameters used for the BLASTN algorithm on the NCBI website include: (i) an expected threshold set to 10; (ii) a word length set to 28; (iii) the maximum match within a query range set to 0; (iv) match / non-match scores set to 1 or -2; (v) a space cost set to linear; and (vi) a filter for the low-complexity region used.In some embodiments, the algorithm parameters used for the BLASTP algorithm on the NCBI website include: (i) an expected threshold set to 10; (ii) a word length set to 3; (iii) the maximum match within a query range set to 0; (iv) a matrix set to BLOSUM62; (v) a space cost set to Existence: 11 Extension: 1; and (vi) conditional combination score matrix adjustment. When discussed herein, methods and computer programs / software known in the art, such as, but not limited to, the BESTFIT program (Wisconsin Sequence Analysis Package, Unix Version 8, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wisconsin 53711), can be used to determine whether any particular polypeptide is at least about 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to another polypeptide. BESTFIT uses the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2:482-489 (1981) to find the optimal homology region between two sequences. When using BESTFIT or any other sequence alignment program to determine whether a particular sequence is, for example, 95% identical to a reference sequence according to this disclosure, parameters are set such that the percentage of identity is calculated over the full length of the reference polypeptide sequence and that homology vacancies are allowed to be at most 5% of the total number of amino acids in the reference sequence.
[0137] As used herein, alignment is used to identify “corresponding amino acids” or “equivalent amino acids” in VWF or FVIII protein sequences to maximize the identity or similarity between the first VWF or FVIII sequence and the second VWF or FVIII. The numbering used to identify equivalent amino acids in the second VWF or FVIII sequence is based on the numbering used to identify the corresponding amino acids in the first VWF or FVIII sequence.
[0138] As used herein, the term "insertion site" refers to a location in an FVIII polypeptide or a fragment, variant, or derivative thereof that is immediately downstream of a location where an extended half-life portion or a heterologous portion may be inserted. An "insertion site" is designated as a number corresponding to the amino acid at the insertion site in mature natural FVIII (SEQ ID NO: 8), immediately adjacent to the C-terminus of the insertion site. For example, the phrase "containing an ELNN polypeptide at an insertion site corresponding to amino acid 1656 of SEQ ID NO: 8" indicates that the heterologous portion is located between the two amino acids corresponding to amino acids 1656 and 1657 of SEQ ID NO: 8.
[0139] As used herein, the phrase "immediately downstream of an amino acid" refers to a position immediately adjacent to the terminal carboxyl group of an amino acid. For example, an insertion site immediately downstream of amino acid 745 corresponding to the mature wild-type FVIII protein (SEQ ID NO: 8) means that the insertion site is between amino acids 745 and 746 corresponding to the mature wild-type FVIII protein. Similarly, the phrase "immediately upstream of an amino acid" refers to a position immediately adjacent to the terminal amino group of an amino acid.
[0140] As used herein, the phrase “between two amino acids at the insertion site” refers to the location where the ELNN polypeptide or any other polypeptide is inserted between two adjacent amino acids. Therefore, the phrases “inserted downstream of the adjacent amino acid” and “inserted between two amino acids at the insertion site” are used synonymously with “inserted at the insertion site”.
[0141] As used herein with respect to the insertion of the ELNN peptide into FVIII, the terms “inserted,” “is inserted,” “inserted into,” or grammatically relevant terms refer to the position of the ELNN peptide in the chimeric protein relative to a similar position in native mature human FVIII. As used herein, the terms refer to the characteristics of the recombinant FVIII peptide relative to native mature human FVIII and do not indicate, imply, or infer any method or process for preparing the chimeric protein. For example, with respect to the chimeric protein provided herein, the phrase “the ELNN peptide is inserted downstream of residue 745 of the FVIII peptide” means that the chimeric protein comprises an ELNN peptide immediately downstream of an amino acid corresponding to amino acid 745 in native mature human FVIII, for example, defined by amino acids corresponding to amino acids 745 and 746 of native mature human FVIII (without the presence of amino acid 746 corresponding to native mature human FVIII), and does not imply a sequence or method of production for constructing the chimeric protein.
[0142] As used herein, the terms “ELNN polypeptide” and “ELNN” are synonymous and refer to an extended-length polypeptide having a substantially non-repeating sequence that is not naturally occurring, consisting primarily of small hydrophilic amino acids, and having a low degree or absence of secondary or tertiary structure under physiological conditions. When linked to a VWF protein or FVIII sequence of this disclosure to generate a chimeric polypeptide, ELNN can confer certain desired pharmacokinetic, physicochemical, and pharmaceutical properties. These desired properties include, but are not limited to, enhanced pharmacokinetic parameters and solubility characteristics. As used herein, the terms “ELNN polypeptide” and “ELNN” specifically exclude antibodies or antibody fragments, such as single-chain antibodies or Fc fragments of light or heavy chains. ELNN peptides are known in the art, and non-limiting descriptions and examples of ELNN peptides referred to as XTEN® peptides can be found in the following literature: Schellenberger et al., (2009) Nat Biotechnol 27(12):1186-90; Brandl et al., (2020) Journal of Controlled Release 327:186-197; and Radon et al., (2021) Advanced Functional Materials 31, 2101633 (pp. 1-33), the entire contents of each of which are incorporated herein by reference.
[0143] A “fusion” or “chimeric” protein comprises a first amino acid sequence linked to a second amino acid sequence, which is not naturally linked to the second amino acid sequence in nature. Amino acid sequences typically present in individual proteins can be aggregated in a fusion polypeptide, or amino acid sequences typically present in the same protein can be arranged in a new manner within a fusion polypeptide (e.g., a fusion of the factor VIII domain and the Ig Fc domain of this disclosure). Fusion proteins are produced, for example, by chemical synthesis or by generating and translating polynucleotides in which peptide regions are encoded in an ideal relationship. Chimeric proteins may also comprise a second amino acid sequence associated with the first amino acid sequence via a covalent non-peptide bond or a non-covalent bond.
[0144] Regarding sequences, as used herein, the term "link" means covalently or non-covalently joining a first amino acid sequence or nucleotide sequence to a second amino acid sequence or nucleotide sequence, respectively. The first amino acid or nucleotide sequence may be directly joined or juxtaposed with the second amino acid or nucleotide sequence, or alternatively, an insertion sequence may covalently join the first sequence to the second sequence. Depending on the context, the term "link" means not only the fusion of the first amino acid sequence and the second amino acid sequence at the C-terminus or N-terminus, but also the insertion of the complete first amino acid sequence (or the second amino acid sequence) into any two amino acids in the second amino acid sequence (or, respectively, the first amino acid sequence). In some embodiments, the first amino acid sequence may be linked to the second amino acid sequence via a peptide bond or a linker. The first nucleotide sequence may be linked to the second nucleotide sequence via a phosphodiester bond or a linker. The linker may be a peptide or polypeptide (for polypeptide chains), a nucleotide or nucleotide chain (for nucleotide chains), or any chemical part (for both polypeptide and polynucleotide chains). The term "link" may also be indicated by a hyphen (-).
[0145] Regarding two polypeptides, the term "association with" refers to one or more covalent or non-covalent bonds formed between the first polypeptide and the second polypeptide. In some embodiments, the term "association with" refers to a covalent, non-peptide, or non-covalent bond. This association can be indicated by a colon, i.e., (:). In some embodiments, it means a covalent bond other than a peptide bond. For example, the amino acid cysteine contains a thiol group, which can form a disulfide bond or disulfide bridge with the thiol group on the second cysteine residue. In most naturally occurring IgG molecules, the CH1 and CL regions are associated by disulfide bonds, and these two heavy chains are associated by two disulfide bonds at positions 239 and 242 (positions 226 or 229, EU numbering system) corresponding to positions using the Kabat numbering system. Examples of covalent bonds include, but are not limited to, peptide bonds, metallic bonds, hydrogen bonds, disulfide bonds, σ bonds, π bonds, δ bonds, glycosidic bonds, grasping hydrogen bonds, bent bonds, dipole bonds, feedback π bonds, double bonds, triple bonds, tetrabonds, pentabonds, hexabonds, conjugation, hyperconjugation, aromaticity, Haptor number, or antibonding. Non-limiting examples of non-covalent bonds include ionic bonds (e.g., cation-π bonds or salt bonds), metallic bonds, hydrogen bonds (e.g., dihydrogen bonds, molecular hydrogen complexes, low-barrier hydrogen bonds, or symmetric hydrogen bonds), van der Waals forces, London dispersion forces, mechanical bonds, halogen bonds, metalophilic interactions, intercalation, stacking, entropic forces, or chemical polarity. In some embodiments, one or more covalent bonds between a first amino acid chain and a second amino acid chain are two disulfide bonds. In some embodiments, one or more covalent bonds between a first amino acid chain and a second amino acid chain are two disulfide bonds between a first Fc moiety on the first amino acid chain and a second Fc moiety on the second amino acid chain, wherein the two disulfide bonds occur in the hinge regions of the two Fc moietyes.
[0146] In some embodiments, the polypeptide has an enzymatic cleavage site that is cleaved by an enzyme initiated during a coagulation cascade reaction, such that cleavage at such sites occurs at the site of clot formation. Exemplary such sites include, for example, those recognized by thrombin, factor XIa, or factor Xa. Other enzymatic cleavage sites are known in the art and described elsewhere herein. In constructs containing more than one processing or cleavage site, it should be understood that these sites may be the same or different. As used herein, the term “half-life” refers to the biological half-life of a specific polypeptide in vivo. Half-life can be expressed as the time required for half of the amount administered to an individual to be cleared from the circulation and / or other tissues of an animal. In some embodiments, when constructing a clearance curve for a given polypeptide as a function of time, the curve is typically biphasic, having a rapid α phase and a longer β phase. The α phase typically represents the equilibrium of the administered Fc polypeptide between the intravascular and extravascular spaces and depends in part on the size of the polypeptide. The β phase typically represents the catabolic metabolism of the polypeptide in the intravascular space. In some embodiments, FVIII and the chimeric protein containing FVIII are monophasic and therefore do not have an α phase, but only a single β phase. Therefore, in some embodiments, as used herein, the term half-life refers to the half-life of the peptide in the β phase. In humans, the typical β-phase half-life of human antibodies is 21 days. In some embodiments, half-life is expressed as the half-life of the terminal phase.
[0147] In some embodiments, the individual suffers from hemophilia A. In some embodiments, the hemophilia A is severe hemophilia A.
[0148] As used herein, “administer” or “administering” refers to the delivery of the composition (e.g., chimeric protein) described herein to an individual. The composition (e.g., chimeric protein) can be administered to an individual using methods known in the art. In particular, the composition can be administered intravenously, subcutaneously, intramuscularly, intradermally, or via any mucosal surface, such as orally, sublingually, buccally, nasally, rectally, vaginally, or via the lungs. In some embodiments, the administration is intravenous. In some embodiments, the administration is subcutaneous. In some embodiments, the administration is self-administered. In some embodiments, a parent administers the chimeric protein to a child. In some embodiments, the chimeric protein is administered to an individual by a healthcare practitioner (e.g., a physician, medical professional, or nurse).
[0149] As used herein, the term “dosage” refers to a single administration of the composition to an individual. A single dose may be administered at once, such as as a bolus, or over a period of time, such as via intravenous infusion. The term “multiple doses” means more than one dose, such as more than one administration.
[0150] When referring to the co-administration of more than one composition, a dose of composition A may be administered concurrently with a dose of composition B. Alternatively, a dose of composition A may be administered before or after a dose of composition B. In some embodiments, composition A and composition B are combined into a single formulation.
[0151] As used herein, the term “interval” or “dosage interval” refers to the amount of time elapsed between a first dose of composition A administered to an individual and a subsequent dose of the same composition. A dosing interval may refer to the time elapsed between a first dose and a second dose, or it may refer to the amount of time elapsed between multiple doses.
[0152] As used herein, the term “dosage frequency” refers to the number of doses administered at each specific dosing interval. For example, a dosing frequency may be described as once a week, once every two weeks, etc. Therefore, a 7-day dosing interval may also be described as a dosing interval of once every 7 days, once a week, or once a week.
[0153] As used herein, the term “prophylactic treatment” refers to a therapy administered for the treatment of hemophilia A, wherein such treatment aims to prevent or reduce the severity of one or more symptoms of hemophilia A, such as bleeding episodes (e.g., one or more spontaneous bleeding episodes) and / or joint damage. See Jimenez-Yuste et al., Blood Transfus. 12(3):314-19 (2014). To prevent or reduce the severity of such symptoms (e.g., bleeding episodes and progression of joint disease), patients with hemophilia A may receive regular infusions of clotting factors as part of a prophylactic treatment regimen. This prophylactic treatment is based on the observation that patients with clotting factors (e.g., FVIII) levels of 1% or higher experience fewer spontaneous bleeding episodes and have fewer hemophilia-related comorbidities compared to patients with severe hemophilia. See, for example, Coppola A. et al., Semin. Thromb. Hemost. 38(1): 79-94 (2012). Healthcare practitioners treating these hemophilia patients speculated that maintaining factor levels at around 1% through regular infusions might potentially reduce the risk of hemophilia symptoms, including bleeding episodes and joint damage. (See above.) Subsequent studies have confirmed these benefits in pediatric hemophilia patients receiving prophylactic treatment with clotting factors, making prophylactic treatment a target for patients with severe hemophilia. (See above.)
[0154] "Prophylactic" treatment can also refer to the preemptive administration of the compositions described herein (e.g., proteins such as chimeric proteins) to an individual to control, manage, prevent, or reduce the incidence or severity of one or more symptoms of hemophilia A (e.g., bleeding episodes). In some embodiments, prophylactic treatment using clotting factors (e.g., FVIII) is used to treat an individual with severe hemophilia A. In some embodiments, prophylactic treatment refers to the administration of the compositions disclosed herein to an individual in need to reduce the incidence of one or more symptoms of hemophilia A. Prophylactic treatment may include administration of multiple doses. The multiple doses used in prophylactic treatment are typically administered at specific dosing intervals. In some embodiments, the annual bleeding rate may be reduced to less than 10, less than 9, less than 8, less than 7, less than 6, less than 5, less than 4, less than 3, less than 2, or less than 1.
[0155] The terms “on-demand treatment” or “episodic treatment” refer to the administration of chimeric molecules “on demand” in response to symptoms of hemophilia A (e.g., a bleeding episode) or prior to activities that may cause bleeding. In some aspects, on-demand treatment may be administered to an individual at the onset of bleeding (e.g., after an injury) or when bleeding is anticipated (e.g., before surgery). In some aspects, on-demand treatment may be administered prior to activities that increase the risk of bleeding (e.g., contact sports). In some embodiments, on-demand treatment is administered as a single dose. In some embodiments, on-demand treatment is administered as a first dose, followed by one or more additional doses. When chimeric proteins are administered on demand, one or more additional doses may be administered at least about 12 hours, at least about 24 hours, at least about 36 hours, at least about 48 hours, at least about 60 hours, at least about 72 hours, at least about 84 hours, at least about 96 hours, at least about 108 hours, or at least about 120 hours after the first dose. However, it should be noted that the dosing intervals associated with on-demand treatment differ from those used for prophylactic treatment.
[0156] In some embodiments, the individual requiring a universal hemostatic agent is undergoing or about to undergo surgery. The chimeric protein of this disclosure can be administered before or after surgery. The chimeric protein of this disclosure can also be administered during or after surgery to control acute bleeding episodes. When the chimeric protein is administered before surgery, administration may be at least about 1 hour, at least about 2 hours, at least about 4 hours, at least about 8 hours, at least about 12 hours, at least about 24 hours, at least about 36 hours, at least about 48 hours, or at least about 72 hours prior to surgery. When the chimeric protein is administered after surgery, administration may be at least about 1 hour, at least about 2 hours, at least about 4 hours, at least about 8 hours, at least about 12 hours, at least about 24 hours, at least about 36 hours, at least about 48 hours, or at least about 72 hours post-surgery. Surgery may include, but is not limited to, liver transplantation, hepatectomy, dental surgery, or stem cell transplantation.
[0157] As used herein, “treat” means, for example, a reduction in the severity of a disease or condition; a reduction in the duration of a disease; an improvement in one or more symptoms associated with a disease or condition; providing a beneficial effect to an individual suffering from a disease or condition, but not necessarily curing the disease or condition; or preventing one or more symptoms associated with a disease or condition. In some embodiments, treatment includes maintaining an individual's trough level of FVIII at at least about 1 IU / dL, 2 IU / dL, 3 IU / dL, 4 IU / dL, 5 IU / dL, 6 IU / dL, 7 IU / dL, 8 IU / dL, 9 IU / dL, 10 IU / dL, 11 IU / dL, 12 IU / dL, 13 IU / dL, 14 IU / dL, 15 IU / dL, 16 IU / dL, 17 IU / dL, 18 IU / dL, 19 IU / dL, or 20 IU / dL by administering the chimeric protein of this disclosure. As used herein, a "trough level" in a patient with hemophilia A is a measurement of the lowest concentration achieved by factor therapy (e.g., FVIII therapy) prior to administering the next dose. In some embodiments, "treating" means maintaining a trough level of at least about 1 IU / dL for FVIII between dosing intervals. In some embodiments, "treating" means maintaining a trough level of at least about 3 IU / dL for FVIII between dosing intervals. In some embodiments, "treating" means maintaining a trough level of at least about 5 IU / dL for FVIII between dosing intervals. In some embodiments, "treating" means maintaining the FVIII trough level between about 1 IU / dL and about 20 IU / dL, about 2 IU / dL and about 20 IU / dL, about 3 IU / dL and about 20 IU / dL, about 4 IU / dL and about 20 IU / dL, about 5 IU / dL and about 20 IU / dL, about 6 IU / dL and about 20 IU / dL, about 7 IU / dL and about 20 IU / dL, about 8 IU / dL and about 20 IU / dL, about 9 IU / dL and about 20 IU / dL, or about 10 IU / dL and about 20 IU / dL.
[0158] In some embodiments, treating the disease includes maintaining an individual's FVIII activity at a level comparable to at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% of the FVIII activity of a non-hemophilic individual between doses. In some embodiments, treating means maintaining an FVIII activity level of at least about 1% between doses. In some embodiments, treating means maintaining an FVIII activity level of at least about 2% between doses. In some embodiments, treating means maintaining an FVIII activity level of at least about 3% between doses. In some embodiments, treating means maintaining an FVIII activity level of at least about 4% between doses. In some embodiments, treating means maintaining an FVIII activity level of at least about 5% between doses. In some embodiments, "treating" means maintaining an FVIII activity level of at least about 6% between dosing intervals. In some embodiments, "treating" means maintaining an FVIII activity level of at least about 7% between dosing intervals. In some embodiments, "treating" means maintaining an FVIII activity level of at least about 8% between dosing intervals. In some embodiments, "treating" means maintaining an FVIII activity level of at least about 9% between dosing intervals. In some embodiments, "treating" means maintaining an FVIII activity level of at least about 10% between dosing intervals. In some embodiments, the minimum trough level required for treatment can be measured by one or more known methods (e.g., activated partial thromboplastin time (aPTT) assays or chromogenic assays well known in the art) and can be adjusted (increased or decreased) for each individual. Non-limiting examples of assays for measuring trough levels are disclosed in U.S. Application Publication No. 20190375822, which is incorporated herein by reference in its entirety. II. Chimeric Proteins
[0159] In one aspect, this disclosure relates to pharmaceutical compositions comprising a chimeric protein or protein comprising: a first polypeptide chain comprising a factor VIII (“FVIII”) protein or a portion thereof and a first immunoglobulin (“Ig”) constant region or a portion thereof, and a second polypeptide chain comprising a von Willebrand factor (“VWF”) protein and a second Ig constant region or a portion thereof. In some embodiments, the chimeric protein comprises (i) an FVIII protein comprising an FVIII polypeptide, an ELNN polypeptide inserted into a B domain of the FVIII polypeptide, and a first Fc region; and (ii) a VWF protein comprising a VWF fragment, a second ELNN sequence, an a2 linker, and a second Fc region. In some embodiments, the chimeric protein disclosed herein is an FVIII-ELNN-Fc / D'D3-ELNN-Fc heterodimer. Non-limiting examples of chimeric proteins that may be used in various embodiments are described in U.S. Patent Nos. 10,138,291 and 11,192,936 B2, the entire contents of each of which are incorporated herein by reference.
[0160] In some embodiments, the chimeric protein is efanesoctocogum α. efanesoctocogum α, also known as “BIVV001”, “efanesoctocogum alfa”, and “rFVIIIFc-VWF-XTEN”, is described in Chhabra et al. Blood 135(17): 1484-1496 (2020), the entire contents of which are hereby incorporated by reference. A schematic diagram of efanesoctocogum α as an exemplary FVIII-ELNN-Fc / D'D3-ELNN-Fc heterodimer is presented in Figure 1.
[0161] Evans thrombin α is a large protein (over 300 kDa) comprising multiple moieties associated by covalent and non-covalent interactions on each of two polypeptide chains. The protein is prone to aggregation under certain conditions, and unless an excipient such as L-arginine is chosen and present in an amount sufficient to reduce aggregation, the protein may degrade the stability of the formulation. For example, aggregation can be reduced by adding a high level of L-arginine (e.g., about 250 mM).
[0162] Further information regarding Evansin α can be found in International Nonproprietary Names for Pharmaceutical Substances (INN) WHO Drug Information, 2019, Vol. 33, No. 4, pp. 828-30. In some embodiments, the chimeric protein is an FVIII-ELNN-Fc / D'D3-ELNN-Fc heterodimer comprising (i) a first polypeptide containing the amino acid sequence of SEQ ID NO: 1 and (ii) a second polypeptide containing the amino acid sequence of SEQ ID NO: 2. In some embodiments, the chimeric protein comprises (i) the first polypeptide and (ii) the second polypeptide covalently linked via one or more disulfide bonds (e.g., two disulfide bonds). In some embodiments, the chimeric protein comprises an FVIII protein encoded by the nucleic acid sequence of SEQ ID NO: 4. In some embodiments, the chimeric protein comprises a VWF protein encoded by the nucleic acid sequence of SEQ ID NO: 6. In some embodiments, the activity of Evansin α is at least 1600 IU / mg. In some embodiments, the activity of eparginine α is at least 1700 IU / mg. In some embodiments, the activity of eparginine α is at least 1800 IU / mg. In some embodiments, the activity of eparginine α is at least 1900 IU / mg. In some embodiments, the activity of eparginine α is from 1600 IU / mg to 2000 IU / mg.
[0163] In some embodiments, the chimeric protein comprises an FVIII protein containing the amino acid sequence of SEQ ID NO: 1. In some embodiments, the chimeric protein comprises an FVIII protein containing one or more disulfide bridges at one or more of the following positions: residues 153-179, 248-329, 528-554, 630-711, 1220-1246, 1287-1291, 1409-1557, 1562-1714, 1761-1821 and / or 1867-1925 of SEQ ID NO: 1. In some embodiments, the chimeric protein comprises an FVIII protein containing one or more disulfide bridges at each of the following positions: residues 153-179, 248-329, 528-554, 630-711, 1220-1246, 1287-1291, 1409-1557, 1562-1714, 1761-1821, and 1867-1925 of SEQ ID NO: 1. In some embodiments, the chimeric protein comprises an FVIII protein containing one or more Cys-SH residues at residues 310, 692, and / or 1388 of SEQ ID NO: 1. In some embodiments, the chimeric protein comprises an FVIII protein containing Cys-SH residues at each of residues 310, 692, and / or 1388 of SEQ ID NO: 1.
[0164] In some embodiments, the chimeric protein comprises an FVIII protein containing one or more N-glycosylation sites at residues N41, N239, N1198, N1506 and / or N1797 of SEQ ID NO: 1. In some embodiments, the chimeric protein comprises an FVIII protein containing one or more O-glycosylation sites at residues 746-1036 of SEQ ID NO: 1 and / or Ser and Thr residues in the linker peptide. In some embodiments, the chimeric protein comprises an FVIII protein containing one or more Tyr sulfation sites at residues 346, 718, 719, 723, 729, 1052 and / or 1068 of SEQ ID NO: 1.
[0165] In some embodiments, the chimeric protein comprises a VWF protein containing the amino acid sequence of SEQ ID NO: 2. In some embodiments, the chimeric protein comprises a VWF protein containing one or more disulfide bridges at one or more of the following positions: residues 4-45, 13-41, 25-36, 29-64, 47-58, 66-88, 83-100, 86-95, 104-233, 126-268, 135-230, 151-158, 283-326, 297-321, 308-348, 328-334, 338-363, 367-410, 386-406, 390-402, 394-433, 414-427, 436-464, 459-474, 462-471, 698-758 and / or 804-862 of SEQ ID NO: 2. In some embodiments, the chimeric protein comprises a VWF protein containing one or more disulfide bridges at each of the following positions: residues 4-45, 13-41, 25-36, 29-64, 47-58, 66-88, 83-100, 86-95, 104-233, 126-268, 135-230, 151-158, 283-326, 297-321, 308-348, 328-334, 338-363, 367-410, 386-406, 390-402, 394-433, 414-427, 436-464, 459-474, 462-471, 698-758 and / or 804-862 of SEQ ID NO: 2.
[0166] In some embodiments, the chimeric protein comprises a VWF protein containing one or more N-glycosylation sites at residues N94, N384, and N734 of SEQ ID NO: 2. In some embodiments, the chimeric protein comprises a VWF protein containing one or more O-glycosylation sites at residues 478-625 of SEQ ID NO: 2 and / or Ser and Thr residues in the linker peptide. In some embodiments, the chimeric protein comprises a VWF protein containing one or more Tyr sulfation sites at residues 632, 633, 637, and / or 643 of SEQ ID NO: 2. In some embodiments, the VWF protein comprises a VWF fragment containing the D1, D2, D', and / or D3 domains of VWF. In one embodiment, the VWF fragment comprises the D1D2 region of VWF containing the amino acid sequence of SEQ ID NO: 20. In some embodiments, the VWF protein further comprises a VWF signal peptide sequence. In one embodiment, the VWF signal peptide comprises the amino acid sequence of SEQ ID NO: 19. In a specific embodiment, the VWF protein comprises the VWF signal peptide containing the amino acid sequence of SEQ ID NO: 19, the D1D2 region of VWF containing the amino acid sequence of SEQ ID NO: 20, the D' domain of VWF containing the amino acid sequence of SEQ ID NO: 21, the D3 domain of VWF containing the amino acid sequence of SEQ ID NO: 22, the ELNN polypeptide sequence containing the amino acid sequence of SEQ ID NO: 14 (AE144_5A), the a2 linker containing the amino acid sequence of SEQ ID NO: 15, and / or the Fc region containing the amino acid sequence of SEQ ID NO: 23.
[0167] In some embodiments, the chimeric protein of this disclosure comprises: (i) an FVIII protein containing an FVIII polypeptide, a first ELNN polypeptide sequence, and a first Fc region; and (ii) a D' domain and a D3 domain of a VWF, a second ELNN polypeptide sequence, an a2 linker of FVIII, and a VWF fragment of the second Fc region; wherein: the FVIII protein has deletions of amino acids 746 to 1648 corresponding to mature FVIII; the first ELNN polypeptide sequence is inserted into the FVIII polypeptide, immediately downstream of amino acid 745 corresponding to mature FVIII; the first ELNN polypeptide sequence comprises an amino acid sequence corresponding to AE288 (SEQ ID NO: 9) An amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity; the first Fc region is fused to the C-terminus of the FVIII polypeptide; the second ELNN polypeptide sequence is fused to the C-terminus of the VWF fragment; the second ELNN polypeptide sequence comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity with the amino acid sequence of AE144_5A (SEQ ID NO: 14); the a2 linker is fused to the C-terminus of the ELNN polypeptide; the a2 linker ... The amino acid sequence of 15 has an amino acid sequence with at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity; the second Fc region is fused to the C-terminus of the a2 linker; and the first Fc region is covalently connected to the second Fc region via disulfide bonds (e.g., two disulfide bonds).
[0168] In some embodiments, the chimeric protein of this disclosure comprises two polypeptide sequences: a first polypeptide sequence comprising at least about 80%, 90%, 95%, or 100% of the amino acid sequence shown in SEQ ID NO: 1; and a second polypeptide sequence comprising a VWF fragment containing the D' domain and the D3 domain of the VWF, and an Fc region. In some embodiments, the chimeric protein of this disclosure comprises two polypeptide sequences: a first polypeptide sequence comprising an FVIII polypeptide and an Fc region; and a second polypeptide sequence comprising at least about 80%, 90%, 95%, or 100% of the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the chimeric protein of this disclosure comprises two polypeptide sequences: a first polypeptide sequence comprising at least about 80%, 90%, 95%, or 100% of the amino acid sequence shown in SEQ ID NO: 1, and a second polypeptide sequence comprising at least about 80%, 90%, 95%, or 100% of the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the chimeric protein of this disclosure comprises two polypeptide sequences: a first polypeptide sequence comprising the amino acid sequence shown in SEQ ID NO: 7, and a second polypeptide sequence comprising the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the chimeric protein of this disclosure comprises two polypeptide sequences: a first polypeptide sequence comprising the amino acid sequence shown in SEQ ID NO: 1, and a second polypeptide sequence comprising the amino acid sequence shown in SEQ ID NO: 2, wherein the first polypeptide sequence and the second polypeptide sequence are linked to each other by disulfide bonds. In some embodiments, the chimeric protein of this disclosure comprises two polypeptide sequences: a first polypeptide sequence comprising the amino acid sequence shown in SEQ ID NO: 1 and a second polypeptide sequence comprising the amino acid sequence shown in SEQ ID NO: 2, wherein the first polypeptide sequence and the second polypeptide sequence are linked together by two disulfide bonds. In some embodiments, the chimeric protein of this disclosure comprises two polypeptide sequences: a first polypeptide sequence comprising the amino acid sequence shown in SEQ ID NO: 1 and a second polypeptide sequence comprising the amino acid sequence shown in SEQ ID NO: 2, wherein the first polypeptide sequence comprises a first Fc portion, wherein the second polypeptide sequence comprises a second Fc portion, wherein the first Fc portion and the second Fc portion are linked together by two disulfide bonds in a hinge region.
[0169] In some embodiments, the chimeric protein of this disclosure comprises: an FVIII protein containing at least about 80%, 90%, 95%, or 100% of the same amino acid sequence as SEQ ID NO: 7, SEQ ID NO: 3, or SEQ ID NO: 1; and a VWF protein containing at least about 80%, 90%, 95%, or 100% of the same amino acid sequence as SEQ ID NO: 2 or SEQ ID NO: 5.
[0170] In some embodiments, the chimeric protein of this disclosure comprises: (i) an FVIII protein comprising a first FVIII polypeptide fragment containing the amino acid sequence of SEQ ID NO: 17; a first ELNN polypeptide sequence containing the amino acid sequence of SEQ ID NO: 9 (AE288); a second FVIII polypeptide fragment containing the amino acid sequence of SEQ ID NO: 18; and a first Fc region containing the amino acid sequence of SEQ ID NO: 23; and (ii) a VWF protein comprising: a D' domain of VWF containing the amino acid sequence of SEQ ID NO: 21; a D3 domain of VWF containing the amino acid sequence of SEQ ID NO: 22; a second ELNN polypeptide sequence containing the amino acid sequence of SEQ ID NO: 14 (AE144_5A); an a2 linker containing the amino acid sequence of SEQ ID NO: 15; and a region containing the amino acid sequence of SEQ ID NO: 17. The second Fc region of the amino acid sequence 23, wherein the first Fc region is covalently connected to the second Fc region by disulfide bonds (e.g., two disulfide bonds).
[0171] In some embodiments, the chimeric protein of this disclosure comprises an FVIII protein comprising an FVIII polypeptide, a first ELNN polypeptide sequence, and a first Fc region; and a VWF protein comprising a D' domain of VWF, a D3 domain of VWF, a second ELNN polypeptide sequence, an a2 linker of FVIII, and a second Fc region, wherein the FVIII polypeptide comprises the amino acid sequence of SEQ ID NO: 17, the first ELNN polypeptide sequence comprises the amino acid sequence of AE288 (SEQ ID NO: 9) fused to the C-terminus of SEQ ID NO: 17, the FVIII polypeptide further comprises the amino acid sequence of SEQ ID NO: 18, the first Fc region comprises the amino acid sequence of SEQ ID NO: 23 and fused to the C-terminus of SEQ ID NO: 18; the D' domain of VWF comprises the amino acid sequence of SEQ ID NO: 21; the D3 domain of VWF comprises the amino acid sequence of SEQ ID NO: 23; The first Fc region comprises the amino acid sequence of SEQ ID NO: 21, wherein the second ELNN polypeptide sequence contains the amino acid sequence of AE144_5A (SEQ ID NO: 14) and is fused to the C-terminus of the D3 domain of the VWF; the a2 linker contains the amino acid sequence of SEQ ID NO: 15 and is fused to the C-terminus of the second ELNN polypeptide sequence; the second Fc region contains the amino acid sequence of SEQ ID NO: 23 and is fused to the C-terminus of the a2 linker; and wherein the first Fc region is covalently linked to the second Fc region by a disulfide bond.
[0172] In some embodiments, the chimeric protein of this disclosure comprises an FVIII protein, the FVIII protein comprising an FVIII signal peptide containing the amino acid sequence of SEQ ID NO: 16. In some embodiments, the chimeric protein comprises a VWF protein, the VWF protein comprising a VWF signal peptide containing the amino acid sequence of SEQ ID NO: 19. In some embodiments, the chimeric protein comprises a VWF protein, the VWF protein comprising a D1D2 domain of VWF containing the amino acid sequence of SEQ ID NO: 20.
[0173] In some embodiments, the chimeric protein comprises a first polypeptide containing the amino acid sequence of SEQ ID NO: 3 and a second polypeptide containing the amino acid sequence of SEQ ID NO: 5. In some embodiments, the chimeric protein comprises a first polypeptide containing the amino acid sequence of SEQ ID NO: 7 and a second polypeptide containing the amino acid sequence of SEQ ID NO: 2. In some embodiments, the chimeric protein comprises a first polypeptide containing the amino acid sequence of SEQ ID NO: 1 and a second polypeptide containing the amino acid sequence of SEQ ID NO: 2.
[0174] In some embodiments, the chimeric protein comprises one or more disulfide bridges between the first polypeptide and the second polypeptide. In some embodiments, the chimeric protein comprises two disulfide bridges between the first polypeptide and the second polypeptide. In some embodiments, the chimeric protein comprises a first polypeptide containing the amino acid sequence of SEQ ID NO: 1 and a second polypeptide containing the amino acid sequence of SEQ ID NO: 2, wherein the chimeric protein comprises a disulfide bridge between residue 1726 of SEQ ID NO: 1 and residue 663 of SEQ ID NO: 2 and a disulfide bridge between residue 1729 of SEQ ID NO: 1 and residue 666 of SEQ ID NO: 2. IV. Pharmaceutical Composition
[0175] In one aspect, this disclosure relates to pharmaceutical compositions of chimeric proteins, said pharmaceutical compositions being formulated to improve protein stability. In some embodiments, the disclosed pharmaceutical compositions exhibit improved stability based on analysis of visual inspection, protein concentration, pH stability, formation of high molecular weight substances (HMWS), and / or changes in turbidity. These properties of stability can be analyzed using conventional techniques, including size exclusion chromatography (SEC), reversed-phase high performance liquid chromatography (RP-HPLC), etc.
[0176] The pharmaceutical compositions disclosed herein comprise a specified amount of chimeric protein. In some embodiments, the concentration of the chimeric protein in the pharmaceutical composition is from about 0.8 to about 1.2 mg / mL. In some embodiments, the concentration of the chimeric protein in the pharmaceutical composition is about 0.8 mg / mL. In some embodiments, the concentration of the chimeric protein in the pharmaceutical composition is about 0.9 mg / mL. In some embodiments, the concentration of the chimeric protein in the pharmaceutical composition is about 1.0 mg / mL. In some embodiments, the concentration of the chimeric protein in the pharmaceutical composition is about 1.1 mg / mL. In some embodiments, the concentration of the chimeric protein in the pharmaceutical composition is about 1.2 mg / mL.
[0177] In some embodiments, the pharmaceutical composition comprises about 75 IU / mL to about 2,000 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 75 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 100 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 150 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 200 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 250 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 300 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 350 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 400 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 450 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 500 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 550 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 600 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 650 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 700 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 750 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 800 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 850 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 900 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 950 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1000 IU / mL of chimeric protein.
[0178] In some embodiments, the pharmaceutical composition comprises about 1100 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1150 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1200 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1250 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1300 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1350 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1400 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1450 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1500 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1550 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1600 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1650 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1700 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1750 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1800 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1850 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1900 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1950 IU / mL of chimeric protein. In some embodiments, the pharmaceutical composition comprises about 2000 IU / mL of chimeric protein.
[0179] Pharmaceutical compositions containing the chimeric proteins of this disclosure also contain suitable pharmaceutically acceptable carriers. For example, the compositions may contain excipients and / or adjuvants that provide enhanced stability to the chimeric protein or facilitate the processing of the active compound into a formulation designed for delivery to the site of action.
[0180] In one aspect, this document discloses pharmaceutical compositions comprising a specified amount of a chimeric protein together with excipients as disclosed. The pharmaceutical compositions disclosed herein comprise these excipients in various concentrations disclosed herein, and the concentrations can be expressed in various ways. For example, the concentration of a given excipient can be expressed as a molar concentration (e.g., M or mM), a weight / volume percentage (e.g., g / 100 ml diluent), or a milligram / milliliter (mg / ml). The pharmaceutical compositions provided herein may contain a specified amount of various excipients at a level of precision ranging from approximately, for example, only expressed to one significant figure (e.g., about 0.1% (w / v)) to more precisely, for example, to 2, 3, 4, 5, or 6 significant figures (e.g., about 3.88 mg / ml, accurate to three significant figures). The necessary level of precision may vary depending on, for example, the requirements of a given regulatory agency or the method of manufacture.
[0181] The pharmaceutical compositions disclosed herein may include stabilizers.
[0182] In some embodiments, the pharmaceutical compositions disclosed herein include a specified amount or concentration of sucrose.
[0183] In some embodiments, the pharmaceutical composition comprises 4.5% (w / v) to 8% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 5% (w / v) to about 7.5% (w / v) sucrose.
[0184] In some embodiments, the pharmaceutical composition comprises about 4.5% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 4.6% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 4.7% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 4.8% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 4.9% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 5.0% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 5.1% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 5.2% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 5.3% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 5.4% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 5.5% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 5.6% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 5.7% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 5.8% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 5.9% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6.0% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6.1% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6.2% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6.3% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6.4% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6.5% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6.6% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6.7% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6.8% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6.9% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 7.0% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 7.1% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 7.2% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 7.3% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 7.4% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 7.5% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 7.6% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 7.7% (w / v) sucrose.In some embodiments, the pharmaceutical composition comprises about 7.8% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 7.9% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 8% (w / v) sucrose.
[0185] In some embodiments, the pharmaceutical composition comprises 168.3 mg of sucrose. In some embodiments, the pharmaceutical composition comprises about 168.3 mg of sucrose. In some embodiments, the amount of sucrose can vary up to 10% of a specified amount. In some embodiments, the specific amount of sucrose is 168.3 mg. In some embodiments, the amount of sucrose can vary up to 5% of a specific amount. In some embodiments, the specific amount of sucrose is 168.3 mg. In some embodiments, the amount of sucrose can vary up to 1% of a specific amount. In some embodiments, the specific amount of sucrose is 168.3 mg.
[0186] In some embodiments, the pharmaceutical composition comprises 1% (w / v) to 4% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.5% (w / v) to about 2.5% (w / v) sucrose.
[0187] In some embodiments, the pharmaceutical composition comprises about 1.0% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.1% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.2% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.3% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.4% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.5% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.6% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.7% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.8% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.9% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 2.0% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 2.1% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 2.2% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 2.3% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 2.4% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 2.5% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 2.6% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 2.7% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 2.8% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 2.9% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 3.0% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 3.1% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 3.2% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 3.3% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 3.4% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 3.5% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 3.6% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 3.7% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 3.8% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 3.9% (w / v) sucrose. In some embodiments, the pharmaceutical composition comprises about 4.0% (w / v) sucrose.
[0188] In some embodiments, the pharmaceutical composition comprises 67.34 mg of sucrose. In some embodiments, the pharmaceutical composition comprises about 67.34 mg of sucrose. In some embodiments, the amount of sucrose can vary up to 10% of a specified amount. In some embodiments, the specific amount of sucrose is 67.34 mg. In some embodiments, the amount of sucrose can vary up to 5% of a specific amount. In some embodiments, the specific amount of sucrose is 67.34 mg. In some embodiments, the amount of sucrose can vary up to 1% of a specific amount. In some embodiments, the specific amount of sucrose is 67.34 mg.
[0189] The pharmaceutical compositions disclosed herein may include buffer solutions. In some embodiments, the pharmaceutical compositions disclosed herein include a specified amount or concentration of histidine. In some embodiments, the histidine included in the pharmaceutical composition is L-histidine. In some embodiments, the pharmaceutical composition contains about 5 mM to about 15 mM of histidine.
[0190] In some embodiments, the pharmaceutical composition comprises about 5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 5.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 6 mM histidine. In some embodiments, the pharmaceutical composition comprises about 6.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 7 mM histidine. In some embodiments, the pharmaceutical composition comprises about 7.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 8 mM histidine. In some embodiments, the pharmaceutical composition comprises about 8.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 9 mM histidine. In some embodiments, the pharmaceutical composition comprises about 9.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 10 mM histidine. In some embodiments, the pharmaceutical composition comprises about 10.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 11 mM histidine. In some embodiments, the pharmaceutical composition comprises about 11.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 12 mM histidine. In some embodiments, the pharmaceutical composition comprises about 12.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 13 mM histidine. In some embodiments, the pharmaceutical composition comprises about 13.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 14 mM histidine. In some embodiments, the pharmaceutical composition comprises about 14.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 15 mM histidine. In some embodiments, the histidine is L-histidine.
[0191] In some embodiments, the pharmaceutical compositions disclosed herein include a specified amount or concentration of arginine. In some embodiments, the pharmaceutical composition comprises arginine salt (HCl). In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises L-arginine-HCl.
[0192] In some embodiments, the pharmaceutical composition comprises at least 150 mM arginine. In some embodiments, the pharmaceutical composition comprises at least 200 mM arginine. In some embodiments, the pharmaceutical composition comprises at least 250 mM arginine. In some embodiments, the pharmaceutical composition comprises about 150 mM to about 300 mM arginine.
[0193] In some embodiments, the pharmaceutical composition comprises about 200 mM to about 300 mM arginine.
[0194] In some embodiments, the pharmaceutical composition comprises about 150 mM arginine. In some embodiments, the pharmaceutical composition comprises about 160 mM arginine. In some embodiments, the pharmaceutical composition comprises about 170 mM arginine. In some embodiments, the pharmaceutical composition comprises about 180 mM arginine. In some embodiments, the pharmaceutical composition comprises about 190 mM arginine. In some embodiments, the pharmaceutical composition comprises about 200 mM arginine. In some embodiments, the pharmaceutical composition comprises about 210 mM arginine. In some embodiments, the pharmaceutical composition comprises about 220 mM arginine. In some embodiments, the pharmaceutical composition comprises about 230 mM arginine. In some embodiments, the pharmaceutical composition comprises about 240 mM arginine. In some embodiments, the pharmaceutical composition comprises about 250 mM arginine. In some embodiments, the pharmaceutical composition comprises about 260 mM arginine. In some embodiments, the pharmaceutical composition comprises about 270 mM arginine. In some embodiments, the pharmaceutical composition comprises about 280 mM arginine. In some embodiments, the pharmaceutical composition comprises about 290 mM arginine. In some embodiments, the pharmaceutical composition comprises about 300 mM arginine. In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises L-arginine-HCl.
[0195] The pharmaceutical compositions disclosed herein may include fillers. In some embodiments, the pharmaceutical compositions disclosed herein include a specified amount or concentration of calcium chloride (CaCl2). In some embodiments, the composition comprises CaCl2●2H2O, CaCl2 (anhydrous), CaCl2●4H2O, or CaCl2●6H2O. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition comprises about 2.5 mM to about 10 mM calcium chloride. In some embodiments, the composition comprises calcium chloride dihydrate.
[0196] In some embodiments, the pharmaceutical composition comprises about 2.5 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 3 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 3.5 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 4 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 4.5 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 5 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 5.5 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 6 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 6.5 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 7 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 7.5 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 8 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 8.5 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 9 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 9.5 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 10 mM calcium chloride. In some embodiments, the composition comprises calcium chloride dihydrate.
[0197] In some embodiments, the pharmaceutical compositions disclosed herein do not include fillers other than calcium chloride. In some embodiments, calcium chloride is the only filler. In some embodiments, the pharmaceutical composition contains less than 8.8 mg / mL sodium chloride (NaCl). In some embodiments, the pharmaceutical composition is substantially free of sodium chloride. In some embodiments, the pharmaceutical composition is free of sodium chloride.
[0198] In some embodiments, the pharmaceutical compositions disclosed herein include a specified amount or concentration of polysorbate 20 (PS20) or polysorbate 80 (PS80). In some embodiments, the pharmaceutical composition comprises about 0.008% (w / v) to about 0.1% (w / v) PS80 or PS20. In some embodiments, the pharmaceutical composition comprises at least about 0.03% PS20 or PS80. In some embodiments, the pharmaceutical composition comprises about 0.05% PS20 or PS80. In some embodiments, the pharmaceutical composition comprises PS20. In some embodiments, the pharmaceutical composition comprises PS80.
[0199] In some embodiments, the pharmaceutical composition comprises about 0.008% (w / v) polysorbate 20. In some embodiments, the pharmaceutical composition comprises about 0.01% (w / v) polysorbate 20. In some embodiments, the pharmaceutical composition comprises about 0.02% (w / v) polysorbate 20. In some embodiments, the pharmaceutical composition comprises about 0.03% (w / v) polysorbate 20. In some embodiments, the pharmaceutical composition comprises about 0.04% (w / v) polysorbate 20. In some embodiments, the pharmaceutical composition comprises about 0.05% (w / v) polysorbate 20. In some embodiments, the pharmaceutical composition comprises about 0.06% (w / v) polysorbate 20. In some embodiments, the pharmaceutical composition comprises about 0.07% (w / v) polysorbate 20. In some embodiments, the pharmaceutical composition comprises about 0.08% (w / v) polysorbate 20. In some embodiments, the pharmaceutical composition comprises about 0.09% (w / v) polysorbate 20. In some embodiments, the pharmaceutical composition comprises about 0.1% (w / v) polysorbate 20.
[0200] In some embodiments, the pharmaceutical composition comprises about 0.008% (w / v) polysorbate 80. In some embodiments, the pharmaceutical composition comprises about 0.01% (w / v) polysorbate 80. In some embodiments, the pharmaceutical composition comprises about 0.02% (w / v) polysorbate 80. In some embodiments, the pharmaceutical composition comprises about 0.03% (w / v) polysorbate 80. In some embodiments, the pharmaceutical composition comprises about 0.04% (w / v) polysorbate 80. In some embodiments, the pharmaceutical composition comprises about 0.05% (w / v) polysorbate 80. In some embodiments, the pharmaceutical composition comprises about 0.06% (w / v) polysorbate 80. In some embodiments, the pharmaceutical composition comprises about 0.07% (w / v) polysorbate 80. In some embodiments, the pharmaceutical composition comprises about 0.08% (w / v) polysorbate 80. In some embodiments, the pharmaceutical composition comprises about 0.09% (w / v) polysorbate 80. In some embodiments, the pharmaceutical composition comprises about 0.1% (w / v) polysorbate 80.
[0201] In some embodiments, the pharmaceutical composition is a pre-lyophilized solution. In some embodiments, the pre-lyophilized solution does not contain NaCl. In some embodiments, the pre-lyophilized solution does not contain NaOH. In some embodiments, the pre-lyophilized solution does not contain sodium ions.
[0202] In some embodiments, the pharmaceutical composition comprises (a) about 1% (w / v) to about 4% (w / v) sucrose; (b) about 5 mM to about 15 mM histidine; (c) about 150 mM to about 300 mM arginine; (d) about 2.5 mM to about 10 mM calcium chloride; and (e) about 0.008% (w / v) to about 0.1% (w / v) polysorbate 20 or polysorbate 80.
[0203] In some embodiments, the pharmaceutical composition comprises (a) about 1% (w / v) to about 4% (w / v) sucrose; (b) about 5 mM to about 15 mM histidine; (c) about 200 mM to about 300 mM arginine; (d) about 2.5 mM to about 10 mM calcium chloride; and (e) about 0.008% (w / v) to about 0.1% (w / v) polysorbate 20 or polysorbate 80. In some embodiments, the composition comprises polysorbate 80. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0204] In some embodiments, the pharmaceutical composition comprises (a) 2% (w / v) to 3% (w / v) sucrose; (b) 7.5 mM to 12.5 mM histidine; (c) 225 mM to about 300 mM arginine; (d) 5 mM to 6 mM calcium chloride; and (e) 0.01% (w / v) to about 0.075% (w / v) polysorbate 20 or polysorbate 80. In some embodiments, the composition comprises polysorbate 80. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises 225 mM to about 300 mM L-arginine-HCl. In some embodiments, the composition comprises 5 mM to 6 mM calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0205] In some embodiments, the pharmaceutical composition comprises (a) 2% (w / v) to 3% (w / v) sucrose; (b) 7.5 mM to 12.5 mM L-histidine; (c) 225 mM to about 300 mM L-arginine; (d) 5 mM to 6 mM calcium chloride; and (e) 0.01% (w / v) to about 0.075% (w / v) polysorbate 80.
[0206] In some embodiments, the pharmaceutical composition comprises (a) 2% (w / v) to 3% (w / v) sucrose; (b) 7.5 mM to 12.5 mM L-histidine; (c) 225 mM to about 300 mM L-arginine-HCl; (d) 5 mM to 6 mM calcium chloride; and (e) 0.01% (w / v) to about 0.075% (w / v) polysorbate 80.
[0207] In some embodiments, the pharmaceutical composition comprises (a) 2% (w / v) to 3% (w / v) sucrose; (b) 7.5 mM to 12.5 mM L-histidine; (c) 225 mM to about 300 mM L-arginine-HCl; (d) 5 mM to 6 mM calcium chloride dihydrate; and (e) 0.01% (w / v) to about 0.075% (w / v) polysorbate 80.
[0208] In some embodiments, the pharmaceutical composition comprises: (a) about 2.25% (w / v) sucrose; (b) about 11.2 mM L-histidine; (c) about 280.58 mM L-arginine-HCl; (d) about 5.61 mM calcium chloride dihydrate; and (e) 0.056% (w / v) polysorbate 80.
[0209] In some embodiments, the pharmaceutical composition comprises: (a) about 2.25% (w / v) sucrose; (b) about 11.2 mM L-histidine; (c) about 280.58 mM L-arginine; (d) about 5.61 mM calcium chloride; and (e) about 0.056% (w / v) polysorbate 80.
[0210] In some embodiments, the pharmaceutical composition comprises: (a) 2.25% (w / v) sucrose; (b) 11.2 mM L-histidine; (c) 280.58 mM L-arginine-HCl; (d) about 5.61 mM calcium chloride dihydrate; and (e) 0.056% (w / v) polysorbate 80.
[0211] In some embodiments, the pharmaceutical composition comprises: (a) 2.25% (w / v) sucrose; (b) 11.2 mM L-histidine; (c) 280.58 mM L-arginine; (d) 5.61 mM calcium chloride; and (e) 0.056% (w / v) polysorbate 80.
[0212] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 2.25% (w / v) sucrose; (b) about 11.2 mM L-histidine; (c) about 280.58 mM L-arginine-HCl; (d) about 5.61 mM calcium chloride dihydrate; and (e) 0.056% (w / v) polysorbate 80.
[0213] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 2.25% (w / v) sucrose; (b) about 11.2 mM L-histidine; (c) about 280.58 mM L-arginine; (d) about 5.61 mM calcium chloride; and (e) about 0.056% (w / v) polysorbate 80.
[0214] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 2.25% (w / v) sucrose; (b) 11.2 mM L-histidine; (c) 280.58 mM L-arginine-HCl; (d) about 5.61 mM calcium chloride dihydrate (5.61 mM calcium chloride); and (e) 0.056% (w / v) polysorbate 80.
[0215] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 2.25% (w / v) sucrose; (b) 11.2 mM L-histidine; (c) 280.58 mM L-arginine; (d) 5.61 mM calcium chloride; and (e) 0.056% (w / v) polysorbate 80.
[0216] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 2% (w / v) to 3% (w / v) sucrose; (b) 11.2 mM L-histidine; (c) 280.58 mM L-arginine; (d) 5.61 mM calcium chloride; and (e) 0.056% (w / v) polysorbate 80.
[0217] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 2.25% (w / v) sucrose; (b) 7.5 mM to 12.5 mM L-histidine; (c) 280.58 mM L-arginine; (d) 5.61 mM calcium chloride; and (e) 0.056% (w / v) polysorbate 80.
[0218] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 2.25% (w / v) sucrose; (b) 11.2 mM L-histidine; (c) 225 mM to about 300 mM L-arginine; (d) 5.61 mM calcium chloride; and (e) 0.056% (w / v) polysorbate 80.
[0219] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 2.25% (w / v) sucrose; (b) 11.2 mM L-histidine; (c) 280.58 mM L-arginine; (d) 5 mM to 6 mM calcium chloride; and (e) 0.056% (w / v) polysorbate 80.
[0220] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 2.25% (w / v) sucrose; (b) 11.2 mM L-histidine; (c) 280.58 mM L-arginine; (d) 5.61 mM calcium chloride; and (e) 0.01% (w / v) to about 0.075% (w / v) (w / v) polysorbate 80.
[0221] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution does not contain NaCl. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution does not contain NaOH. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution does not contain sodium ions.
[0222] In some embodiments, the pharmaceutical composition comprises (a) about 2% (w / v) sucrose; (b) about 10 mM histidine; (c) about 250 mM arginine; (d) about 5 mM calcium chloride; and (e) about 0.05% polysorbate 20 or polysorbate 80. In some embodiments, the composition comprises polysorbate 80. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0223] In some embodiments, the pharmaceutical composition comprises (a) about 2% (w / v) to about 3% (w / v) sucrose; (b) about 10 mM histidine; (c) about 250 mM arginine; (d) about 5 mM calcium chloride; and (e) about 0.05% polysorbate 20 or polysorbate 80. In some embodiments, the composition comprises polysorbate 80. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0224] In some embodiments, the pharmaceutical composition comprises (a) about 2% (w / v) sucrose; (b) about 5 mM to about 15 mM histidine; (c) about 250 mM arginine; (d) about 5 mM calcium chloride; and (e) about 0.05% polysorbate 80. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0225] In some embodiments, the pharmaceutical composition comprises (a) about 2% (w / v) sucrose; (b) about 10 mM histidine; (c) about 200 mM to about 300 mM arginine; (d) about 5 mM calcium chloride; and (e) about 0.05% polysorbate 80. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0226] In some embodiments, the pharmaceutical composition comprises (a) about 2% (w / v) sucrose; (b) about 10 mM histidine; (c) about 250 mM arginine; (d) about 2.5 mM to about 10 mM calcium chloride; and (e) about 0.05% polysorbate 80. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0227] In some embodiments, the pharmaceutical composition comprises (a) about 2% (w / v) sucrose; (b) about 10 mM histidine; (c) about 250 mM arginine; (d) about 5 mM calcium chloride; and
[0228] (e) About 0.008% (w / v) to about 0.1% (w / v) of polysorbate 80. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0229] In some embodiments, the pharmaceutical composition comprises: (a) about 20 mg / ml sucrose; (b) about 1.552 mg / ml L-histidine; (c) about 52.665 mg / ml L-arginine-HCl; (d) about 0.735 mg / ml calcium chloride; and (e) about 0.5 mg / ml polysorbate 80.
[0230] In some embodiments, the pharmaceutical composition comprises: (a) about 20 mg / ml sucrose; (b) about 1.552 mg / ml L-histidine; (c) about 52.665 mg / ml L-arginine-HCl; (d) about 0.735 mg / ml calcium chloride dihydrate; and (e) about 0.5 mg / ml polysorbate 80.
[0231] In some embodiments, the pharmaceutical composition comprises: (a) about 20 mg / ml sucrose; (b) about 1.552 mg / ml L-histidine; (c) about 52.665 mg / ml L-arginine-HCl; (d) about 0.555 mg / ml calcium chloride; and (e) about 0.5 mg / ml polysorbate 80. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0232] In some embodiments, the pharmaceutical composition comprises: (a) about 20 mg / ml sucrose; (b) about 1.552 mg / ml L-histidine; (c) about 43.550 mg / ml L-arginine; (d) about 0.735 mg / ml calcium chloride dihydrate; and (e) about 0.5 mg / ml polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0233] In some embodiments, the pharmaceutical composition comprises: (a) about 20 mg / ml sucrose; (b) about 1.552 mg / ml L-histidine; (c) about 43.550 mg / ml L-arginine; (d) about 0.735 mg / ml calcium chloride; and (e) about 0.5 mg / ml polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0234] In some embodiments, the pharmaceutical composition comprises: (a) about 20 mg / ml sucrose; (b) about 1.552 mg / ml L-histidine; (c) about 43.550 mg / ml L-arginine; (d) about 0.555 mg / ml calcium chloride; and (e) about 0.5 mg / ml polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0235] In some embodiments, the pharmaceutical composition comprises: (a) 22.45 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 59.11 mg / ml L-arginine-HCl; (d) 0.82 mg / ml calcium chloride dihydrate; and (e) 0.56 mg / ml polysorbate 80.
[0236] In some embodiments, the pharmaceutical composition comprises: (a) 22.45 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 59.11 mg / ml L-arginine-HCl; (d) 0.62 mg / ml calcium chloride; and (e) 0.56 mg / ml polysorbate 80. In some embodiments, the composition comprises calcium chloride dihydrate.
[0237] In some embodiments, the pharmaceutical composition comprises: (a) 22.45 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 48.88 mg / ml L-arginine; (d) 0.82 mg / ml calcium chloride dihydrate; and (e) 0.56 mg / ml polysorbate 80.
[0238] In some embodiments, the pharmaceutical composition comprises: (a) 22.45 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 48.88 mg / ml L-arginine; (d) 0.62 mg / ml calcium chloride; and (e) 0.56 mg / ml polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0239] In some embodiments, the pharmaceutical composition comprises (a) about 5% (w / v) to about 7.5% (w / v) sucrose; (b) about 5 mM to about 15 mM histidine; (c) about 150 mM to about 300 mM arginine; (d) about 2.5 mM to about 10 mM calcium chloride; and (e) about 0.008% (w / v) to about 0.1% (w / v) polysorbate 20 or polysorbate 80.
[0240] In some embodiments, the pharmaceutical composition comprises (a) about 5% (w / v) to about 7.5% (w / v) sucrose; (b) about 5 mM to about 15 mM histidine; (c) about 200 mM to about 300 mM arginine; (d) about 2.5 mM to about 10 mM calcium chloride; and (e) about 0.008% (w / v) to about 0.1% (w / v) polysorbate 20 or polysorbate 80. In some embodiments, the composition comprises polysorbate 80. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0241] In some embodiments, the pharmaceutical composition comprises (a) 5% (w / v) to 6% (w / v) sucrose; (b) 7.5 mM to 12.5 mM histidine; (c) 225 mM to about 300 mM arginine; (d) 5 mM to 6 mM calcium chloride; and (e) 0.01% (w / v) to about 0.075% (w / v) polysorbate 20 or polysorbate 80. In some embodiments, the composition comprises polysorbate 80. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises 225 mM to about 300 mM L-arginine-HCl. In some embodiments, the composition comprises 5 mM to 6 mM calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0242] In some embodiments, the pharmaceutical composition comprises (a) 5% (w / v) to 6% (w / v) sucrose; (b) 7.5 mM to 12.5 mM L-histidine; (c) 225 mM to about 300 mM L-arginine; (d) 5 mM to 6 mM calcium chloride; and (e) 0.01% (w / v) to about 0.075% (w / v) polysorbate 80.
[0243] In some embodiments, the pharmaceutical composition comprises (a) 5% (w / v) to 6% (w / v) sucrose; (b) 7.5 mM to 12.5 mM L-histidine; (c) 225 mM to about 300 mM L-arginine-HCl; (d) 5 mM to 6 mM calcium chloride; and (e) 0.01% (w / v) to about 0.075% (w / v) polysorbate 80.
[0244] In some embodiments, the pharmaceutical composition comprises (a) 5% (w / v) to 6% (w / v) sucrose; (b) 7.5 mM to 12.5 mM L-histidine; (c) 225 mM to about 300 mM L-arginine-HCl; (d) 5 mM to 6 mM calcium chloride dihydrate; and (e) 0.01% (w / v) to about 0.075% (w / v) polysorbate 80.
[0245] In some embodiments, the pharmaceutical composition comprises: (a) about 5.61% (w / v) sucrose; (b) about 11.2 mM L-histidine; (c) about 280.58 mM L-arginine-HCl; (d) about 5.61 mM calcium chloride dihydrate; and (e) 0.056% (w / v) polysorbate 80.
[0246] In some embodiments, the pharmaceutical composition comprises: (a) about 5.61% (w / v) sucrose; (b) about 11.2 mM L-histidine; (c) about 280.58 mM L-arginine; (d) about 5.61 mM calcium chloride; and (e) about 0.056% (w / v) polysorbate 80.
[0247] In some embodiments, the pharmaceutical composition comprises: (a) 5.61% (w / v) sucrose; (b) 11.2 mM L-histidine; (c) 280.58 mM L-arginine-HCl; (d) about 5.61 mM calcium chloride dihydrate; and (e) 0.056% (w / v) polysorbate 80.
[0248] In some embodiments, the pharmaceutical composition comprises: (a) 5.61% (w / v) sucrose; (b) 11.2 mM L-histidine; (c) 280.58 mM L-arginine; (d) 5.61 mM calcium chloride; and (e) 0.056% (w / v) polysorbate 80.
[0249] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 5.61% (w / v) sucrose; (b) about 11.2 mM L-histidine; (c) about 280.58 mM L-arginine-HCl; (d) about 5.61 mM calcium chloride dihydrate; and (e) 0.056% (w / v) polysorbate 80.
[0250] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 5.61% (w / v) sucrose; (b) about 11.2 mM L-histidine; (c) about 280.58 mM L-arginine; (d) about 5.61 mM calcium chloride; and (e) about 0.056% (w / v) polysorbate 80.
[0251] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 5.61% (w / v) sucrose; (b) 11.2 mM L-histidine; (c) 280.58 mM L-arginine-HCl; (d) about 5.61 mM calcium chloride dihydrate (5.61 mM calcium chloride); and (e) 0.056% (w / v) polysorbate 80.
[0252] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 5.61% (w / v) sucrose; (b) 11.2 mM L-histidine; (c) 280.58 mM L-arginine; (d) 5.61 mM calcium chloride; and (e) 0.056% (w / v) polysorbate 80.
[0253] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 5% (w / v) to 6% (w / v) sucrose; (b) 11.2 mM L-histidine; (c) 280.58 mM L-arginine; (d) 5.61 mM calcium chloride; and (e) 0.056% (w / v) polysorbate 80.
[0254] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 5.61% (w / v) sucrose; (b) 7.5 mM to 12.5 mM L-histidine; (c) 280.58 mM L-arginine; (d) 5.61 mM calcium chloride; and (e) 0.056% (w / v) polysorbate 80.
[0255] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 5.61% (w / v) sucrose; (b) 11.2 mM L-histidine; (c) 225 mM to about 300 mM L-arginine; (d) 5.61 mM calcium chloride; and (e) 0.056% (w / v) polysorbate 80.
[0256] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 5.61% (w / v) sucrose; (b) 11.2 mM L-histidine; (c) 280.58 mM L-arginine; (d) 5 mM to 6 mM calcium chloride; and (e) 0.056% (w / v) polysorbate 80.
[0257] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 5.61% (w / v) sucrose; (b) 11.2 mM L-histidine; (c) 280.58 mM L-arginine; (d) 5.61 mM calcium chloride; and (e) 0.01% (w / v) to about 0.075% (w / v) (w / v) polysorbate 80.
[0258] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution does not contain NaCl. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution does not contain NaOH. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution does not contain sodium ions.
[0259] In some embodiments, the pharmaceutical composition comprises (a) about 5% (w / v) sucrose; (b) about 10 mM histidine; (c) about 250 mM arginine; (d) about 5 mM calcium chloride; and (e) about 0.05% polysorbate 20 or polysorbate 80. In some embodiments, the composition comprises polysorbate 80. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0260] In some embodiments, the pharmaceutical composition comprises (a) about 5% (w / v) to about 7.5% (w / v) sucrose; (b) about 10 mM histidine; (c) about 250 mM arginine; (d) about 5 mM calcium chloride; and (e) about 0.05% polysorbate 20 or polysorbate 80. In some embodiments, the composition comprises polysorbate 80. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0261] In some embodiments, the pharmaceutical composition comprises (a) about 5% (w / v) sucrose; (b) about 5 mM to about 15 mM histidine; (c) about 250 mM arginine; (d) about 5 mM calcium chloride; and (e) about 0.05% polysorbate 80. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0262] In some embodiments, the pharmaceutical composition comprises (a) about 5% (w / v) sucrose; (b) about 10 mM histidine; (c) about 200 mM to about 300 mM arginine; (d) about 5 mM calcium chloride; and (e) about 0.05% polysorbate 80. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0263] In some embodiments, the pharmaceutical composition comprises (a) about 5% (w / v) sucrose; (b) about 10 mM histidine; (c) about 250 mM arginine; (d) about 2.5 mM to about 10 mM calcium chloride; and (e) about 0.05% polysorbate 80. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0264] In some embodiments, the pharmaceutical composition comprises (a) about 5% (w / v) sucrose; (b) about 10 mM histidine; (c) about 250 mM arginine; (d) about 5 mM calcium chloride; and (e) about 0.008% (w / v) to about 0.1% (w / v) polysorbate 80. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0265] In some embodiments, the pharmaceutical composition comprises: (a) about 50 mg / ml sucrose; (b) about 1.552 mg / ml L-histidine; (c) about 52.665 mg / ml L-arginine-HCl; (d) about 0.735 mg / ml calcium chloride; and (e) about 0.5 mg / ml polysorbate 80.
[0266] In some embodiments, the pharmaceutical composition comprises: (a) about 50 mg / ml sucrose; (b) about 1.552 mg / ml L-histidine; (c) about 52.665 mg / ml L-arginine-HCl; (d) about 0.735 mg / ml calcium chloride dihydrate; and (e) about 0.5 mg / ml polysorbate 80.
[0267] In some embodiments, the pharmaceutical composition comprises: (a) about 50 mg / ml sucrose; (b) about 1.552 mg / ml L-histidine; (c) about 52.665 mg / ml L-arginine-HCl; (d) about 0.555 mg / ml calcium chloride; and (e) about 0.5 mg / ml polysorbate 80. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0268] In some embodiments, the pharmaceutical composition comprises: (a) about 50 mg / ml sucrose; (b) about 1.552 mg / ml L-histidine; (c) about 43.550 mg / ml L-arginine; (d) about 0.735 mg / ml calcium chloride dihydrate; and (e) about 0.5 mg / ml polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0269] In some embodiments, the pharmaceutical composition comprises: (a) about 50 mg / ml sucrose; (b) about 1.552 mg / ml L-histidine; (c) about 43.550 mg / ml L-arginine; (d) about 0.735 mg / ml calcium chloride; and (e) about 0.5 mg / ml polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0270] In some embodiments, the pharmaceutical composition comprises: (a) about 50 mg / ml sucrose; (b) about 1.552 mg / ml L-histidine; (c) about 43.550 mg / ml L-arginine; (d) about 0.555 mg / ml calcium chloride; and (e) about 0.5 mg / ml polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilized solution.
[0271] In some embodiments, the pharmaceutical composition comprises: (a) 56.12 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 59.11 mg / ml L-arginine-HCl; (d) 0.82 mg / ml calcium chloride dihydrate; and (e) 0.56 mg / ml polysorbate 80.
[0272] In some embodiments, the pharmaceutical composition comprises: (a) 56.12 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 59.11 mg / ml L-arginine-HCl; (d) 0.62 mg / ml calcium chloride; and (e) 0.56 mg / ml polysorbate 80. In some embodiments, the composition comprises calcium chloride dihydrate.
[0273] In some embodiments, the pharmaceutical composition comprises: (a) 56.12 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 48.88 mg / ml L-arginine; (d) 0.82 mg / ml calcium chloride dihydrate; and (e) 0.56 mg / ml polysorbate 80.
[0274] In some embodiments, the pharmaceutical composition comprises: (a) 56.12 mg / ml sucrose; (b) 1.74 mg / ml L-histidine; (c) 48.88 mg / ml L-arginine; (d) 0.62 mg / ml calcium chloride; and (e) 0.56 mg / ml polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0275] In some embodiments, the pH of the pharmaceutical composition is about 6.5 to about 7.5. In some embodiments, the pH of the pharmaceutical composition is about 7.0. In some embodiments, the pH of the pharmaceutical composition is about 6.8.
[0276] In some embodiments, the pH of the pharmaceutical composition is about 6.5. In some embodiments, the pH of the pharmaceutical composition is about 6.6. In some embodiments, the pH of the pharmaceutical composition is about 6.7. In some embodiments, the pH of the pharmaceutical composition is about 6.8. In some embodiments, the pH of the pharmaceutical composition is about 6.9. In some embodiments, the pH of the pharmaceutical composition is about 7.0. In some embodiments, the pH of the pharmaceutical composition is about 7.1. In some embodiments, the pH of the pharmaceutical composition is about 7.2. In some embodiments, the pH of the pharmaceutical composition is about 7.3. In some embodiments, the pH of the pharmaceutical composition is about 7.4. In some embodiments, the pH of the pharmaceutical composition is about 7.5.
[0277] In some embodiments, the pH of the pharmaceutical composition is 6.5. In some embodiments, the pH of the pharmaceutical composition is 6.6. In some embodiments, the pH of the pharmaceutical composition is 6.7. In some embodiments, the pH of the pharmaceutical composition is 6.8. In some embodiments, the pH of the pharmaceutical composition is 6.9. In some embodiments, the pH of the pharmaceutical composition is 7.0. In some embodiments, the pH of the pharmaceutical composition is 7.1. In some embodiments, the pH of the pharmaceutical composition is 7.2. In some embodiments, the pH of the pharmaceutical composition is 7.3. In some embodiments, the pH of the pharmaceutical composition is 7.4. In some embodiments, the pH of the pharmaceutical composition is 7.5.
[0278] In some embodiments, a pre-lyophilized solution with a volume of 3.367 mL is added to a container or vial. In some embodiments, the pre-lyophilized solution is subjected to lyophilization to obtain a lyophilized pharmaceutical composition.
[0279] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) about 30 mg to about 135 mg of sucrose; (b) about 2.5 mg to about 7.5 mg of histidine; (c) about 140 mg to about 200 mg of arginine; (d) about 1.5 mg to about 5 mg of calcium chloride; and (e) about 1 mg to about 5 mg of polysorbate 20 or polysorbate 80.
[0280] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) about 30 mg to about 135 mg of sucrose; (b) about 2.5 mg to about 7.5 mg of L-histidine; (c) about 140 mg to about 200 mg of L-arginine; (d) about 1.5 mg to about 5 mg of calcium chloride; and (e) about 1 mg to about 5 mg of polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0281] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 30 mg to 135 mg sucrose; (b) 2.5 mg to 7.5 mg histidine; (c) 140 mg to 200 mg arginine; (d) 1.5 mg to 5 mg calcium chloride; and (e) 1 mg to 5 mg polysorbate 20 or polysorbate 80.
[0282] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 30 mg to 135 mg sucrose; (b) 2.5 mg to 7.5 mg L-histidine; (c) 140 mg to 200 mg L-arginine-HCl; (d) 1.5 mg to 5 mg calcium chloride; and (e) 1 mg to 5 mg polysorbate 80. In some embodiments, the composition comprises calcium chloride dihydrate.
[0283] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 30 mg to 135 mg sucrose; (b) 2.5 mg to 7.5 mg L-histidine; (c) 140 mg to 200 mg L-arginine; (d) 1.5 mg to 5 mg calcium chloride; and (e) 1 mg to 5 mg polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0284] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) about 67.34 mg of sucrose; (b) about 5.2 mg of L-histidine; (c) about 177.3 mg of L-arginine-HCl; (d) about 2.5 mg of calcium chloride; and (e) about 1.7 mg of polysorbate 20 or polysorbate 80.
[0285] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) about 67.34 mg of sucrose; (b) about 5.2 mg of L-histamine; (c) about 146.6 mg of L-arginine; (d) about 2.5 mg of calcium chloride; and (e) about 1.7 mg of polysorbate 20 or polysorbate 80.
[0286] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 67.34 mg sucrose; (b) 5.2 mg L-histidine; (c) 177.3 mg L-arginine-HCl; (d) 2.5 mg calcium chloride; and (e) 1.7 mg polysorbate 80.
[0287] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 67.34 mg sucrose; (b) 5.2 mg L-histidine; (c) 146.6 mg L-arginine; (d) 2.5 mg calcium chloride; and (e) 1.7 mg polysorbate 80.
[0288] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 67.34 mg sucrose; (b) 5.23 mg L-histidine; (c) 177.32 mg L-arginine-HCl; (d) 2.47 mg calcium chloride dihydrate; and
[0289] (e) 1.68 mg polysorbate 80. In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 67.34 mg sucrose; (b) 5.23 mg L-histidine; (c) 177.32 mg L-arginine-HCl; (d) 1.87 mg calcium chloride; and (e) 1.68 mg polysorbate 80.
[0290] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 67.34 mg sucrose; (b) 5.23 mg L-histidine; (c) 146.63 mg L-arginine; (d) 2.47 mg calcium chloride dihydrate; and (e) 1.68 mg polysorbate 80.
[0291] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 67.34 mg sucrose; (b) 5.23 mg L-histidine; (c) 146.63 mg L-arginine; (d) 1.87 mg calcium chloride; and (e) 1.68 mg polysorbate 80.
[0292] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 30 mg to 135 mg sucrose; (b) 5.2 mg L-histidine; (c) 177.3 mg L-arginine-HCl; (d) 2.5 mg calcium chloride dihydrate; and (e) 1.7 mg polysorbate 80.
[0293] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 30 mg to 135 mg sucrose; (b) 5.2 mg L-histidine; (c) 177.3 mg L-arginine-HCl; (d) 1.9 mg calcium chloride; and (e) 1.7 mg polysorbate 80.
[0294] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 30 mg to 135 mg sucrose; (b) 5.2 mg L-histidine; (c) 146.6 mg L-arginine; (d) 2.5 mg calcium chloride dihydrate; and (e) 1.7 mg polysorbate 80.
[0295] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 30 mg to 135 mg sucrose; (b) 5.2 mg L-histidine; (c) 146.6 mg L-arginine; (d) 1.9 mg calcium chloride; and (e) 1.7 mg polysorbate 80.
[0296] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 67.34 mg sucrose; (b) 2.5 mg to 7.5 mg L-histidine; (c) 177.3 mg L-arginine-HCl; (d) 2.5 mg calcium chloride dihydrate; and (e) 1.7 mg polysorbate 80.
[0297] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 67.34 mg sucrose; (b) 2.5 mg to 7.5 mg L-histidine; (c) 177.3 mg L-arginine-HCl; (d) 1.9 mg calcium chloride; and (e) 1.7 mg polysorbate 80.
[0298] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 67.34 mg sucrose; (b) 2.5 mg to 7.5 mg L-histidine; (c) 146.6 mg L-arginine; (d) 2.5 mg calcium chloride dihydrate; and (e) 1.7 mg polysorbate 80.
[0299] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 67.34 mg sucrose; (b) 2.5 mg to 7.5 mg L-histidine; (c) 146.6 mg L-arginine; (d) 1.9 mg calcium chloride; and (e) 1.7 mg polysorbate 80.
[0300] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 67.34 mg sucrose; (b) 5.23 mg L-histidine; (c) 140 mg to 200 mg L-arginine; (d) 1.5 mg to 5 mg calcium chloride; and (e) 1.7 mg polysorbate 80. In some embodiments, the composition comprises 140 mg to 200 mg L-arginine-HCl.
[0301] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 67.34 mg sucrose; (b) 5.23 mg L-histidine; (c) 177.32 mg L-arginine-HCl; (d) 1.5 mg to 5 mg calcium chloride; and (e) 1.7 mg polysorbate 80.
[0302] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 67.34 mg sucrose; (b) 5.23 mg L-histidine; (c) 146.63 mg L-arginine; (d) 1.5 mg to 5 mg calcium chloride; and (e) 1.7 mg polysorbate 80.
[0303] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 67.34 mg sucrose; (b) 5.23 mg L-histidine; (c) 177.32 mg L-arginine-HCl; (d) 2.47 mg calcium chloride dihydrate; and (e) 1 mg to 5 mg polysorbate 80.
[0304] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 67.34 mg sucrose; (b) 5.23 mg L-histidine; (c) 177.32 mg L-arginine-HCl; (d) 1.87 mg calcium chloride; and (e) 1 mg to 5 mg polysorbate 80.
[0305] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 67.34 mg sucrose; (b) 5.23 mg L-histidine; (c) 146.63 mg L-arginine; (d) 2.47 mg calcium chloride dihydrate; and (e) 1 mg to 5 mg polysorbate 80.
[0306] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 67.34 mg sucrose; (b) 5.23 mg L-histidine; (c) 146.63 mg L-arginine; (d) 1.87 mg calcium chloride; and (e) 1 mg to 5 mg polysorbate 80.
[0307] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) about 160 mg to about 200 mg of sucrose; (b) about 2.5 mg to about 7.5 mg of histidine; (c) about 140 mg to about 200 mg of arginine; (d) about 1.5 mg to about 5 mg of calcium chloride; and (e) about 1 mg to about 5 mg of polysorbate 20 or polysorbate 80.
[0308] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) about 160 mg to about 200 mg of sucrose; (b) about 2.5 mg to about 7.5 mg of L-histidine; (c) about 140 mg to about 200 mg of L-arginine; (d) about 1.5 mg to about 5 mg of calcium chloride; and (e) about 1 mg to about 5 mg of polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0309] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 160 mg to 200 mg sucrose; (b) 2.5 mg to 7.5 mg histidine; (c) 140 mg to 200 mg arginine; (d) 1.5 mg to 5 mg calcium chloride; and (e) 1 mg to 5 mg polysorbate 20 or polysorbate 80.
[0310] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 160 mg to 200 mg sucrose; (b) 2.5 mg to 7.5 mg L-histidine; (c) 140 mg to 200 mg L-arginine-HCl; (d) 1.5 mg to 5 mg calcium chloride; and (e) 1 mg to 5 mg polysorbate 80. In some embodiments, the composition comprises calcium chloride dihydrate.
[0311] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 160 mg to 200 mg sucrose; (b) 2.5 mg to 7.5 mg L-histidine; (c) 140 mg to 200 mg L-arginine; (d) 1.5 mg to 5 mg calcium chloride; and (e) 1 mg to 5 mg polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0312] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) about 168.3 mg of sucrose; (b) about 5.2 mg of L-histidine; (c) about 177.3 mg of L-arginine-HCl; (d) about 2.5 mg of calcium chloride; and (e) about 1.7 mg of polysorbate 20 or polysorbate 80.
[0313] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) about 168.3 mg of sucrose; (b) about 5.2 mg of L-histamine; (c) about 146.6 mg of L-arginine; (d) about 2.5 mg of calcium chloride; and (e) about 1.7 mg of polysorbate 20 or polysorbate 80.
[0314] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 168.3 mg sucrose; (b) 5.2 mg L-histidine; (c) 177.3 mg L-arginine-HCl; (d) 2.5 mg calcium chloride; and (e) 1.7 mg polysorbate 80.
[0315] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 168.3 mg sucrose; (b) 5.2 mg L-histidine; (c) 146.6 mg L-arginine; (d) 2.5 mg calcium chloride; and (e) 1.7 mg polysorbate 80.
[0316] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 168.35 mg sucrose; (b) 5.23 mg L-histidine; (c) 177.32 mg L-arginine-HCl; (d) 2.47 mg calcium chloride dihydrate; and (e) 1.68 mg polysorbate 80.
[0317] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 168.35 mg sucrose; (b) 5.23 mg L-histidine; (c) 177.32 mg L-arginine-HCl; (d) 1.87 mg calcium chloride; and (e) 1.68 mg polysorbate 80.
[0318] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 168.35 mg sucrose; (b) 5.23 mg L-histidine; (c) 146.63 mg L-arginine; (d) 2.47 mg calcium chloride dihydrate; and (e) 1.68 mg polysorbate 80.
[0319] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 168.35 mg sucrose; (b) 5.23 mg L-histidine; (c) 146.63 mg L-arginine; (d) 1.87 mg calcium chloride; and (e) 1.68 mg polysorbate 80.
[0320] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 160 mg to 200 mg sucrose; (b) 5.2 mg L-histidine; (c) 177.3 mg L-arginine-HCl; (d) 2.5 mg calcium chloride dihydrate; and (e) 1.7 mg polysorbate 80.
[0321] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 160 mg to 200 mg sucrose; (b) 5.2 mg L-histidine; (c) 177.3 mg L-arginine-HCl; (d) 1.9 mg calcium chloride; and (e) 1.7 mg polysorbate 80.
[0322] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 160 mg to 200 mg sucrose; (b) 5.2 mg L-histidine; (c) 146.6 mg L-arginine; (d) 2.5 mg calcium chloride dihydrate; and (e) 1.7 mg polysorbate 80.
[0323] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 160 mg to 200 mg sucrose; (b) 5.2 mg L-histidine; (c) 146.6 mg L-arginine; (d) 1.9 mg calcium chloride; and (e) 1.7 mg polysorbate 80.
[0324] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 168.3 mg sucrose; (b) 2.5 mg to 7.5 mg L-histidine; (c) 177.3 mg L-arginine-HCl; (d) 2.5 mg calcium chloride dihydrate; and (e) 1.7 mg polysorbate 80.
[0325] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 168.3 mg sucrose; (b) 2.5 mg to 7.5 mg L-histidine; (c) 177.3 mg L-arginine-HCl; (d) 1.9 mg calcium chloride; and (e) 1.7 mg polysorbate 80.
[0326] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 168.3 mg sucrose; (b) 2.5 mg to 7.5 mg L-histidine; (c) 146.6 mg L-arginine; (d) 2.5 mg calcium chloride dihydrate; and (e) 1.7 mg polysorbate 80.
[0327] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 168.3 mg sucrose; (b) 2.5 mg to 7.5 mg L-histidine; (c) 146.6 mg L-arginine; (d) 1.9 mg calcium chloride; and (e) 1.7 mg polysorbate 80.
[0328] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 168.35 mg sucrose; (b) 5.23 mg L-histidine; (c) 140 mg to 200 mg L-arginine; (d) 1.5 mg to 5 mg calcium chloride; and (e) 1.7 mg polysorbate 80. In some embodiments, the composition comprises 140 mg to 200 mg L-arginine-HCl.
[0329] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 168.35 mg sucrose; (b) 5.23 mg L-histidine; (c) 177.32 mg L-arginine-HCl; (d) 1.5 mg to 5 mg calcium chloride; and (e) 1.7 mg polysorbate 80.
[0330] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 168.35 mg sucrose; (b) 5.23 mg L-histidine; (c) 146.63 mg L-arginine; (d) 1.5 mg to 5 mg calcium chloride; and (e) 1.7 mg polysorbate 80.
[0331] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 168.35 mg sucrose; (b) 5.23 mg L-histidine; (c) 177.32 mg L-arginine-HCl; (d) 2.47 mg calcium chloride dihydrate; and (e) 1 mg to 5 mg polysorbate 80.
[0332] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 168.35 mg sucrose; (b) 5.23 mg L-histidine; (c) 177.32 mg L-arginine-HCl; (d) 1.87 mg calcium chloride; and (e) 1 mg to 5 mg polysorbate 80.
[0333] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 168.35 mg sucrose; (b) 5.23 mg L-histidine; (c) 146.63 mg L-arginine; (d) 2.47 mg calcium chloride dihydrate; and (e) 1 mg to 5 mg polysorbate 80.
[0334] In some embodiments, the lyophilized pharmaceutical composition comprises: (a) 168.35 mg sucrose; (b) 5.23 mg L-histidine; (c) 146.63 mg L-arginine; (d) 1.87 mg calcium chloride; and (e) 1 mg to 5 mg polysorbate 80.
[0335] In some embodiments, the moisture content of the freeze-dried pharmaceutical composition is less than 2%. In some embodiments, the moisture content of the freeze-dried pharmaceutical composition is less than 1.8%. In some embodiments, the moisture content of the freeze-dried pharmaceutical composition is less than 1.6%.
[0336] In some embodiments, the lyophilized pharmaceutical composition is a lyophilized cake. In some embodiments, the lyophilized cake is white. In some embodiments, the lyophilized cake is smaller than Y4 in the European Pharmacopoeia color scale. See Degree of Coloration of Liquids (Method 2.2.2), European Pharmacopoeia, 10th edition (2021).
[0337] In some embodiments, the lyophilized pharmaceutical composition is combined with sterile water to produce an injectable solution. In some embodiments, the lyophilized pharmaceutical composition is combined with about 2 mL to about 5 mL of sterile water. In some embodiments, the lyophilized pharmaceutical composition is combined with about 3 mL of sterile water. In some embodiments, the lyophilized pharmaceutical composition is combined with 3 mL of sterile water. In some embodiments, the sterile water is USP-grade sterile water. In some embodiments, the sterile water is USP-grade sterile water for injection. In some embodiments, the sterile water is pyrogen-free or nonpyrogenic. In some embodiments, the sterile water does not contain bacteriostatic agents or antimicrobial agents. In some embodiments, the sterile water contains bacteriostatic agents or antimicrobial agents. In some embodiments, the sterile water is sterilized using a filter. In some embodiments, the sterile water is sterilized using a 0.1 μm filter. In some embodiments, the sterile water is distilled water. In some embodiments, the sterile water is sterile, pyrogen-free distilled water that is hypotonic, has a volume molar osmolality of 0 mOsmol / L, and does not contain bacteriostatic agents or antimicrobial agents.
[0338] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 10 mg / mL to 40 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 50 mg / mL to 70 mg / mL L-arginine; (d) 0.7 mg / mL to 0.9 mg / mL calcium chloride dihydrate; and
[0339] (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 10 mg / mL to 40 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histamine; (c) 50 mg / mL to 70 mg / mL L-arginine; (d) 0.5 mg / mL to 0.8 mg / mL calcium chloride; and (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0340] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 59.11 mg / ml L-arginine-HCl; (d) about 0.82 mg / ml calcium chloride dihydrate; and (e) about 0.56 mg / ml polysorbate 80.
[0341] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 59.11 mg / ml L-arginine-HCl; (d) about 0.62 mg / ml calcium chloride; and (e) about 0.56 mg / ml polysorbate 80. In some embodiments, the composition comprises calcium chloride dihydrate.
[0342] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 48.88 mg / ml L-arginine; (d) about 0.82 mg / ml calcium chloride dihydrate; and (e) about 0.56 mg / ml polysorbate 80.
[0343] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 48.88 mg / ml L-arginine; (d) about 0.62 mg / ml calcium chloride; and (e) about 0.56 mg / ml polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0344] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 10 mg / mL to about 40 mg / mL sucrose; (b) about 1.74 mg / mL L-histidine; (c) about 59.11 mg / mL L-arginine-HCl; (d) about 0.82 mg / mL calcium chloride dihydrate; and (e) about 0.56 mg / mL polysorbate 80.
[0345] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 10 mg / mL to about 40 mg / mL sucrose; (b) about 1.74 mg / mL L-histidine; (c) about 59.11 mg / mL L-arginine-HCl; (d) about 0.62 mg / mL calcium chloride; and (e) about 0.56 mg / mL polysorbate 80. In some embodiments, the composition comprises calcium chloride dihydrate.
[0346] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 10 mg / mL to about 40 mg / mL sucrose; (b) about 1.74 mg / mL L-histidine; (c) about 44.88 mg / mL L-arginine; (d) about 0.82 mg / mL calcium chloride dihydrate; and (e) about 0.56 mg / mL polysorbate 80.
[0347] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 10 mg / mL to about 40 mg / mL sucrose; (b) about 1.74 mg / mL L-histidine; (c) about 44.88 mg / mL L-arginine; (d) about 0.62 mg / mL calcium chloride; and (e) about 0.56 mg / mL polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0348] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / mL sucrose; (b) about 1.5 mg / mL to about 2.0 mg / mL L-histidine; (c) about 59.11 mg / mL L-arginine-HCl; (d) about 0.82 mg / mL calcium chloride dihydrate; and (e) about 0.56 mg / mL polysorbate 80.
[0349] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / mL sucrose; (b) about 1.5 mg / mL to about 2.0 mg / mL L-histidine; (c) about 59.11 mg / mL L-arginine-HCl; (d) about 0.62 mg / mL calcium chloride; and (e) about 0.56 mg / mL polysorbate 80. In some embodiments, the composition comprises calcium chloride dihydrate.
[0350] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / mL sucrose; (b) about 1.5 mg / mL to about 2.0 mg / mL L-histidine; (c) about 48.88 mg / mL L-arginine; (d) about 0.82 mg / mL calcium chloride dihydrate; and (e) about 0.56 mg / mL polysorbate 80.
[0351] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / mL sucrose; (b) about 1.5 mg / mL to about 2.0 mg / mL L-histidine; (c) about 48.88 mg / mL L-arginine; (d) about 0.62 mg / mL calcium chloride; and (e) about 0.56 mg / mL polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0352] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 50 mg / mL to about 70 mg / mL L-arginine-HCl; (d) about 0.62 mg / ml calcium chloride dihydrate; and (e) about 0.56 mg / ml polysorbate 80.
[0353] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 50 mg / mL to about 70 mg / mL L-arginine-HCl; (d) about 0.62 mg / ml calcium chloride; and (e) about 0.56 mg / ml polysorbate 80. In some embodiments, the composition comprises calcium chloride dihydrate.
[0354] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 40 mg / mL to about 60 mg / mL L-arginine; (d) about 0.82 mg / ml calcium chloride dihydrate; and (e) about 0.56 mg / ml polysorbate 80.
[0355] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 40 mg / mL to about 60 mg / mL L-arginine; (d) about 0.62 mg / ml calcium chloride; and (e) about 0.56 mg / ml polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0356] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 59.11 mg / ml L-arginine-HCl; (d) about 0.7 mg / mL to about 0.9 mg / mL calcium chloride dihydrate; and (e) about 0.56 mg / ml polysorbate 80.
[0357] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 59.11 mg / ml L-arginine-HCl; (d) about 0.5 mg / mL to about 0.9 mg / mL calcium chloride; and (e) about 0.56 mg / ml polysorbate 80. In some embodiments, the composition comprises calcium chloride dihydrate.
[0358] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 48.88 mg / ml L-arginine; (d) about 0.7 mg / mL to about 0.9 mg / mL calcium chloride dihydrate; and (e) about 0.56 mg / ml polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl.
[0359] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 48.88 mg / ml L-arginine; (d) about 0.5 mg / mL to about 0.7 mg / mL calcium chloride; and (e) about 0.56 mg / ml polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0360] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 59.11 mg / ml L-arginine-HCl; (d) about 0.82 mg / ml calcium chloride dihydrate; and (e) about 0.4 mg / mL to about 0.7 mg / mL polysorbate 80.
[0361] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 59.11 mg / ml L-arginine-HCl; (d) about 0.62 mg / ml calcium chloride; and (e) about 0.4 mg / mL to about 0.7 mg / mL polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0362] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 48.88 mg / ml L-arginine; (d) about 0.82 mg / ml calcium chloride dihydrate; and (e) about 0.4 mg / mL to about 0.7 mg / mL polysorbate 80.
[0363] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 48.88 mg / ml L-arginine; (d) about 0.62 mg / ml calcium chloride; and (e) about 0.4 mg / mL to about 0.7 mg / mL polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0364] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 59.11 mg / ml L-arginine-HCl; (d) about 0.82 mg / ml calcium chloride dihydrate; and (e) about 0.56 mg / ml polysorbate 80.
[0365] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 59.11 mg / ml L-arginine-HCl; (d) about 0.62 mg / ml calcium chloride; and (e) about 0.56 mg / ml polysorbate 80.
[0366] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 48.88 mg / ml L-arginine; (d) about 0.82 mg / ml calcium chloride dihydrate; and (e) about 0.56 mg / ml polysorbate 80.
[0367] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 22.45 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 48.88 mg / ml L-arginine; (d) about 0.62 mg / ml calcium chloride; and (e) about 0.56 mg / ml polysorbate 80.
[0368] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 67.34 mg of sucrose; (b) about 5.23 mg of L-histidine; (c) about 177.32 mg of L-arginine-HCl; (d) about 2.47 mg of calcium chloride; and (e) about 1.68 mg of polysorbate 80 in 3 mL of sterile water.
[0369] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 67.34 mg of sucrose; (b) about 5.23 mg of L-histidine; (c) about 146.63 mg of L-arginine; (d) about 2.47 mg of calcium chloride dihydrate; and (e) about 1.68 mg of polysorbate 80 in 3 mL of sterile water.
[0370] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 67.34 mg of sucrose; (b) about 5.23 mg of L-histidine; (c) about 146.63 mg of L-arginine; (d) about 1.87 mg of calcium chloride; and (e) about 1.68 mg of polysorbate 80 in 3 mL of sterile water.
[0371] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 67.34 mg sucrose; (b) 5.23 mg L-histidine; (c) 177.32 mg L-arginine-HCl; (d) 2.47 mg calcium chloride dihydrate; and (e) 1.68 mg polysorbate 80 in 3 mL sterile water.
[0372] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 67.34 mg sucrose; (b) 5.23 mg L-histidine; (c) 177.32 mg L-arginine-HCl; (d) 1.87 mg calcium chloride; and (e) 1.68 mg polysorbate 80 in 3 mL sterile water.
[0373] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 67.34 mg sucrose; (b) 5.23 mg L-histidine; (c) 146.63 mg L-arginine; (d) 2.47 mg calcium chloride dihydrate; and (e) 1.68 mg polysorbate 80 in 3 mL sterile water.
[0374] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 67.34 mg sucrose; (b) 5.23 mg L-histidine; (c) 146.63 mg L-arginine; (d) 1.87 mg calcium chloride; and (e) 1.68 mg polysorbate 80 in 3 mL of sterile water.
[0375] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 45 mg / mL to 60 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 50 mg / mL to 70 mg / mL L-arginine; (d) 0.7 mg / mL to 0.9 mg / mL calcium chloride dihydrate; and
[0376] (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 45 mg / mL to 60 mg / mL sucrose; (b) 1.5 mg / mL to 2.0 mg / mL L-histidine; (c) 50 mg / mL to 70 mg / mL L-arginine; (d) 0.5 mg / mL to 0.8 mg / mL calcium chloride; and (e) 0.4 mg / mL to 0.7 mg / mL polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0377] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 59.11 mg / ml L-arginine-HCl; (d) about 0.82 mg / ml calcium chloride dihydrate; and (e) about 0.56 mg / ml polysorbate 80.
[0378] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 59.11 mg / ml L-arginine-HCl; (d) about 0.62 mg / ml calcium chloride; and (e) about 0.56 mg / ml polysorbate 80. In some embodiments, the composition comprises calcium chloride dihydrate.
[0379] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 48.88 mg / ml L-arginine; (d) about 0.82 mg / ml calcium chloride dihydrate; and (e) about 0.56 mg / ml polysorbate 80.
[0380] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 48.88 mg / ml L-arginine; (d) about 0.62 mg / ml calcium chloride; and (e) about 0.56 mg / ml polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0381] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 45 mg / mL to about 60 mg / mL sucrose; (b) about 1.74 mg / mL L-histidine; (c) about 59.11 mg / mL L-arginine-HCl; (d) about 0.82 mg / mL calcium chloride dihydrate; and (e) about 0.56 mg / mL polysorbate 80.
[0382] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 45 mg / mL to about 60 mg / mL sucrose; (b) about 1.74 mg / mL L-histidine; (c) about 59.11 mg / mL L-arginine-HCl; (d) about 0.62 mg / mL calcium chloride; and (e) about 0.56 mg / mL polysorbate 80. In some embodiments, the composition comprises calcium chloride dihydrate.
[0383] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 45 mg / mL to about 60 mg / mL sucrose; (b) about 1.74 mg / mL L-histidine; (c) about 44.88 mg / mL L-arginine; (d) about 0.82 mg / mL calcium chloride dihydrate; and (e) about 0.56 mg / mL polysorbate 80.
[0384] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 45 mg / mL to about 60 mg / mL sucrose; (b) about 1.74 mg / mL L-histidine; (c) about 44.88 mg / mL L-arginine; (d) about 0.62 mg / mL calcium chloride; and (e) about 0.56 mg / mL polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0385] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / mL sucrose; (b) about 1.5 mg / mL to about 2.0 mg / mL L-histidine; (c) about 59.11 mg / mL L-arginine-HCl; (d) about 0.82 mg / mL calcium chloride dihydrate; and (e) about 0.56 mg / mL polysorbate 80.
[0386] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / mL sucrose; (b) about 1.5 mg / mL to about 2.0 mg / mL L-histidine; (c) about 59.11 mg / mL L-arginine-HCl; (d) about 0.62 mg / mL calcium chloride; and (e) about 0.56 mg / mL polysorbate 80. In some embodiments, the composition comprises calcium chloride dihydrate.
[0387] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / mL sucrose; (b) about 1.5 mg / mL to about 2.0 mg / mL L-histidine; (c) about 48.88 mg / mL L-arginine; (d) about 0.82 mg / mL calcium chloride dihydrate; and (e) about 0.56 mg / mL polysorbate 80.
[0388] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / mL sucrose; (b) about 1.5 mg / mL to about 2.0 mg / mL L-histidine; (c) about 48.88 mg / mL L-arginine; (d) about 0.62 mg / mL calcium chloride; and (e) about 0.56 mg / mL polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0389] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 50 mg / mL to about 70 mg / mL L-arginine-HCl; (d) about 0.62 mg / ml calcium chloride dihydrate; and (e) about 0.56 mg / ml polysorbate 80.
[0390] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 50 mg / mL to about 70 mg / mL L-arginine-HCl; (d) about 0.62 mg / ml calcium chloride; and (e) about 0.56 mg / ml polysorbate 80. In some embodiments, the composition comprises calcium chloride dihydrate.
[0391] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 40 mg / mL to about 60 mg / mL L-arginine; (d) about 0.82 mg / ml calcium chloride dihydrate; and (e) about 0.56 mg / ml polysorbate 80.
[0392] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 40 mg / mL to about 60 mg / mL L-arginine; (d) about 0.62 mg / ml calcium chloride; and (e) about 0.56 mg / ml polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0393] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 59.11 mg / ml L-arginine-HCl; (d) about 0.7 mg / mL to about 0.9 mg / mL calcium chloride dihydrate; and (e) about 0.56 mg / ml polysorbate 80.
[0394] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 59.11 mg / ml L-arginine-HCl; (d) about 0.5 mg / mL to about 0.9 mg / mL calcium chloride; and (e) about 0.56 mg / ml polysorbate 80. In some embodiments, the composition comprises calcium chloride dihydrate.
[0395] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 48.88 mg / ml L-arginine; (d) about 0.7 mg / mL to about 0.9 mg / mL calcium chloride dihydrate; and (e) about 0.56 mg / ml polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl.
[0396] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 48.88 mg / ml L-arginine; (d) about 0.5 mg / mL to about 0.7 mg / mL calcium chloride; and (e) about 0.56 mg / ml polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0397] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 59.11 mg / ml L-arginine-HCl; (d) about 0.82 mg / ml calcium chloride dihydrate; and (e) about 0.4 mg / mL to about 0.7 mg / mL polysorbate 80.
[0398] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 59.11 mg / ml L-arginine-HCl; (d) about 0.62 mg / ml calcium chloride; and (e) about 0.4 mg / mL to about 0.7 mg / mL polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0399] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 48.88 mg / ml L-arginine; (d) about 0.82 mg / ml calcium chloride dihydrate; and (e) about 0.4 mg / mL to about 0.7 mg / mL polysorbate 80.
[0400] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 48.88 mg / ml L-arginine; (d) about 0.62 mg / ml calcium chloride; and (e) about 0.4 mg / mL to about 0.7 mg / mL polysorbate 80. In some embodiments, the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.
[0401] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 59.11 mg / ml L-arginine-HCl; (d) about 0.82 mg / ml calcium chloride dihydrate; and (e) about 0.56 mg / ml polysorbate 80.
[0402] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 59.11 mg / ml L-arginine-HCl; (d) about 0.62 mg / ml calcium chloride; and (e) about 0.56 mg / ml polysorbate 80.
[0403] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 48.88 mg / ml L-arginine; (d) about 0.82 mg / ml calcium chloride dihydrate; and (e) about 0.56 mg / ml polysorbate 80.
[0404] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 56.12 mg / ml sucrose; (b) about 1.74 mg / ml L-histidine; (c) about 48.88 mg / ml L-arginine; (d) about 0.62 mg / ml calcium chloride; and (e) about 0.56 mg / ml polysorbate 80.
[0405] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 168.4 mg of sucrose; (b) about 5.23 mg of L-histidine; (c) about 177.32 mg of L-arginine-HCl; (d) about 2.47 mg of calcium chloride; and (e) about 1.68 mg of polysorbate 80 in 3 mL of sterile water.
[0406] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 168.4 mg of sucrose; (b) about 5.23 mg of L-histidine; (c) about 146.63 mg of L-arginine; (d) about 2.47 mg of calcium chloride dihydrate; and (e) about 1.68 mg of polysorbate 80 in 3 mL of sterile water.
[0407] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) about 168.4 mg of sucrose; (b) about 5.23 mg of L-histidine; (c) about 146.63 mg of L-arginine; (d) about 1.87 mg of calcium chloride; and (e) about 1.68 mg of polysorbate 80 in 3 mL of sterile water.
[0408] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 168.35 mg sucrose; (b) 5.23 mg L-histidine; (c) 177.32 mg L-arginine-HCl; (d) 2.47 mg calcium chloride dihydrate; and (e) 1.68 mg polysorbate 80 in 3 mL sterile water.
[0409] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 168.35 mg sucrose; (b) 5.23 mg L-histidine; (c) 177.32 mg L-arginine-HCl; (d) 1.87 mg calcium chloride; and (e) 1.68 mg polysorbate 80 in 3 mL sterile water.
[0410] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 168.35 mg sucrose; (b) 5.23 mg L-histidine; (c) 146.63 mg L-arginine; (d) 2.47 mg calcium chloride dihydrate; and (e) 1.68 mg polysorbate 80 in 3 mL sterile water.
[0411] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution comprises: (a) 168.35 mg sucrose; (b) 5.23 mg L-histidine; (c) 146.63 mg L-arginine; (d) 1.87 mg calcium chloride; and (e) 1.68 mg polysorbate 80 in 3 mL of sterile water.
[0412] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the lyophilized pharmaceutical composition is reconstituted within 7 to 12 seconds.
[0413] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a weight molar osmolality of about 525 to about 725 mOsm / kg. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a weight molar osmolality of about 600 to about 650 mOsm / kg.
[0414] In some embodiments, the weight molar osmolality of the pharmaceutical composition is about 525 mOsm / kg. In some embodiments, the weight molar osmolality of the pharmaceutical composition is about 550 mOsm / kg. In some embodiments, the weight molar osmolality of the pharmaceutical composition is about 575 mOsm / kg. In some embodiments, the weight molar osmolality of the pharmaceutical composition is about 600 mOsm / kg. In some embodiments, the weight molar osmolality of the pharmaceutical composition is about 625 mOsm / kg. In some embodiments, the weight molar osmolality of the pharmaceutical composition is about 650 mOsm / kg. In some embodiments, the weight molar osmolality of the pharmaceutical composition is about 675 mOsm / kg. In some embodiments, the weight molar osmolality of the pharmaceutical composition is about 700 mOsm / kg. In some embodiments, the weight molar osmolality of the pharmaceutical composition is about 725 mOsm / kg.
[0415] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a pH of about 6.5 to about 7.5. In some embodiments, the pharmaceutical composition has a pH of about 7.0. In some embodiments, the pharmaceutical composition has a pH of about 6.8. In some embodiments, the pharmaceutical composition has a pH of 6.8.
[0416] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a pH of about 6.5. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a pH of about 6.6. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a pH of about 6.7. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a pH of about 6.8. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a pH of about 6.9. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a pH of about 7.0. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a pH of about 7.1. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a pH of about 7.2. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a pH of about 7.3. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a pH of about 7.4. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a pH of about 7.5.
[0417] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a protein concentration of about 0.8 to about 1.2 mg / mL.
[0418] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a protein concentration of about 0.8 mg / mL. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a protein concentration of about 0.9 mg / mL. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a protein concentration of about 1.0 mg / mL. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a protein concentration of about 1.1 mg / mL. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the resulting solution has a protein concentration of about 1.2 mg / mL.
[0419] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the protein concentration of the resulting solution is 0.8 mg / mL. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the protein concentration of the resulting solution is 0.9 mg / mL. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the protein concentration of the resulting solution is 1.0 mg / mL. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the protein concentration of the resulting solution is 1.1 mg / mL. In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the protein concentration of the resulting solution is 1.2 mg / mL.
[0420] In some embodiments, when the lyophilized pharmaceutical composition is combined with the sterile water, the turbidity of the resulting solution is less than about 7 turbidimetric units.
[0421] In some embodiments, less than 1% of the chimeric protein aggregates when the lyophilized pharmaceutical composition is combined with sterile water. In some embodiments, less than 2% of the chimeric protein aggregates when the lyophilized pharmaceutical composition is combined with sterile water. In some embodiments, less than 2.5% of the chimeric protein aggregates when the lyophilized pharmaceutical composition is combined with sterile water. In some embodiments, less than 3% of the chimeric protein aggregates when the lyophilized pharmaceutical composition is combined with sterile water. In some embodiments, less than 3.5% of the chimeric protein aggregates when the lyophilized pharmaceutical composition is combined with sterile water. In some embodiments, less than 4% of the chimeric protein aggregates when the lyophilized pharmaceutical composition is combined with sterile water. V. Pharmaceutical Kit
[0422] In some embodiments, the pharmaceutical composition is provided together with a second container containing sterile water. This document discloses pharmaceutical kits comprising a first container containing a pharmaceutical composition and a second container containing sterile water.
[0423] This document discloses a pharmaceutical kit comprising: (i) a first container containing a lyophilized pharmaceutical composition comprising (a) a chimeric protein comprising a first polypeptide chain comprising a factor VIII (“FVIII”) protein and a constant region or portion thereof of a first immunoglobulin (“Ig”), and a second polypeptide chain comprising a von Willebrand factor (“VWF”) protein and a constant region or portion thereof of a second Ig; (b) sucrose; (c) histidine; (d) arginine; (e) calcium chloride; and (f) polysorbate (such as polysorbate 20 or polysorbate 80), and (ii) a second container containing sterile water.
[0424] This document also discloses a pharmaceutical kit comprising: (i) a first container containing a lyophilized pharmaceutical composition comprising (a) a chimeric protein comprising a first polypeptide chain comprising a factor VIII (“FVIII”) protein and a constant region or portion thereof of a first immunoglobulin (“Ig”), and a second polypeptide chain comprising a von Willebrand factor (“VWF”) protein and a constant region or portion thereof of a second Ig; (b) about 30 mg to about 135 mg of sucrose; (c) about 2.5 mg to about 7.5 mg of histidine; (d) about 140 mg to about 200 mg of arginine; (e) about 1.5 mg to about 5 mg of calcium chloride; and (f) about 1 mg to about 5 mg of polysorbate (such as polysorbate 20 or polysorbate 80); and (ii) a second container containing sterile water.
[0425] This document also discloses a pharmaceutical kit comprising: (i) a first container containing a lyophilized pharmaceutical composition comprising (a) a chimeric protein comprising a first polypeptide chain comprising a factor VIII (“FVIII”) protein and a constant region or portion thereof of a first immunoglobulin (“Ig”), and a second polypeptide chain comprising a von Willebrand factor (“VWF”) protein and a constant region or portion thereof of a second Ig; (b) about 160 mg to about 200 mg of sucrose; (c) about 2.5 mg to about 7.5 mg of histidine; (d) about 140 mg to about 200 mg of arginine; (e) about 1.5 mg to about 5 mg of calcium chloride; and (f) about 1 mg to about 5 mg of polysorbate (such as polysorbate 20 or polysorbate 80); and (ii) a second container containing sterile water.
[0426] In some embodiments, the first container contains 100 IU to 10,000 IU of chimeric protein.
[0427] In some embodiments, the first container contains 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU, or 4000 IU of chimeric protein. In some embodiments, the first container contains 250 IU of chimeric protein. In some embodiments, the first container contains 500 IU of chimeric protein. In some embodiments, the first container contains 1000 IU of chimeric protein. In some embodiments, the first container contains 2000 IU of chimeric protein. In some embodiments, the first container contains 3000 IU of chimeric protein. In some embodiments, the first container contains 4000 IU of chimeric protein.
[0428] In some embodiments, the second container contains about 2 mL to about 5 mL of sterile water. In some embodiments, the second container contains 2 mL to 5 mL of sterile water. In some embodiments, the second container contains about 3 mL of sterile water. In some embodiments, the second container contains 3 mL of sterile water.
[0429] In some embodiments, the second container contains about 2 mL of sterile water. In some embodiments, the second container contains about 2.1 mL of sterile water. In some embodiments, the second container contains about 2.2 mL of sterile water. In some embodiments, the second container contains about 2.3 mL of sterile water. In some embodiments, the second container contains about 2.4 mL of sterile water. In some embodiments, the second container contains about 2.5 mL of sterile water. In some embodiments, the second container contains about 2.6 mL of sterile water. In some embodiments, the second container contains about 2.7 mL of sterile water. In some embodiments, the second container contains about 2.8 mL of sterile water. In some embodiments, the second container contains about 2.9 mL of sterile water. In some embodiments, the second container contains about 3 mL of sterile water. In some embodiments, the second container contains about 3.1 mL of sterile water. In some embodiments, the second container contains about 3.2 mL of sterile water. In some embodiments, the second container contains about 3.3 mL of sterile water. In some embodiments, the second container contains about 3.4 mL of sterile water. In some embodiments, the second container contains about 3.5 mL of sterile water. In some embodiments, the second container contains about 3.6 mL of sterile water. In some embodiments, the second container contains about 3.7 mL of sterile water. In some embodiments, the second container contains about 3.8 mL of sterile water. In some embodiments, the second container contains about 3.9 mL of sterile water. In some embodiments, the second container contains about 4 mL of sterile water. In some embodiments, the second container contains about 4.1 mL of sterile water. In some embodiments, the second container contains about 4.2 mL of sterile water. In some embodiments, the second container contains about 4.3 mL of sterile water. In some embodiments, the second container contains about 4.4 mL of sterile water. In some embodiments, the second container contains about 4.5 mL of sterile water. In some embodiments, the second container contains about 4.6 mL of sterile water. In some embodiments, the second container contains about 4.7 mL of sterile water. In some embodiments, the second container contains about 4.8 mL of sterile water. In some embodiments, the second container contains about 4.9 mL of sterile water. In some embodiments, the second container contains about 5 mL of sterile water.
[0430] In some embodiments, the pharmaceutical kit further includes instructions for combining the lyophilized pharmaceutical composition with sterile water.
[0431] In some embodiments, the first container is a glass vial containing a rubber stopper.
[0432] In some embodiments, the second container is a syringe body. In some embodiments, the syringe body is associated with a plunger. In some embodiments, the pharmaceutical kit further includes an adapter connecting the glass vial to the syringe body. In some embodiments, the pharmaceutical kit further includes an infusion tubing associated with a needle and connected to the syringe body, suitable for intravenous infusion. In some embodiments, the second container is a pre-filled syringe. VI. Methods and Uses of Pharmaceutical Compositions
[0433] This document also discloses the use of a pharmaceutical composition or a method of treating hemophilia A in an individual in need, the method comprising administering an effective amount of the pharmaceutical composition of this disclosure to the individual. In some embodiments, treatment of hemophilia A includes preventing bleeding episodes in the individual in need. In some embodiments, treatment of hemophilia A includes treating bleeding episodes in the individual in need. In some embodiments, treatment of hemophilia A includes controlling the incidence or frequency of bleeding episodes in the individual in need. In some embodiments, treatment of hemophilia A includes reducing the incidence or frequency of bleeding episodes in the individual in need.
[0434] In some embodiments, the composition is used to treat bleeding disorders or conditions in an individual in need. Bleeding disorders or conditions are selected from bleeding coagulation disorders, joint effusion, muscle bleeding, oral bleeding, hemorrhage, bleeding into muscles, trauma, head trauma (trauma capitis), gastrointestinal bleeding, intracranial hemorrhage, intra-abdominal hemorrhage, intrathoracic hemorrhage, fractures, central nervous system bleeding, retropharyngeal bleeding, retroperitoneal bleeding, iliopsoas sheath bleeding, and any combination thereof. In still other embodiments, the individual is scheduled for surgery. In some embodiments, the treatment is preventative or on-demand.
[0435] In some embodiments, the use or method includes combining a lyophilized pharmaceutical composition of the kit of this disclosure with sterile water and administering an effective amount of the resulting combination to the individual. In some embodiments, the individual combines the lyophilized pharmaceutical composition of the kit with sterile water. In some embodiments, the combination is self-administered by the individual.
[0436] In some embodiments, the plurality of doses includes at least two doses, at least three doses, at least four doses, at least five doses, at least six doses, at least seven doses, at least eight doses, at least nine doses, at least ten doses, at least eleven doses, at least twelve doses, at least thirteen doses, at least fourteen doses, at least fifteen doses, at least sixteen doses, at least seventeen doses, at least eighteen doses, at least nineteen doses, at least twenty doses, or more. In some embodiments, the plurality of doses are administered for at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 12 months, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years, at least about 10 years, at least about 15 years, at least about 20 years, or at least about 25 years.
[0437] The chimeric protein described herein may be administered by any means known in the art. In some embodiments, the chimeric protein is administered via a route selected from: intravenous injection, intravenous infusion, subcutaneous administration, intramuscular administration, oral administration, nasal administration, and pulmonary administration. In some embodiments, the chimeric protein is administered intravenously. In some embodiments, the chimeric protein is administered subcutaneously.
[0438] This disclosure has now been described in detail, and the invention will become more apparent from the following examples, which are included herein for illustrative purposes only and are not intended to limit the scope of this disclosure. All patents, publications, and articles cited herein are expressly and specifically incorporated herein by reference. Example 1: Evaluation of the effects of buffer selection and target pH on the stability of chimeric proteins
[0439] This example demonstrates favorable pH and buffering agents from various buffers such as acetate, succinate, histidine, potassium phosphate, and Tris over a wide pH range of 4.0–8.0. Eleven buffers were investigated in combination with a target concentration of 1 mg / mL of levonorgestrel α. The buffers studied are shown in Table 1. No additional excipients were included in the pharmaceutical compositions used in this study. Each pharmaceutical composition containing levonorgestrel α and a specific buffer was evaluated by measuring actual protein concentration, pH, visual inspection, high molecular weight substances (HMWS), and turbidity. The samples studied were stored at 5ºC, 25ºC, and 40ºC for up to 4 weeks. Table 1: The buffer solution under study abbreviation Full name A4.0 10 mM sodium acetate, pH 4.0 A5.0 10 mM sodium acetate, pH 5.0 S5.5 10 mM sodium succinate, pH 5.5 H5.5 10 mM histidine-HCl pH 5.5 H6.0 10 mM histidine-HCl pH 6.0 H6.5 10 mM histidine-HCl pH 6.5 H7.0 10 mM histidine-HCl pH 7.0 H7.5 10 mM histidine-HCl pH 7.5 KP6.5 10 mM potassium phosphate, pH 6.5 KP7.0 10 mM potassium phosphate, pH 7.0 T8.0 10 mM Tris pH 8.0
[0440] The initial visual appearance, measured protein concentrations, and pH results for the 1 mg / mL formulation of ephemeral thrombin α in their respective buffers are shown in Table 2. For H7.0, H7.5, and T8.0, the measured pH values were 6.88, 7.05, and 7.84, respectively, which are below the target (expected) pH. Table 2: buffer solution Visual appearance Measured concentration (mg / mL) Measured pH A4.0 precipitation Not measured Not measured A5.0 Turbid, white, with no visible particles Not measured Not measured S5.5 Clear, white, with no visible particles. 1.06 5.48 H5.5 Clear, white, with no visible particles. 1.06 5.46 H6.0 Clear, white, with no visible particles. 1.04 5.99 H6.5 Clear, white, with no visible particles. 1.05 6.40 H7.0 Clear, white, with no visible particles. 1.04 6.88 H7.5 Clear, white, with no visible particles. 1.06 7.05 KP6.5 Clear, white, with no visible particles. 1.03 6.49 KP7.0 Clear, white, with no visible particles. 1.07 6.94 T8.0 Turbid, white, with no visible particles 1.04 7.84
[0441] Pharmaceutical compositions A4.0 and A5.0 were removed from further studies because they exhibited precipitation and poor visual appearance. The remaining pharmaceutical compositions were stored at 5ºC, and the percentage of HMWS (%HMWS) was measured by size exclusion chromatography (SEC) at 0, 7, and 30 days. The results are shown in Table 3. Table 3: Aggregates (%HMWS) as measured by SEC at 5ºC sample 0 days 7 days 30 days S5.5 88.14 86.50 95.15 H5.5 58.21 60.79 87.86 H6.0 68.38 68.50 69.73 H6.5 28.39 27.64 28.64 H7.0 7.01 6.31 4.32 H7.5 6.63 7.07 4.29 KP6.5 24.00 22.15 23.92 KP7.0 18.48 17.34 16.86 T8.0 27.25 49.11 65.52 standard 2.56 2.48 2.85
[0442] Pharmaceutical compositions containing histidine buffer at pH 6.88 (H7.0) and pH 7.05 (H7.5) exhibited the lowest %HMWS. A slight loss of HMWS was observed at 1 month (30 days). Pharmaceutical compositions containing histidine buffer at pH 6.5 (H6.5) or potassium phosphate buffer at pH 6.5 (KP6.5) and pH 7 (KP7.0) produced comparable %HMWS, but showed significantly higher %HMWS than pharmaceutical compositions containing histidine buffer at pH 6.88 (H7.0) and pH 7.05 (H7.5).
[0443] The pharmaceutical compositions were stored at 25ºC, and the %HMWS was measured by size exclusion chromatography (SEC) at 0, 0.25, 4, and 7 days. The results are shown in Table 4. At the start of the experiment (day 0), the pharmaceutical compositions containing histidine buffer at pH 6.88 (H7.0) and pH 7.05 (H7.5) showed the lowest %HMWS. Table 4: Aggregates (%HMWS) measured by SEC at 25ºC sample 0 days 0.25 days 4 days 7 days S5.5 88.14 87.53 94.28 95.30 H5.5 58.21 87.23 93.53 93.63 H6.0 68.38 78.07 91.17 93.00 H6.5 28.39 28.39 39.27 65.32 H7.0 7.01 7.47 14.07 16.72 H7.5 6.63 5.23 39.41 46.55 KP6.5 24.00 22.99 24.77 25.26 KP7.0 18.48 19.43 19.61 20.22 T8.0 27.25 27.45 25.17 46.22 standard 2.56 2.36 2.85 2.27
[0444] The pharmaceutical composition was stored at 40ºC, and the %HMWS was measured by size exclusion chromatography (SEC) at 0, 0.25, 1, and 7 days. The results are shown in Table 5. Table 5: Aggregates (%HMWS) measured by SEC at 40ºC Sample 0 days 0.25 days 1 day 7 days S5.5 88.14 97.11 97.25 97.21 H5.5 58.21 98.85 97.44 98.35 H6.0 68.38 72.70 82.80 96.48 H6.5 28.39 73.51 85.18 93.39 H7.0 7.01 22.06 42.36 68.71 H7.5 6.63 7.79 14.71 46.99 KP6.5 24.00 23.14 25.82 35.79 KP7.0 18.48 18.69 20.00 28.70 T8.0 27.25 30.33 24.96 58.07 standard 2.56 2.28 2.79 2.79
[0445] Initially, the pharmaceutical compositions containing histidine buffers at pH 6.88 (H7.0) and pH 7.05 (H7.5) exhibited the lowest %HMWS. Significant degradation of eprenin α was observed at 40ºC for all tested buffers.
[0446] The concentration stability of the pharmaceutical compositions at different time points at 5ºC, 25ºC, and 40ºC was also evaluated. The results are shown in Table 6. Except for one sample, all samples showed a slight increase in concentration (mg / mL) at 5ºC after 1 month, indicating possible instability or aggregation; only potassium phosphate at pH 6.5 (KP6.5) did not show an increase in concentration. After 1 week at all temperatures, the samples did not show any significant changes in concentration. Table 6: Concentration Stability Results pH buffer solution study: concentration (mg / mL), time (days) 5°C sample 0 7 30 25°C sample 0 0.25 4 7 40°C sample 0 0.25 1 7 S5.5 1.01 1.01 1.25 S5.5 1.01 1.06 0.95 1.04 S5.5 1.01 1.02 0.97 1.04 H5.5 1.05 1.04 1.68 H5.5 1.05 0.99 1.04 1.07 H5.5 1.05 1.06 0.96 1.06 H6.0 1.05 1.05 1.50 H6.0 1.05 1.07 1.04 1.09 H6.0 1.05 1.06 1.01 1.12 H6.5 1.06 1.06 1.62 H6.5 1.06 0.97 1.07 1.04 H6.5 1.06 1.11 1.08 1.11 H6.8 1.06 1.04 1.38 H6.8 1.06 0.96 1.01 1.04 H6.8 1.06 1.10 1.07 1.07 H7.3 1.07 1.06 1.41 H7.3 1.07 1.01 1.05 1.06 H7.3 1.07 1.03 1.05 1.03 KP6.5 1.06 1.06 1.06 KP6.5 1.06 1.08 0.99 1.00 KP6.5 1.06 1.11 0.92 1.04 KP7.0 1.07 1.01 1.36 KP7.0 1.07 1.07 1.04 1.04 KP7.0 1.07 1.08 1.08 1.02 T 8.0 1.10 1.00 1.55 T8.0 1.10 1.05 1.07 1.08 T8.0 1.10 1.11 1.03 1.06
[0447] The pH stability of the pharmaceutical composition at 5ºC, 25ºC, and 40ºC at different time points was also evaluated. The pH of the samples did not change significantly when stored at 5ºC for one month, at 25ºC for one week, or at 40ºC for one week (data not shown). At all time points, measurements were within + / - 0.5 units from time zero.
[0448] The turbidity of the pharmaceutical compositions at different time points at 5ºC, 25ºC, and 40ºC was also evaluated. After 7 days at 25ºC and 40ºC, respectively, the absorbance of the compositions containing potassium phosphate 7.0 (KP7.0) and histidine 5.5 (H5.5) increased by 2 to 3 times. In summary, the absorbance values did not change significantly when stored at 5ºC for one month, at 25ºC for one week, or at 40ºC for one week (data not shown).
[0449] Summary
[0450] Pharmaceutical compositions containing histidine and potassium phosphate in the pH range of 6.8 to 7.3 showed small variations in concentration, pH, and turbidity, as well as low aggregation (%HMWS). Evans thrombin α exhibited the greatest stability in pharmaceutical compositions with a pH range of 6.8 to 7.3.
[0451] Initial aggregation in histidine buffer was significantly lower than that in potassium phosphate buffer. Minimal increases in aggregation were observed over 7 days in phosphate buffer at pH 6.5 and pH 7.0 at stress temperatures of 25ºC and 40ºC. Example 2: Evaluation of the effects of histidine molar concentration and protein concentration on the stability of Evans thrombin α.
[0452] These determined the effect of histidine molar concentration and protein concentration on achieving the target pH of 7.0. Further studies were conducted to determine the effect of buffer molar concentration on the stability of ephemeral thrombin α at protein concentrations of 1, 0.67, and 0.045 mg / mL.
[0453] Study Design: Pharmaceutical compositions containing one of three different molar concentrations of histidine (10 mM, 20 mM, and 50 mM) and one of three different concentrations of eparginine α (1 mg / mL, 0.67 mg / mL (4000 IU), and 0.045 mg / mL (250 IU / ml)) in the presence of other excipients at constant concentrations were investigated. Except for histidine and eparginine α, all pharmaceutical compositions were formulated to include the following excipients: 250 mM arginine salt (ArgHCl), 5 mM CaCl2, 5% sucrose, and 0.05% polysorbate 80 (PS80). Liquid stability was evaluated for one week at 5ºC, 25ºC, and 40ºC. The stability of each pharmaceutical composition was assessed by visual inspection, turbidity, protein concentration (Lunatic, Unchained Labs, Pleasanton CA), pH, and weight mole osmolality. The %HMWS of each pharmaceutical composition was assessed by SEC, and the protein concentration of each pharmaceutical composition was assessed by RP-HPLC.
[0454] At any protein concentration (1 mg / mL, 4000 IU / mL, or 250 IU / mL), the maximum pH values of pharmaceutical compositions containing 10 mM, 20 mM, and 50 mM histidine were 6.8, 6.95, and 7.1, respectively. The target pH of 7.0 was achieved at 20 mM and 50 mM histidine. The pH of the formulation increased with increasing molar concentration of histidine, likely due to increased buffering capacity (see Figure 2). Protein concentration had no significant effect on pH, and pH did not change significantly with time and temperature (data not shown).
[0455] At the start of the experiment (T0), a higher molar osmolality was observed as the molar concentration of histidine increased from 10 mM to 50 mM. Visual inspection showed that the nine formulations studied at T0 and 1 week were clear and colorless at 5ºC, 25ºC, and 40ºC. However, after 1 week, the protein aggregated significantly at 40ºC, and %HMWS increased significantly at 40ºC at 1 week. At the three different temperatures, molar concentration had no effect on concentration and molar osmolality over 1 week (data not shown).
[0456] Turbidity results are shown in Table 7. Turbidity (NTU) shows a direct correlation with protein concentration. At 5ºC and 25ºC, samples were clear at T0 and remained clear after 1 week. Although the turbidity of 1 mg / mL and 4000 IU samples increased significantly at 40ºC, the 1 mg / mL sample remained clear after 1 week. Further results of the turbidity test are shown in Figure 3. The %HMWS analysis results of the samples observed at 5ºC and 25ºC in Table 7 are shown in Figure 4. At 40ºC, aggregation was significantly higher for all mole and protein concentrations (data not shown). The SEC test revealed that the higher the protein concentration, the greater the %HMWS at T0. It was also observed that the %HMWS of eparginine α was comparable at 5ºC, 25ºC, and 40ºC for all histidine concentrations tested (10, 20, or 50 mM). Therefore, changes in histidine molar concentration did not show an effect on aggregation levels. Samples containing 1 mg / mL of protein showed aggregation increasing with temperature.
[0457] After one week at 25ºC, samples containing 4000 IU / mL (0.67 mg / mL) of protein showed a loss of aggregation. After one week at both 25ºC and 40ºC, samples containing 250 IU / mL (0.045 mg / mL) showed a loss of aggregation. Typically, some HMWS aggregation is present at 25ºC, but over time, HMWS shows decomposition into smaller molecules and presents as an LMW peak after a short duration (approximately 25 minutes). Compared to 25ºC, HMWS did not show decomposition into LMW substances at 40ºC. The 250 IU / mL (0.045 mg / mL) sample was unstable at 40ºC.
[0458] Summary
[0459] For pharmaceutical compositions containing 1 mg / mL, 4000 IU / mL, or 250 IU / mL of Evans thrombin α; 10 mM histidine; 250 mM ArgHCl; 5% sucrose; 5 mM Cacl2; and 0.05% PS80, a maximum pH of 6.8 was achieved. Increasing the molar concentration of the histidine buffer showed no significant effect on pH, molar osmolality, protein concentration, turbidity, or stability at T0 (%HMWS) or after 1 week at 5ºC, 25ºC, and 40ºC. For all protein concentrations studied, Evans thrombin α showed significant aggregation after 1 week at a stress temperature of 40ºC. For pharmaceutical compositions containing 4000 IU / mL and 250 IU / mL protein, significant loss of aggregation peaks was observed at 25ºC and 40ºC after 1 week. For pharmaceutical compositions containing 1 mg / mL and 4000 IU / mL of Evansin α, turbidity increased significantly after 1 week at 40ºC. Example 3: Evaluation of the effect of polysorbate 80 (PS80) concentration on protein stability.
[0460] These studies determined the effect of PS80 concentration on the stability of Evans α formulations.
[0461] Two concentrations of levulin α (0.67 mg / mL (4000 IU / mL) and 0.045 mg / mL (250 IU / mL)) were investigated in 10 mM histidine, 250 mM arginine phosphate (ArgHCl), 5 mM CaCl2, 5% sucrose, and polysorbate 80 (PS80). The concentration of PS80 in the 250 IU / mL sample ranged from 0.002% to 0.07%. The concentration of PS80 in the 4000 IU / mL sample ranged from 0.03% to 0.1%. The samples were subjected to stress for 0, 1, 3, and 5 cycles by orbital agitation (250 rpm for 0, 6, and 24 hours) or freeze-thaw (-80ºC for at least 24 h, followed by thawing at room temperature). The analyses included aggregation by SEC analysis, PS80 concentration analysis by high-performance liquid chromatography with electrosol detection (CAD), particle testing by microfluidic imaging (MFI) and high-accuracy liquid particle counter (HIAC), pH, turbidity, and protein concentration. The results of each analysis are shown in Table 8.
[0462] Summary
[0463] The results of this study indicate that a PS80 concentration ≥ 0.03% stabilized both 250 IU and 4000 IU concentrations of Evans α. No changes in PS80 content were observed in samples after 24 h of agitation or 5 freeze-thaw cycles. No trend in particulate matter was observed throughout the study across the PS80 range. No trend or change in pH or turbidity was observed within the PS80 range. Therefore, pharmaceutical compositions containing a PS80 concentration ≥ 0.03% improve the stability of Evans α at minimum concentrations of 250 IU and maximum concentrations of 4000 IU, with minimal impact on other compositional properties. Table 8: Subvisible particles detected by MFI and HIAC strength PS80 concentration (%) Stirring Research Freeze-thaw research T0 T6 hours T24 hours F / T 1X F / T 3X F / T 5X ≥ 10 µm ≥ 25 µm ≥ 10 µm ≥ 25 µm ≥ 10 µm ≥ 25 µm ≥ 10 µm ≥ 25 µm ≥ 10 µm ≥ 25 µm ≥ 10 µm ≥ 25 µm Particles MFI number 250 IU 0.002 44 11 14 5 twenty three 2 14 7 7 2 28 5 0.005 11 5 11 7 9 5 9 0 11 0 9 2 0.010 14 2 11 5 28 5 14 0 11 5 28 9 0.030 39 7 39 7 14 7 2 0 21 0 5 2 0.050 18 0 9 5 41 11 50 7 57 0 32 9 0.070 14 7 57 18 25 5 16 5 9 0 0 0 4000 IU 0.030 7 2 9 2 257 64 18 5 5 0 twenty one 5 0.050 7 2 11 0 18 5 41 14 16 5 7 5 0.070 9 0 7 0 156 48 41 5 32 7 9 0 0.100 11 2 9 5 119 32 7 0 16 2 11 2 Granules HIAC number 250 IU 0.002 60 8 18 0 15 0 100 25 2 0 7 0 0.005 27 0 27 0 7 2 0 0 0 0 0 0 0.010 20 0 17 0 27 2 2 0 3 2 0 0 0.030 28 3 20 0 33 2 2 2 3 0 2 0 0.050 22 2 10 2 23 2 7 0 0 0 0 0 0.070 17 2 43 2 10 0 23 7 2 0 2 0 4000 IU 0.030 25 0 17 0 18 0 0 0 5 2 2 0 0.050 12 2 25 0 12 2 2 0 2 0 2 0 0.070 10 2 2 0 17 3 0 0 2 0 3 0 0.100 32 0 12 0 13 2 2 0 52 twenty two 2 0 Example 4: Evaluating the effect of excipient concentration on protein stability
[0464] The experiments described in this example evaluated the stability of a pharmaceutical composition comprising 1000 IU of Evans α-thrombin (DP) formulated with diluents containing various concentrations of excipients. Minimum and maximum excipient concentration ranges deviating from current manufacturing tolerances were intentionally designed to challenge formulation robustness. A series of 13 different diluents were evaluated (see Table 9). The Design of Experiments (DoE) model was based on five parameters (i.e., five excipients) at two levels (i.e., ±5% of the target value). This included a control center point with the target formulation excipient amount (i.e., buffer 13).
[0465] Evanthrolin α active pharmaceutical ingredient (DS) was pre-reconstituted at a concentration of 1 mg / mL in 10 mM L-histidine, 250 mM L-arginine salt (HCl), 5 mM chloride, 5% (w / v) sucrose, and 0.05% (w / v) polysorbate 80 (PS80) at pH 7.01. Evanthrolin α DS was down-diluted to one of several strengths using one of 13 dilution buffers to produce diluted Evanthrolin α active pharmaceutical ingredient (DDS). Table 9: Dilution buffers tested Buffer number L-Arginine HCl (g / L) Sucrose (g / L) L-histidine (g / L) Calcium chloride dihydrate (g / L) Polysorbate-80 (g / L) 1 50.032 52.500 1.630 0.698 0.475 2 55.298 47.500 1.474 0.698 0.525 3 55.298 52.500 1.474 0.698 0.475 4 55.298 47.500 1.630 0.772 0.525 5 50.032 47.500 1.630 0.772 0.475 6 55.298 52.500 1.630 0.772 0.525 7 50.032 52.500 1.474 0.772 0.525 8 50.032 52.500 1.630 0.698 0.525 9 55.298 47.500 1.630 0.698 0.475 10 50.032 47.500 1.474 0.698 0.525 11 55.298 52.500 1.474 0.772 0.475 12 50.032 47.500 1.474 0.772 0.475 13 52.665 50,000 1.552 0.735 0.500
[0466] The levonorgestrel α DDS was then freeze-dried to produce levonorgestrel α DP with a desired strength of 1000 IU per vial. The resulting pharmaceutical composition containing 1000 IU of levonorgestrel α DP was evaluated under various stability conditions (2ºC–8ºC and 30ºC) and stability time points (T0, 1 month (T1), 3 months (T3), 6 months (T6), and 12 months (T12)). Specific activity, protein concentration, aggregation, visual inspection, recombination time, pH, residual moisture, product / excipient crystallization, and glass transition temperature of the pharmaceutical composition samples were tested.
[0467] Protein concentration was measured using an RP-HPLC method with fluorescence detection. The stability specification range of 75%–125% of the initial value is intended for protein concentration.
[0468] Table 10 and Figure 11 show the concentration stability data over a period of up to 6 months (T6). Concentration values were generally below the relevant target value of 167 μg / mL, but remained within 75%–125% of the initial DP concentration, thus falling within the acceptable range of the stated specifications. Table 10: Protein Concentration Results (μg / mL) buffer solution serial number T0 DDS T0 DP 2ºC-8ºC T1 DP 30ºC T3 DP 2ºC-8ºC T3 DP 30ºC T6 DP 2ºC-8ºC T6 DP 30ºC DP% decrease T0→T6 1 159.7 156.1 151.6 160.6 148.1 138.5 138.6 11.21 2 165.2 158.2 148.9 154.5 149.5 139.7 142 10.24 3 151.5 158.5 144.7 152.5 151.7 138 139.2 12.18 4 160.4 160.6 144.7 160 154.5 139.6 139.9 12.89 5 155.6 161.8 150.1 159.7 153.2 144 140.3 13.29 6 159.6 156.0 152.8 162 156 140.2 138.9 10.96 7 165.8 163.8 154.7 153.6 THAT 138.9 144.5 11.78 8 155.4 161.8 156.3 150.7 154.2 134.9 140.7 13.04 9 157 162.2 160.8 153.1 155.2 134.1 141.8 12.58 10 157.7 169.5 161.9 154 157.6 140.6 141.8 16.34 11 154.1 165.8 160.6 155.4 151.1 135.4 138.2 16.65 12 161.2 170.2 170.4 160.6 159.9 141.8 141.2 17.04 13 145.4 167.9 162.7 152.6 153.1 142.5 137.6 18.05 average value 157.58 162.49 155.40 156.10 156.62 139.09 140.36 N / A standard deviation 5.49 4.76 7.63 3.88 11.10 2.96 1.91 N / A
[0469] The specific activities of DP and DDS were calculated using the concentration data from Figure 11. The results are shown in Table 11 and Figure 13. The specific activity specification for DDS is >1600 IU / mg, and the specific activity specification for DP at all intensities is >1280 IU / mg. For DP, the specific activity of each test sample at each time point exceeded the specified specification.
[0470] Testing of Evans α DDS revealed that the activity value before lyophilization was within the acceptable range of 80%-125% of the specified value. Table 11: Specific activity results (IU / mg) buffer solution serial number T0 DDS DDS Specification T0 DP (2ºC-8ºC) T1 DP (30ºC) T3 DP (2ºC-8ºC) T3 DP (30ºC) DP Specification 1 1748.3 1600 2053.7 1528.5 N / A 1497.0 1280.0 2 1679.8 1600 2138.1 1409.6 N / A 1554.5 1280.0 3 2093.7 1600 2251.5 1361.5 N / A 1624.3 1280.0 4 1791.1 1600 2036.6 1563.5 N / A 1622.7 1280.0 5 1822.0 1600 2060.9 1416.6 N / A 1560.1 1280.0 6 1830.8 1600 1946.4 1550.0 N / A 1443.6 1280.0 7 1769.6 1600 2040.5 1473.7 N / A 1352.60 1280.0 8 1718.8 1600 2098.6 1542.0 N / A 1655.0 1280.0 9 1759.2 1600 1600.6 1496.3 N / A 1607.6 1280.0 10 1750.8 1600 1620.5 1423.6 N / A N / A 1280.0 11 1835.8 1600 1591.8 1504.8 N / A 1653.9 1280.0 12 1719.6 1600 1608.5 1426.6 N / A 1627.9 1280.0 13 N / A 1600 1626.2 1432.4 N / A 1659.0 1280.0
[0471] Aggregation tests for DP and DDS were performed by SEC-HPLC, and the results are shown in Figure 7. At T0, DP aggregation ranged from 1.8% to 1.9%. At T3 and T6, the 30ºC samples showed reduced aggregation values as low as 1.1%, which may be due to column performance or system variations. No significant changes in aggregation were observed when comparing the T0 results with the T6 2ºC–8ºC results. For Evansin α DP, all obtained aggregation values were below 5%. Aggregation analysis of samples at T1 30ºC and T3 2ºC–8ºC has not yet been completed.
[0472] The residual moisture values did not show a significant change in stability, with all results below 1.2%, within the 3% stability specification limit.
[0473] Upon visual inspection, the lyophilized cakes of Ivanin α DP were observed to be white to grayish-white in color. These cakes completely dissolved within approximately 60 seconds upon reconstruction. The reconstruction values at time points T0 and T1 were slightly lower (within 25 seconds). All Ivanin α DP samples were reconstructed within 70 seconds (far below the proposed 3.5-minute specification), and no undesirable appearance was observed.
[0474] The sample was tested using powder X-ray diffraction. The sample showed amorphous contents at time points T1 to T6, as confirmed by the amorphous halo pattern in the diffraction pattern. No evidence of crystallization of the product or excipient (e.g., crystallization peaks) was observed.
[0475] The glass transition temperature (Tg) of each sample was measured by differential scanning calorimetry (DSC) in duplicate; the average results are shown in Figure 16. The highest and lowest Tg values were 71.75ºC (T6 30ºC buffer #10) and 61.95ºC (buffer #3 T6 2ºC–8ºC), respectively. The highest Tg value (buffer #10 T6 30ºC) is consistent with the lowest moisture content (0.9%) observed in the sample at this time point. The lowest Tg value (buffer #3 T6 2ºC–8ºC) is consistent with the higher relative moisture content (1.11%) observed in buffer #3 at this time point. Regarding stability, the samples did not show any obvious trend of increasing or decreasing Tg values under different storage conditions. The measured enthalpy values were between 0.19 and 0.46 J / gºC.
[0476] The stability results for all samples shown in Figure 16 exhibit Tg values above 60ºC. This is favorable for the stable long-term storage of Evans thromboplastin α at temperatures ranging from 2ºC to 8ºC (including six months of storage at room temperature). Example 5: Evaluation of the effect of arginine HCl concentration on protein stability
[0477] The experiment described in this example was used to evaluate the stability of Evans thromboplastin α in pharmaceutical compositions formulated with different concentrations of arginine HCl.
[0478] Two pharmaceutical compositions were evaluated with the only difference being the concentration of L-arginine-HCl. The first composition contained 1.0 mg / mL levonorgestrel α in 10 mM histamine pH 7.0, 250 mM L-arginine-HCl, 5 mM CaCl2, 5% sucrose, and 0.05% polysorbate-80. The second composition contained 1.0 mg / mL levonorgestrel α in 10 mM histamine pH 7.0, 175 mM L-arginine-HCl, 5 mM CaCl2, 5% sucrose, and 0.05% polysorbate-80. Each composition was diluted after thawing at room temperature for approximately 60, 120, and 240 minutes to prepare for size exclusion chromatography (SEC) analysis. Two SEC injections were performed for each sample, and %HMWS was determined for each injection.
[0479] The lyophilized Evans α drug product was reconstituted in 3.0 mL of water for injection (WFI). Aliquots of the reconstituted solution were transferred to HPLC vials for analysis.
[0480] SEC analysis used an HPLC instrument equipped with a pump, temperature-controlled autosampler, column heater, and fluorescence detector. The sample solution was analyzed using the following instrument and method parameters: ■ Mobile phase: Duchenne phosphate buffered saline (D-PBS) containing calcium and magnesium, with 0.36 M sodium chloride (0.9 mM calcium chloride, 0.5 mM magnesium chloride, 2.7 mM potassium chloride, 1.5 mM potassium dihydrogen phosphate, 496 mM sodium chloride, 8.1 mM disodium hydrogen phosphate, pH 7.0 ± 0.1) ■ Column heater: 26ºC ■ Execution time: 40 min ■ FL detector: Ex / Em = 280 / 350 nm, PMT gain = 5 ■ Injection loading: 2 μg ■ Autosampler temperature: 5ºC ■ Flow rate: 0.5 mL / min, isogradient
[0481] Pharmaceutical compositions containing 250 mM L-arginine-HCl were found to be more stable than those containing 175 mM L-arginine-HCl. Example 6: Further evaluation of the effect of L-arginine-HCl concentration on protein stability.
[0482] The effect relative to a wider range of arginine concentrations was also examined. Eight concentrations of L-arginine-HCl (50, 100, 125, 150, 175, 200, 250, and 300 mM) were added to a basic formulation containing 10 mM histidine, 5 mM calcium chloride, 5% sucrose, and 0.05% polysorbate 80. A summary of the experimental design is provided in Table 12. After thawing at room temperature (25ºC), the formulations were prepared, placed in HPLC vials, and stored in an autosampler at 5ºC ± 3ºC. HPLC injections at each time point were taken from the same vial. The aggregation percentage (%HMWS) of each formulation was obtained. The aggregation percentage (%HMWS) of each sample was measured by SEC.
[0483] SEC analysis uses HPLC instruments equipped with pumps, temperature-controlled autosamplers, column heaters, and fluorescence detectors. The sample solutions are analyzed using the following instrument and method parameters:
[0484] Mobile phase: Duchenne phosphate-buffered saline (D-PBS) containing calcium and magnesium with 0.36 M sodium chloride (0.9 mM calcium chloride, 0.5 mM magnesium chloride, 2.7 mM potassium chloride, 1.5 mM potassium dihydrogen phosphate, 496 mM sodium chloride, 8.1 mM disodium hydrogen phosphate, pH 7.0 ± 0.1) - Column heater: 26ºC - Execution time: 40 min - FL detector: Ex / Em = 280 / 350 nm, PMT gain = 5 - Injection mass loading: 2 μg - Autosampler temperature: 5ºC - Flow rate: 0.5 mL / min, isogradient Table 12. Overview of Arginine Concentration Studies Research Ivanin α concentration Arginine level Research conditions Research Time Point Quality attributes Selection of L-arginine HCl as a stabilizing excipient 1 mg / mL 50, 100, 125, 150, 175, 200, 250 and 300 mM Freeze at -80ºC and thaw at ambient room temperature. Thawed for 40, 80, 120 and 160 minutes Aggregation percentage measured by SE-HPLC
[0485] Two experiments were conducted (run in duplicate each time) using the conditions outlined in Table 12. The results of Experiment 1 are shown in Table 13 and Figure 27. In Experiment 1, it was found that the percentage of high molecular weight (HMW) aggregates was higher in formulations with lower concentrations of arginine. Higher concentrations of arginine (200 mM to 300 mM) showed a consistently lower percentage of HMW aggregates up to 160 minutes after thawing. Table 13. Percentage of High Molecular Weight Aggregates - Experiment 1 %HMW AREA Arginine 0 min 40 min 80 min 120 min 160 min 0 mM 4.24 4.22 4.25 4.24 4.26 50 mM 8.38 8.27 8.16 8.05 7.93 100 mM 7.36 7.13 6.94 6.83 6.60 125 mM 7.35 6.92 6.56 6.12 5.85 150 mM 4.79 4.42 4.32 4.19 4.01 175 mM 5.73 5.13 4.46 4.26 3.97 200 mM 4.10 3.77 3.78 3.54 3.63 250 mM 3.72 3.71 3.70 3.71 3.70 300 mM 3.60 3.60 3.60 3.59 3.61
[0486] The results of Experiment 2 are shown in Table 14 and Figure 28. In Experiment 2, a higher percentage of HMW aggregates was found in formulations with lower concentrations of arginine. Consistent with the observations in Experiment 1, Experiment 2 also showed that higher concentrations of arginine (200 mM to 300 mM) exhibited a consistently lower percentage of HMW aggregates up to 160 minutes after thawing. Table 14. Percentage of High Molecular Weight Aggregates - Experiment 2 %HMW AREA Arginine 0 min 40 min 80 min 120 min 160 min 0 mM 4.24 4.22 4.25 4.24 4.26 50 mM 8.38 8.27 8.16 8.05 7.93 100 mM 7.36 7.13 6.94 6.83 6.60 125 mM 7.35 6.92 6.56 6.12 5.85 150 mM 4.79 4.42 4.32 4.19 4.01 175 mM 5.73 5.13 3.60 3.60 3.59 3.61
[0487] The weight molar osmolality of samples across a range of arginine concentrations was also investigated in two separate experiments (each run in duplicate). The weight molar osmolality (mOsm / kg) of the preparations is shown to increase with increasing arginine concentration. In Experiment 1, the first set of replicate samples was measured on an osmometer after 24 hours at ambient temperature. The second set of replicate samples came from a retained sample stored at -80ºC. The results of Experiment 1 are shown in Table 15. In Experiment 2, a single set of replicate samples came from a retained sample stored at -80ºC. The results from Experiment 2 are shown in Table 16. Table 15. Weight molar osmolality of preparations with increasing arginine concentrations - Experiment 1 Experiment 1 Repeat 1 (RT) Repeat 2 (-80ºC) Sample ID mOsm / kg mOsm / kg 290references 295 288 0 mM 218 n / a 50 mM Arg 327 331 100 mM Arg 371 420 125 mM Arg 408 425 150 mM Arg 495 484 175 mM Arg 530 524 200 mM Arg 534 537 250 mM Arg 655 667 300 mM Arg 758 699 Table 16. Weight molar osmolality of formulations with gradually increasing arginine concentration – Experiment 2 Experiment 2 (-80ºC) Sample ID mOsm / kg 290references 288 0 mM 184 50 mM Arg 302 100 mM Arg 356 125 mM Arg 398 150 mM Arg 476 175 mM Arg 513 200 mM Arg 538 250 mM Arg n / a 300 mM Arg 701
[0488] The pH was not adjusted for the tested samples, and the pH of the formulations across the arginine concentration range was subsequently evaluated. The results are shown in Table 17.
[0489] Table 17. Ph of formulations with gradually increasing arginine concentration Repeat 1 Repeat 2 Repeat 3 sample Required Arg concentration For example, via pH meter 1 Measured pH For example, via pH meter 2 Measured pH For example, via pH meter 3 Measured pH Preparation 1 0 7.00 6.99 6.95 Preparation 2 50 6.74 6.74 6.76 Preparation 3 100 6.74 6.70 6.75 Preparation 4 125 6.74 6.69 6.70 Preparation 5 150 6.69 6.65 6.67 Preparation 6 175 6.69 6.62 6.67 Preparation 7 200 6.67 6.60 6.70 Preparation 8 250 6.54 6.54 6.65 Preparation 9 300 6.50 6.51 6.62
[0490] Conclusion: In these experiments, unexpectedly, formulations containing arsenic α with at least 250 mM arginine showed the lowest %HMW at time 0 (T0) and subsequent time points (see Figures 27 and 28), while lower levels of arginine at T0 increased aggregation. At the start of time 0, the control (0% arginine) had a T0 area of approximately 4% HMW, and substantially higher %HMWs were observed at 50 mM, 100 mM, 125 mM, and 150 mM, indicating that lower concentrations of arginine in the 50 mM–200 mM range initially exhibited higher aggregation levels than the control (0 mM arginine). At concentrations of 50 mM, 100 mM, 125 mM, and 150 mM, the %HMW area decreased over time.
[0491] Therefore, the use of at least 250 mM arginine in formulations stabilizes ephemeralin α over time with minimal aggregation. Example 7: Evaluation of the effect of low sucrose on protein stability
[0492] The experiments described in this example evaluated the stability of Evans thrombin α in pharmaceutical compositions formulated with different concentrations of sucrose. In addition to sucrose, each composition contained 10 mM L-histidine, 250 mM L-arginine-HCl, 5 mM CaCl2, and 0.05% (w / v) polysorbate 80 at pH 6.8.
[0493] The active pharmaceutical ingredient (DS) of Evansin α comprises 1 mg / mL Evansin α, 10 mM L-histidine, 250 mM L-arginine-HCl, 5 mM CaCl2, and 0.05% (w / v) polysorbate 80 and sucrose at pH 6.8. The pharmaceutical product (DP) of Evansin α is a DS diluted to the desired activity in International Units (IU) (e.g., IU / vial (e.g., when a vial is filled with 3.367 mL of pharmaceutical product, IU / 3.367 mL)). The DP can be lyophilized (e.g., in a vial) to obtain lyophilized DP, which can then be reconstituted prior to injection.
[0494] Aggregation of 1 mg / mL acetylcholine α active pharmaceutical ingredient (DS) compositions containing 5% or 1% sucrose was tested under room temperature (RT) / room lighting (RL) conditions or at 2°C–8°C. As shown in Figures 9 and 10, the DS composition containing 5% sucrose showed less aggregation over time (%HMWS) compared to the DS composition containing 1% sucrose.
[0495] To further analyze the effect of sucrose concentration on the Avanhexin α compositions, pharmaceutical compositions of Avanhexin α at 0, 1%, 2%, and 5% w / v sucrose were subjected to different stability conditions, and stability was assessed using several methods. The compositions were tested at the following product stages: frozen storage stability of the active pharmaceutical ingredient (DS, before lyophilization or adjustment to any specific IU strength), freeze-thaw (FT) stability of DS, post-thaw stability of liquid DS, stability of diluted DS and pharmaceutical product (DP), lyophilized stability of DP, and post-reconstitution of DP. The active pharmaceutical ingredient was tested at freezing temperatures (-80ºC or -30ºC). Pharmaceutical product samples were tested at room temperature (RT), 5ºC, 30ºC, and 40ºC. Lyophilized DP samples were tested at two different DP concentrations (4000 IU and 250 IU).
[0496] Aggregation of 250 IU of Evans α bulk pharmaceutical product (BDP) compositions was tested under room temperature (RT) / room lighting (RL) conditions or at 2ºC–8ºC. BDP compositions containing 0%, 1%, 2%, and 5% w / v sucrose were tested. Results at RT / RL are shown in Figure 11, and results at 2ºC–8ºC are shown in Figure 12. The BDP composition containing 0% sucrose showed the highest aggregation level under both conditions. However, the 250 IU BDP compositions did not show a significant increase in %HMWS over the 24-hour testing period. For all compositions and both conditions, a decrease in aggregation level was observed over time after approximately 7 days (data not shown).
[0497] Aggregation of compositions of 250 IU or 4000 IU of the lyophilized pharmaceutical product Lyo DP (Alpha Hemagglutinin α) was tested at 5ºC, 30ºC, and 40ºC. Aggregation (%HMWS) of each sample was measured by SEC. Lyo DP compositions containing 0%, 1%, 2%, and 5% w / v sucrose were tested. Samples were tested at T0, 1 month, 2 months, 3 months, and 6 months. Results for the 250 IU Lyo DP composition are shown in Figures 13 (5ºC), 14 (30ºC), and 15 (40ºC). Results for the 4000 IU Lyo DP composition are shown in Figures 16 (5ºC), 17 (30ºC), and 18 (40ºC). Generally, no significant increase in %HMWS was observed in any of the sucrose concentrations over 6 months at 5ºC, 30ºC, and 40ºC. None of the compositions tested showed a significant tendency to aggregate.
[0498] Aggregation of Evans α DS and 4000 IU bulk pharmaceutical product (BDP) liquid compositions containing 2% or 5% sucrose was tested by SEC. Samples were stored at room temperature or 5ºC and tested after 0, 5, 7, 25, 43, and 55 hours. Samples were also tested after lyophilization. The results are shown in Figure 19. Less aggregation was observed over time for the composition containing 5% sucrose. However, the composition containing 2% sucrose did not show a significant increase in aggregation during the tested time period.
[0499] Table 18 provides a summary of the aggregation test results. An increase of 1.0 or more in %HMWS relative to the baseline value shown as the corresponding value for 5% sucrose is considered unacceptable. 0% sucrose was found to be unacceptable. Table 18: Sucrose Screening Stability Results (%HMWS). sucrose concentration, % freezing store,% (-80ºC) (1 mg / mL) Liquid DS Rate % / h (1 mg / mL) Liquid BDP Rate % / h (4000 IU) Cum. % / h (4000 IU) Lyo DP(Δ6M) (4000 IU) Lyo DP(Δ6M) (250 IU) Δ6M Δ5XFT room temperature 5ºC room temperature 5ºC / RT 5ºC 30ºC 40ºC 5ºC 30ºC 40ºC 5 0.3 1.0 0.03 0.01 0.02 0.01 0.3 0.2 0.4 0.0 -0.1 0.0 2 0.3 1.2 0.02 0.02 0.02 0.02 0.5 0.7 0.9 0.0 0.2 0.0 1 0.3 1.3 0.08 0.03 0.04 0.03 0.7 0.9 0.3 0.1 0.0 0.0 0 0.6 2.2 ND ND ND ND 0.2 0.0 -0.2 0.2 0.1 0.1 ND = Undetermined
[0500] As shown in Table 18, the stability results indicate favorable freeze-thaw and frozen storage stability data for 1% to 5% w / v sucrose at -80ºC. Freeze-thaw and frozen storage stability data are unfavorable for all concentrations at -30ºC (data not shown). DP samples show small but acceptable aggregation over 6 months at 40ºC for 1% and 2% formulations.
[0501] The glass transition temperature (Tg) of compositions containing 250 IU or 4000 IU of Evans α-DP was tested at 5ºC, 30ºC, and 40ºC. Tg was measured by adjusted differential scanning calorimetry (DSC). DP compositions containing 0, 1%, 2%, and 5% w / v sucrose were tested. Samples were tested at T0, 1 month, 2 months, 3 months, and 6 months. The results are shown in Figures 20 (5ºC), 21 (30ºC), and 22 (40ºC). Overall, Tg was observed to correlate with sucrose concentration, with higher sucrose concentrations showing lower Tg. For all compositions, no significant changes in Tg were observed over 6 months at 5ºC, 30ºC, and 40ºC. No large changes in Tg were observed at different DP concentrations.
[0502] The glass transition temperature (Tg) of ependycin α pharmaceutical products (DP) containing 0%, 1%, 2%, and 5% w / v sucrose was measured by differential scanning calorimetry (DSC). DP samples were tested at two different DP concentrations (4000 IU and 250 IU). The results are shown in Figure 23.
[0503] The DSC procedure for determining Tg includes: (i) equilibration at 15ºC, (ii) adjustment at 1ºC every 60 seconds, (iii) isothermal treatment for 5 minutes, and (iv) heating to 130ºC at 3ºC / min.
[0504] The residual moisture content of compositions of 250 IU or 4000 IU of levonorgestrel α lyophilized pharmaceutical product (Lyo DP) was tested at 5ºC, 30ºC, and 40ºC. Lyo DP compositions containing 0%, 1%, 2%, and 5% w / v sucrose were tested. Samples were tested at T0, 1 month, 2 months, 3 months, and 6 months. Results are shown in Figures 24 (5ºC), 25 (30ºC), and 26 (40ºC). For all compositions, no significant change in residual moisture content was observed over 6 months at 5ºC, 30ºC, and 40ºC. All residual moisture values were below 3% of the specification.
[0505] According to visual inspection, the concentration of sucrose had no effect on the appearance of the cake over a period of 6 months at 2ºC-8ºC, 30ºC and 40ºC (data not shown).
[0506] Based on the results of these experiments, a sucrose concentration of 1% to 2% (w / v) appears to be an acceptable concentration for pharmaceutical compositions of Evans α.
[0507] The foregoing description of the specific embodiments so fully reveals the general nature of this disclosure that others can readily modify and / or adapt such specific embodiments for various applications by applying knowledge within the scope of the art, without excessive experimentation and without departing from the overall concept of this disclosure. Therefore, based on the teachings and guidance provided herein, such modifications and adaptations are intended to be included within the meaning and scope of equivalents of the disclosed embodiments. It should be understood that the wording or terminology in this document is for descriptive and not limiting purposes, and therefore the terminology or terminology in this specification will be interpreted by those skilled in the art based on the teachings and guidance.
[0508] Other embodiments of this disclosure will be apparent to those skilled in the art in light of the description and practice disclosed herein. The description and examples are intended to be illustrative only, and the appended claims indicate the true scope and spirit of this disclosure.
[0509] All patents and publications cited herein are incorporated herein by reference in their entirety. Sequence Listing 19: Exemplary Chimeric Protein Sequences; Sequence Listing 20: Additional Chimeric Protein Sequences [Simplified Explanation of the Diagram]
[0090] Figure 1 is a schematic diagram of Evans thrombin α, namely the exemplary FVIII-ELNN-Fc / D'D3-ELNN-Fc heterodimer. FVIII: Factor VIII; VWF: von Willebrand factor; A1, A2, A3, C1, C2: domains of FVIII; D'D3: domain of VWF; Fc: Fc region of the immunoglobulin constant region.
[0091] Figure 2 shows the pH of pharmaceutical compositions containing various concentrations of L-histidine (10 mM, 20 mM, 50 mM) at 1 mg / mL, 0.67 mg / mL (4000 IU / mL), and 0.045 mg / mL (250 mg / mL) thrombin α concentrations. Compositions without DS, without excipients, or containing only excipients are provided as controls. Abbreviations: DP: Pharmaceutical product. BDP: Bulk pharmaceutical product. DS: Active pharmaceutical ingredient. IU: International Units.
[0092] Figure 3 shows the measured turbidity (NTU) of pharmaceutical compositions containing various concentrations of L-histidine (10 mM, 20 mM, 50 mM) at 1 mg / mL, 0.67 mg / mL (4000 IU / mL), and 0.045 mg / mL (250 mg / mL) phenanthrene α concentrations. Results for the compositions at 5ºC, 25ºC, and 40ºC are depicted. Time points are T0 and 1 week.
[0093] Figure 4 shows the aggregation levels (%HMWS) of pharmaceutical compositions containing various concentrations of L-histidine (10 mM, 20 mM, 50 mM) at 1 mg / mL, 0.67 mg / mL (4000 IU / mL), and 0.045 mg / mL (250 mg / mL) of ephemeral thrombin α. Results for the compositions at 5ºC and 25ºC are depicted. Time points are T0 and 1 week.
[0094] Figure 5 shows the measured concentrations (µg / mL) of ephemeral thrombin α protein for each of the 13 buffer compositions tested. The compositions were tested at 2ºC–8ºC and 30ºC. Measurements were taken at the start of the experiment (T0), one month (T1), three months (T3), and six months (T6). Abbreviations: DP: Pharmaceutical Product. DDS: Diluted Active Pharmaceutical Ingredient. DoE: Experimental Design.
[0095] Figure 6 shows the measured specific activity (IU / mg) of ephemeral thrombin α for each of the 13 buffer compositions tested. The compositions were tested at 2ºC–8ºC and 30ºC. Measurements were taken at the start of the experiment (T0), one month (T1), and three months (T3). Abbreviations: DP: Pharmaceutical product. DDS: Diluted active pharmaceutical ingredient. DoE: Experimental design.
[0096] Figure 7 shows the measured alpha aggregation level (%HMWS) of 13 buffer compositions tested. Compositions were tested at 2ºC–8ºC and 30ºC. Measurements were taken at the start of the experiment (T0), one month (T1), three months (T3), and six months (T6). A 5% specification limit is indicated on the graph. Abbreviations: DP: Pharmaceutical Product. DDS: Diluted Active Pharmaceutical Ingredient. DoE: Experimental Design.
[0097] Figure 8 shows the glass transition temperature (Tg) measured using DSC for each of the 13 buffer compositions tested. The compositions were tested at 2ºC–8ºC and 30ºC. Measurements were taken at the start of the experiment (T0), one month (T1), three months (T3), six months (T6), and twelve months (T12). Abbreviations: DP: Pharmaceutical product. DDS: Diluted active pharmaceutical ingredient. DoE: Experimental design.
[0098] Figure 9 shows the change in aggregation level (%HMWS) over time (hours) of an Avanhexin α active pharmaceutical ingredient (DS) composition (1 mg / mL) containing 5% sucrose (dashed line) or 1% sucrose (solid line) under room temperature (RT) / indoor lighting (RL) conditions.
[0099] Figure 10 shows the change in aggregation level (%HMWS) over time (hours) of an alpha thrombin active pharmaceutical ingredient (DS) composition (1 mg / mL) containing 5% sucrose (dashed line) or 1% sucrose (solid line) at 2ºC-8ºC.
[0100] Figure 11 shows the aggregation level (%HMWS) of 250 IU Evans α bulk pharmaceutical product (BDP) compositions containing 0, 1%, 2% and 5% w / v sucrose concentrations over time (hours) under room temperature (RT) / indoor lighting (RL) conditions.
[0101] Figure 12 shows the change in aggregation level (%HMWS) over time (hours) of 250 IU Evans α bulk pharmaceutical product (BDP) compositions containing 0, 1%, 2% and 5% w / v sucrose concentrations at 2ºC-8ºC.
[0102] Figure 13 shows the aggregation level (%HMWS) of compositions of 250 IU of Evans α lyophilized pharmaceutical product (Lyo DP) at 5ºC. Lyo DP compositions containing 0, 1%, 2%, and 5% w / v sucrose were tested. Samples were tested at T0, 1 month, 2 months, 3 months, and 6 months.
[0103] Figure 14 shows the aggregation level (%HMWS) of compositions of 250 IU of Evans α lyophilized pharmaceutical product (Lyo DP) at 30ºC. Lyo DP compositions containing 0, 1%, 2%, and 5% w / v sucrose were tested. Samples were tested at T0, 1 month, 2 months, 3 months, and 6 months.
[0104] Figure 15 shows the aggregation level (%HMWS) of compositions of 250 IU of Evans α lyophilized pharmaceutical product (Lyo DP) at 40ºC. Lyo DP compositions containing 0, 1%, 2%, and 5% w / v sucrose were tested. Samples were tested at T0, 1 month, 2 months, 3 months, and 6 months.
[0105] Figure 16 shows the aggregation level (%HMWS) of a composition of 4000 IU of levonorgestrel α lyophilized pharmaceutical product (Lyo DP) at 5ºC. Lyo DP compositions containing 0, 1%, 2%, and 5% w / v sucrose were tested. Samples were tested at T0, 1 month, 2 months, 3 months, and 6 months.
[0106] Figure 17 shows the aggregation level (%HMWS) of a composition of 4000 IU of levonorgestrel α lyophilized pharmaceutical product (Lyo DP) at 30ºC. Lyo DP compositions containing 0, 1%, 2%, and 5% w / v sucrose were tested. Samples were tested at T0, 1 month, 2 months, 3 months, and 6 months.
[0107] Figure 18 shows the aggregation level (%HMWS) of a composition of 4000 IU of levonorgestrel α lyophilized pharmaceutical product (Lyo DP) at 40ºC. Lyo DP compositions containing 0, 1%, 2%, and 5% w / v sucrose were tested. Samples were tested at T0, 1 month, 2 months, 3 months, and 6 months.
[0108] Figure 19 shows the change in aggregation level (%HMWS) over time (hours) of the liquid composition of Evans α DS and 4000 IU bulk pharmaceutical product (BDP) containing 2% w / v sucrose (solid line) or 5% w / v sucrose (dashed line). Samples were stored at room temperature or 5ºC and tested after 0, 5, 7, 25, 43 and 55 hours.
[0109] Figure 20 shows the glass transition temperature (Tg) of compositions containing 250 IU or 4000 IU of Evans α DP at 5ºC, measured using DSC. Compositions containing 0, 1%, 2%, and 5% w / v sucrose were tested at two intensities. The time points for measurement were the start of the experiment (T0), one month (T1), three months (T3), and six months (T6).
[0110] Figure 21 shows the glass transition temperature (Tg) of compositions containing 250 IU or 4000 IU of Evans α DP at 30ºC, measured using DSC. Compositions containing 0, 1%, 2%, and 5% w / v sucrose were tested at two intensities. The time points for measurement were the start of the experiment (T0), one month (T1), three months (T3), and six months (T6).
[0111] Figure 22 shows the glass transition temperature (Tg) of compositions containing 250 IU or 4000 IU of Evans α DP at 40ºC, measured using DSC. Compositions containing 0, 1%, 2%, and 5% w / v sucrose were tested at two intensities. The time points for measurement were the start of the experiment (T0), one month (T1), three months (T3), and six months (T6).
[0112] Figure 23 shows the glass transition temperatures (Tg) of 250 IU or 4000 IU levonorgestrel α liquid BDP obtained using DSC. Compositions containing 0, 1%, 2%, and 5% w / v sucrose were tested at two intensities.
[0113] Figure 24 shows the residual moisture content of compositions of 250 IU or 4000 IU of levonorgestrel α lyophilized pharmaceutical product (Lyo DP) at 5ºC. Lyo DP compositions containing 0, 1%, 2%, and 5% w / v sucrose were tested. Measurements were taken at the start of the experiment (T0), one month (T1), three months (T3), and six months (T6).
[0114] Figure 25 shows the residual moisture content of compositions of 250 IU or 4000 IU of levonorgestrel α lyophilized pharmaceutical product (Lyo DP) at 30ºC. Lyo DP compositions containing 0, 1%, 2%, and 5% w / v sucrose were tested. Measurements were taken at the start of the experiment (T0), one month (T1), three months (T3), and six months (T6).
[0115] Figure 26 shows the residual moisture content of compositions of 250 IU or 4000 IU of levonorgestrel α lyophilized pharmaceutical product (Lyo DP) at 40ºC. Lyo DP compositions containing 0, 1%, 2%, and 5% w / v sucrose were tested. Measurements were taken at the start of the experiment (T0), one month (T1), three months (T3), and six months (T6).
[0116] Figure 27 is a graphical depiction of the percentage of high molecular weight (HMW) aggregates of Evans thromboplastin α (BIVV001) as analyzed by size exclusion chromatography (SEC) with buffers of different arginine concentrations (Experiment 1). Data were collected at 0, 40, 80, 120 and 160 minutes after thawing.
[0117] Figure 28 is a graphical depiction of the percentage of high molecular weight (HMW) aggregates of Ivanin α (BIVV001) as analyzed by size exclusion chromatography (SEC) with buffers of different arginine concentrations (Experiment 2). Data were collected at 0, 40, 80, 120 and 160 minutes after thawing. [Sequence List]
Claims
1. A pharmaceutical composition comprising: (a) a chimeric protein comprising about 75 IU / mL to about 2,000 IU / mL, comprising a first polypeptide chain and a second polypeptide chain, the first polypeptide chain comprising an FVIII protein comprising an FVIII polypeptide, an ELNN polypeptide inserted into a B domain of the FVIII polypeptide, and a first Fc region, the second polypeptide chain comprising a VWF protein comprising a VWF fragment, a second ELNN polypeptide sequence, an a2 linker, and a second Fc region; (b) about 1% (w / v) to about 7.5% (w / v) sucrose; (c) about 5 mM to about 15 mM histidine; (d) about 200 mM to about 300 mM arginine; (e) about 2.5 mM to about 10 mM calcium chloride; and (f) about 0.008% (w / v) to about 0.1% (w / v) polysorbate. The pH of the pharmaceutical composition is from about 6.5 to about 7.5, where about represents ±10%.
2. The pharmaceutical composition as claimed in claim 1, wherein the polysorbate is polysorbate 80.
3. The pharmaceutical composition as claimed in claim 2, comprising about 1% (w / v) to about 4% (w / v) sucrose.
4. The pharmaceutical composition as claimed in claim 1, comprising about 5% (w / v) to about 7.5% (w / v) sucrose.
5. The pharmaceutical composition as claimed in claim 4, comprising about 5% (w / v) sucrose.
6. The pharmaceutical composition as claimed in claim 2, wherein the pH of the pharmaceutical composition is about 7.
0.
7. The pharmaceutical composition as claimed in claim 2, wherein the pH of the pharmaceutical composition is about 6.
8.
8. The pharmaceutical composition of claim 2, wherein the histidine is L-histidine and wherein the arginine is L-arginine-HCl.
9. The pharmaceutical composition of claim 1, wherein the calcium chloride is calcium chloride dihydrate.
10. The pharmaceutical composition of claim 2, wherein the first polypeptide chain comprises an amino acid sequence as shown in SEQ ID NO: 1 and the second polypeptide chain comprises an amino acid sequence as shown in SEQ ID NO: 2, wherein the first polypeptide chain and the second polypeptide chain are covalently linked by two disulfide bonds between the Fc domains in the first polypeptide chain and the second polypeptide chain.
11. The pharmaceutical composition as claimed in claim 2, wherein the chimeric protein is efanesoctocog alfa.
12. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises: (a) about 5% (w / v) sucrose; (b) about 10 mM L-histidine; (c) about 250 mM L-arginine-HCl; (d) about 5 mM calcium chloride; and (e) about 0.05% polysorbate 80.
13. A pharmaceutical kit comprising: (i) a first container containing a lyophilized pharmaceutical composition comprising (a) a chimeric protein comprising a first polypeptide chain and a second polypeptide chain, the first polypeptide chain comprising an FVIII protein comprising an FVIII polypeptide, an ELNN polypeptide inserted into a B domain of the FVIII polypeptide, and a first Fc region, the second polypeptide chain comprising a VWF protein comprising a VWF fragment, a second ELNN polypeptide sequence, an a2 linker, and a second Fc region; (b) about 30 mg to about 200 mg of sucrose; (c) about 2.5 mg to about 7.5 mg of histidine; (d) about 140 mg to about 200 mg of arginine; (e) about 1.5 mg to about 5 mg of calcium chloride; and (f) about 1 mg to about 5 mg of polysorbate 80; and (ii) a second container containing sterile water, wherein about represents ±10%.
14. The pharmaceutical kit as claimed in claim 13, wherein the composition comprises about 30 mg to about 135 mg of sucrose.
15. The pharmaceutical kit as claimed in claim 13, wherein the composition comprises about 160 mg to about 200 mg of sucrose.
16. The pharmaceutical kit as claimed in claim 13, wherein the histidine is L-histidine, and wherein the arginine is L-arginine.
17. The pharmaceutical kit as claimed in claim 14, comprising L-arginine-HCl.
18. The pharmaceutical kit as claimed in claim 13, wherein the moisture content of the lyophilized pharmaceutical composition is less than 1.6%.
19. The pharmaceutical kit as claimed in claim 13, wherein the first container contains 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU, or 4000 IU of the chimeric protein.
20. The pharmaceutical kit as claimed in claim 13, wherein the chimeric protein is efanesoctocog alfa.
Citation Information
Patent Citations
Methods of treating hemophilia a
TW202015723A
Stabilizing buffer for factor viii and vwf
WO2021032646A1
